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Abstract
A growing body of evidence suggests that the regular use of non-steroidal anti-inflammatory drugs 
(NSAIDs), especially aspirin, is associated with a reduced risk of many types of cancer including 
colorectal, breast, and prostate malignancies. It has also been shown that they might be beneficial 
in reducing metastasis and lengthening remission periods. However, the prolonged exposure to 
this class of drugs does not come without a cost as it carries with it the risk of augmenting the 
serious side effects of NSAIDs. These include haemorrhages, increased bleeding time, peptic 
ulcers, and hypersensitivity, to name a few. 
This work aimed at employing the principles of nanotherapy to maximise the benefits of NSAIDs 
and minimise the risks of their harmful side effects. By exploiting the enhanced permeability 
and retention effect (EPR) unique to inflammatory tissues, NSAID-loaded nanocarriers could 
delivery high concentrations of the drugs to cancer tissue, compared to conventional therapy, 
while reducing the systemic exposure to their effects.
Block copolymers from a polymeric pro-drug, polysalicylate, and polyethylene glycol were 
synthesised and self-assembled into nanoparticles of a desirable size range. The polysalicylate at 
the core of the particles comprised solely of the active molecule, salicylic acid, and showed a good 
release profile in accelerated conditions, which suggests a possible sustained release in tumour 
tissue.
The cytotoxic activity of the nanoparticles and polysalicylate was tested against triple-negative 
cancer cell lines and neuroblastoma cell lines in vitro and was compared to conventional cytotoxic 
drugs. A modest biological response was observed with the low concentration at which the particles 
could be prepared, indicating that the accumulation of the nanoparticles in targeted tissue could 
produce the desired outcomes.
Developing other polyphosphoester-based polymeric nanocarriers as well as lipid nanocarriers 
was attempted. Possible factors that affected the synthesis of such carriers were discussed.
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Cancer has always been the immortal enemy of mankind. Even before Hippocrates encountered 
an abnormal growth with its veins spreading out in every direction and called it “karkinos” (i.e. 
crab) because it reminded him of the crustacean, the writer of a 5000-year-old papyrus from 
ancient Egypt described a bulging tumour of the breast as a grave disease that has no treatment.1
With all of today’s medical advancements, cancer is still the second cause of death worldwide 
after cardiovascular diseases.2 In 2018 alone, over 18 million new cases of cancer were reported 
and over 9.5 million cancer-related deaths were recorded globally, and projections to 2040 show 
an increase of incidence rate by about 63%.3,4 In the UK, cancer accounts for more than a quarter 
(28%) of all deaths with an average of around 1000 newly-diagnosed cases and around 450 cancer-
related deaths every day.5
Cancer has also a huge economic impact as it costs the world more than any other disease. It 
is estimated that about $895 is spent on cancer each year between diagnosis, treatment, and 
end-of-life care.6 The journey of developing a new drug for cancer treatment, from discovery to 
development and then to clinical trials and drug approval, is estimated to cost about £1.15 billion 
and takes and average of 12.5 years to complete.6
It is for these reasons that researchers have always strived to develop treatments that are not only 
efficacious against cancer, but that are also cost-effective in terms of development, implementation, 
and the reduction of the frequency of hospitalisation that might arise from the need for repeated 
administration of treatment, failure of therapy, or unwanted adverse reactions.
One strategy for developing such treatments entails revisiting old therapeutics that have proven 
their efficacy for the management of other illnesses, understand how their mechanisms of action 
relate to cancer and what their advantages might be, and then design new approaches by which 
these drugs can be used effectively and safely in cancer therapy.
Preface
2
This work is part of the efforts to build on pre-existing knowledge about the effectiveness of safe, 
cheap, conventional drugs and reutilising them in innovative formulations that maximises their 
benefits, reduce their side effects, and enhances the overall quality of life of patients.
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have shown some promising 
potential for the treatment and prevention of certain types of cancer, both clinically and in vitro.7–9 
However, even though they are often considered to be safe for the management of common 
pain and inflammatory conditions, they are not free of side effects and can cause so much harm 
especially with prolonged exposure or in susceptible patients.10
The current work aims at maximising the therapeutic benefits of NISADs in cancer and reducing 
the risks of unwanted adverse effects by formulating these drugs in novel nanoscale delivery systems 
that take advantage of the uniqueness of the solid tumours’ microenvironment to concentrate 
their cargo in targeted cancer tissues and diminish the systemic distribution of the drugs.11
In Chapter 1, the clinical evidence around the role of NSAIDs in the prevention and treatment 
of different types of cancer is reviewed, followed by a discussion about the potential mechanisms 
by which NSAIDs suppress tumours. Then an overview of nanotherapy is presented where the 
pathophysiology of the tumour microenvironment and how it relates to targeted therapy is 
discussed. The types of targeting are then reviewed along with examples of the different types of 
nanocarriers that have been developed for the purposes of targeting tumours.
Chapter 2 presents the work that has been carried to create polymer-based nanoparticles for the 
delivery of NSAIDs. A salicylic acid polymer is first synthesised and characterised and then its 
release profile investigated. The polymer is then conjugated with polyethylene glycol to create an 
amphiphilic block co-polymer that could self-assemble in aqueous solutions. The self-assembled 
nanoparticles are analysed and studied.
The chapter also introduces an attempt to synthesise a biodegradable and biocompatible 
polyphosphoester for the delivery of another NSAID, ibuprofen. The steps towards the making of 
the polymer are presented.
3
In Chapter 3, another type of nanocarriers, liposomes, is prepared with salicylic acid as cargo. The 
chapter exhibits the different methods carried out to synthesise the liposomes and discusses the 
challenges associated with the preparation and stability of these nanocarriers. 
The in vitro studies of the developed nanoparticles are presented in Chapter 4. The Cytotoxicity 
of the nanoparticles is measures against two cancer cell lines and is compared with cytotoxicity 
of the monomer. Combination treatments with other established chemotherapeutic agents is also 
studied and compared to individual agents.
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Chapter
NSAIDs, cancer, and magic bullets
1
6
1.1. NSAIDs and cancer: clinical evidence
The use of aspirin as a potential therapeutic agent in cancer has been contemplated for decades, 
with colorectal cancers (CRCs) being the most extensively studied target. In the early 1970s, it 
was noted that cancer metastasis was associated with platelet aggregation both in vivo and in vitro 
and that thrombocytopenia (the deficiency of blood platelets), which results in the lack of blood 
clotting, caused suppression of metastatic malignancies.1–3 The potential usefulness of aspirin in 
CRC was further supported when the concentration of the prostaglandins responsible for platelet 
aggregation, and whose synthesis can be inhibited with aspirin, was proved to be elevated in the 
colorectal tumour tissues.4,5
Some of the first clinical evidence of the potential effectiveness of aspirin and possibly other non-
steroidal anti-inflammatory drugs (NSAIDs) (Figure 1.1) might have been inferred from early 
trials like the Finnish study6 that was investigating the link between certain types of cancer and 
rheumatoid arthritis. The study found a lower incidence rate of digestive tract tumours in female 
patients with rheumatoid arthritis, and although no direct interpretation could be made, it was 
later speculated that those patients were prone to taking NSAIDs frequently and for prolonged 
periods of time. 
1.1.1. Colorectal cancers 
The aforementioned speculation came from Thun et al.7 who were among the first to investigate 
this effect on a large scale through a longitudinal prospective cohort study in the late 80s and 
the early 90s of the past century. In contrast to a few case-control8,9 and cohort10,11 studies and 
small-scale randomised controlled trials (RCTs)12,13 that were published earlier and had relatively 
a small number of patients producing contradicting results, Thun’s study7 evaluated the effects of 
the frequent use of aspirin on death rates from colon cancer in over 660 thousand patients. After 
following participants over a period of 6 years, it was found that death rates related to colon cancer 
in patients taking aspirin for more than 16 times a week for at least a year decreased by 40% in men 
(relative risk [RR]: 0.6, 95% confidence interval [CI]: 0.40-0.89) and by 42% in women (RR: 0.58, 
95% CI: 0.37-0.90). The research group later published further multivariate statistical analyses14 of 
the same cohort to investigate other types of cancer and concluded that the frequent use of aspirin 
7
might have a positive effect on other types of cancer such as oesophageal (RR: 0.59, 95% CI, 0.34-
1.03, P=0.054), gastric (total adjusted RR: 0.53, 95% CI: 0.34-0.81, P<0.0001), colon (RR: 0.58, 95% 
CI: 0.45-0.74, P<0.0001), and rectal (RR: 0.46, 95% CI: 0.25-0.82, P<0.0001) cancers. This study 
had a few shortcomings such as relying on a short self-administered questionnaire to collect data 
on NSAID use and performed the analysis based on cancer mortality rather than incidence rates 



























































































Fig 1.1. The chemical classification of 
non-steroidal anti-inflammatory drugs 
(NSAIDs) with example of common 
drugs from each family.
Pharmacologically, these drugs are 
classified into non-selective NSAIDs 
(left), and cyclooxygenase-2 (COX-2) 
selective inhibitors or coxibs (top), 
although selectivity is dose-dependent 
and the affinity for the two isoenzymes 
varies among different drugs.46,87
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study might have suffered a “detection bias” where gastrointestinal bleeding that developed from 
taking the aspirin could have resulted in patients receiving more extensive medical examination 
and subsequently an earlier detection of polyps (which are the precursor to most colorectal 
cancers)15 and early-stage tumours thus enhancing survival.
Since stronger clinical evidence would come from randomised controlled trials (RCTs),16 where 
biases are minimised (Figure 1.2), yet it would be ethically controversial to deprive control groups 
of the potential benefits of the treatment, early analyses examined the data from the already-
existing trials in which aspirin was being investigated for its cardiovascular effects. Some of 
the earliest studies nested within two of the largest RCTs of aspirin could not provide proof of 
the drug’s ability to curb the growth of tumours. A cohort study by Gann et al.17 nested within 
the US Physicians’ Health Study (ClinicalTrials.gov identifier: NCT00000500), in which 22071 
participants were randomised between treatment group that took 325 mg of aspirin every other 
day and a placebo group and were followed up for five years, found that aspirin provided no 
reduction in the incidence of CRCs (RR: 1.15, 95% CI: 0.80-1.65). 
The Women’s Health Study (ClinicalTrials.
gov identifier: NCT00000479) was another 
large RCT in the US that had about 40,000 
women randomised between a group using 
100 mg every other day and a placebo group 
and followed up patients for a median of 
10 years for cardiovascular-related effects. 
A study by Cook et al.18 nested within this 
trial found no significant effect of aspirin on 
the risk of colorectal cancer (RR: 0.97, 95% 
CI: 0.77-1.24, P=0.83), although a later analysis by the same research group19 after an extended 
median follow-up period of 18 years of the same study found a reduction of CRC incidence by 
20% (hazard ratio [HR]: 0.80, 95% CI: 0.67-0.97, P=0.021) with a post-trial reduction by 42% 






















Fig 1.2. The pyramid of evidence-based medicine, 
adapted from [16]. Strongest evidence that shape 
clinical guidelines comes from randomised controlled 
trials (RCTs), systematic reviews, and meta-analyses.
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In the UK, similar RCTs that studied the cardiovascular effects of aspirin also investigated the 
potential chemopreventive actions. Among the most noticeable are the British Doctors Aspirin 
Trial (BDAT),20 in which 5139 male doctors were allocated between an aspirin group taking 500 
mg of aspirin a day and a control group (match ratio 2:1) for five years, and the United Kingdom 
transient ischaemic attack (UK-TIA),21 in which  2437 participants were divided into three 
equal groups of 300 mg aspirin per day, 600 mg aspirin per day, and a placebo control group for 
periods between 1-7 years. Rothwell et al.22 investigated the effect of aspirin in these studies at the 
incidence of cancer with a follow-up period of 20 years and found a 26% reduction in colorectal 
cancer incidence. These findings, however, were only statistically significant with a latency of 10 
years or more (HR for years 0-9: 0.92, 95% CI: 0.56-1.49, P=0.73, HR for years 10-19: 0.60, 95% 
CI: 0.42-0.87, P=0.007). The effect of the follow-up period on the statistical significance of all the 
above studies could be explained by the fact that colorectal polyps take 10-15 years to develop into 
cancerous tissue23,24 thus there would be no significance between the aspirin and the non-aspirin 
groups if the follow-up was less than ten years.
A later meta-analysis25 by Rothwell et al. of the BDAT and UK-TIA trials alongside three other 
RCTs26–28 with a median follow-up period of 18.3 years found that taking aspirin for five or more 
years was associated with the greatest reduction of cancer incidence and mortality of proximal 
colon that reached about 70% (incidence HR: 0.35, 95% CI: 0.20–0.63, mortality HR: 0.24, 95% 
CI: 0.11–0.52, both P<0.0001) and rectal cancers of about 50% (incidence HR: 0.58, 95% CI: 0.36–
0.02, P=0.02, mortality HR: 0.47, 95% CI: 0.26–0.87, P=0.01), providing more reliable evidence 
of the effectiveness of the long-term use of aspirin in reducing the incidence of colorectal cancers 
and its consequences.
1.1.2. Prostate Cancer
Prostate cancer (PC) is the most prevalent cancer in males worldwide.29 In the UK alone, it is 
estimated that there are about 47,740 new cases annually, which accounts for about 130 new 
 cases every single day.
30 Given that the risk factors of PC cannot be attenuated through lifestyle 
modifications,31 the prospect of having a preventative measure such as a low-risk protective daily 
dose of aspirin offers a compelling option to reduce the risk of PC. 
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However, the evidence of NSAIDs effectiveness in reducing the incidence rate of PC is inconsistent. 
Two meta-analyses that were conducted around the same time in 2014 came to different 
conclusions. Wang et al.32 (15 cohort studies and 14 case-control studies) found that the use of 
aspirin had very little effect on the incidence of PC (odds ratio [OR]: 0.95, 95% CI: 0.93-0.98) 
and the same was true for non-aspirin (OR: 0.94, 95% CI: 0.90-0.98), while analysing data for 
all-NSAID intake found that it was positively correlated with the incidence rate of PC (OR: 1.18, 
95% CI: 1.15-1.22). Nonetheless, this analysis showed a significantly statistical heterogeneity (I2 = 
92.4%, P<0.001 for aspirin, I2 = 60.7%, P<0.001 for non-aspirin NSAIDs, and I2 = 55.9%, P<0.01 
for all-NSAID use). Liu et al.33 in their analysis (19 cohort studies and 20 case-control studies) 
concluded similarly when they found that the use of aspirin slightly reduced the incidence risk of 
total PC (OR: 0.92, 95% CI: 0.87-0.97, I2 = 66.2%, P<0.001) and advanced PC (OR: 0.81, 95%CI: 
0.73-0.89, I2 = 23.9%, P=0.20). It also slightly reduced the mortality risk of both total (HR: 0.86, 
95% CI: 0.78-0.96, I2 = 39.2%, P=0.145) and advanced (OR: 0.81, 95% CI: 0.71-0.92) PC. The 
pooled analysis for all-NSAID use however found no significantly statistical correlation between 
treatment and incidence risk of total (OR: 0.9, 95% CI: 0.75-1.07, I2 = 93.5%, P<0.001) or advanced 
(OR: 0.86, 95% CI: 0.52-1.40, I2 = 94.2%, P<0.001).
In 2018, Shang et al.34 included more recent large-scale studies in their meta-analysis (a total of 
43 observational studies). The analysis concluded that the regular use of any NSAID reduced the 
risk of PC by about 11% (pooled RR:0.89, 95% CI: 0.81–0.98, I2 = 94%, P<0.001) and that further 
reduction is even noticeable if the use was ≥ 5 years rather than ≥ 4 years (pooled RR:0.882, 95% 
CI: 0.785–0.991, I2 = 27.4%, P=0.248). It also found that the use of aspirin was associated with a 
modest reduction in PC (pooled RR:0.93, 95% CI: 0.89–0.96, I2 = 79.5%, P<0.001) and that this 
reduction was more pronounced (pooled RR:0.875, 95% CI: 0.792–0.967, I2 = 28.4%) with the 
daily use of aspirin (1 or more pill per day) rather than the prolonged overall use (≥ 4 years of any 
use). The pooled analysis of non-aspirin NSAID use, however, showed no statistically significant 
reduction in PC risk.
As presented above, evidence regarding the role of NSAIDs in reducing the risk of PC is indecisive 
with a high degree of heterogeneity in some cases. This can be attributed to multiple factors. 
Firstly and more importantly, all of the analyses were of observational and case-control studies 
11
which can involve many factors that can complicate the analysis, and there is a lack of RCTs that 
can provide stronger evidence, reduce biases, and adjust for confounders. Secondly, most of the 
analysed studies depended on questionnaires and interviews in which patients were asked about 
their NSAID consumption history, which can be prone to recall bias where patients over- or 
underestimate their consumption habits. This can be further complicated by the fact that many 
NSAIDs are available over-the-counter (OTC) and there might not be accurate records of their 
use, and thus recall bias is exaggerated even further.
Thirdly, the regular consumption of NSAIDs has shown to lower the serum levels of prostate-
specific antigen (PSA) although it is unclear whether this is a result of a protective or a masking 
effect.35,36 Since PSA assay is regularly used for screening purposes of PC, false low PSA resulting 
from NSAID use could have complicated the results of the analyses. For example, PC incidence 
could have been underestimated in patients taking NSAIDs for an extended period of time, or 
the stratification of patients between early-stage and advanced PC (in which PSA levels are much 
higher) could have been influenced by misinterpretation of PSA levels leading to selection bias in 
some studies.
Nonetheless, these meta-analyses still provided some evidence on the protective role of NSAIDs 
in prostate cancer, although further well-designed RCTs are necessary to provide more conclusive 
evidence.
1.1.3. Breast cancer
As with prostate cancer, there is a lack of high-grade evidence regarding the chemopreventive 
effects of NSAIDs in breast cancer since data comes mostly from cohort and case-control studies 
rather than large-scale RCTs. Two meta-analyses that analysed data from existing studies, however, 
found an inverse association between the use of NSAIDs and breast cancer incidence. Takkouche 
et al.37 conducted a meta-analysis in 2008 on 38 studies that spanned over 42 years preceding the 
analysis and included over 2.7 women. The analysis found a 12% reduction in breast cancer risk 
with any-NSAID use (RR: 0.88, 95% CI: 0.84-0.93) with a risk reduction of 13% associated with 
aspirin use (RR: 0.87, 95% CI: 0.82-0.92) and 21% with ibuprofen use (RR: 0.79, 95% CI: 0.64-
0.97). Zhao et al.38 conducted a similar meta-analysis around the same time and found similar 
results and, just as with Takkouche’s analysis, they reported high levels of heterogeneity (I2 = 92%, 
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P=0.04). Huang et al.39 concluded in a more recent meta-analysis that included one RCT that 
NSAID use is associated with enhanced survival and decreased breast-cancer-related mortality, 
although the analysis was not statistically significant and had high levels of heterogeneity which 
were attributed to the presence of confounding factors such as the age and race of the participants 
as well as to the hormone receptor status and the subtype of the cancer (i.e. oestrogen-receptor 
[ER], progesterone-receptor [PR], human epidermal-growth-factor-receptor-2 [HER2] statuses), 
although no further details were provided in any of the three analyses in this regards. This could 
be of relevance since prostaglandin E2 (PGE2 ), whose synthesis is catalysed by cyclooxygenase-2 
(COX-2), is thought to be responsible of the local production of oestrogen and thus promoting the 
development of ER+ breast cancer40 although there is also some evidence suggesting that COX-2 
might also play a role in the development of ER- and HER2- breast cancers.41
A few studies have investigated the correlation between the tumour hormone status and the effect 
of NSAID use found different responses depending on the cancer subtype; The Spanish Multi-
Case-Control Study42 found a reduction in risk of hormone-positive (ER+ and/or PR+) breast 
cancer (OR: 0.72, 95% CI: 0.60=0.88, P<0.001) and HER+ breast cancer (OR: 0.63, 95% CI: 0.45-
0.88, P=0.007) but not with triple-negative breast cancer (OR: 0.87, 95% CI: 0.58=1.33, P=0.49) 
with all NSAID use. When analysing data for specific NSAID subgroups, however, the risk 
reduction was only statistically significant for global NSAID use, with acetic acid derivatives (e.g. 
diclofenac and indomethacin), propionic acid derivatives (e.g. ibuprofen, ketoprofen, naproxen), 
and COXIBs (i.e. selective COX-2 inhibitors), but not with aspirin. The Sister Study, a cohort 
study of over 50,000 women who had a sister(s) with breast cancer by Sangmi et al.43 found no 
statistical significance of the breast cancer risk reduction associated with NSAID use by cancer 
subtype. Its conclusion, however, was that the risk of breast cancer in premenopausal women was 
significantly reduced by the prolonged use of NSAIDs (HR4vs1: 0.66, 95% CI: 0.50-0.87, P=0.025) 
and especially aspirin (HR4vs1: 0.57, 95% CI: 0.33-0.98, P=0.038) while it was insignificant with 
all other NSAID (HR4vs1: 0.73, 95% CI: 0.53-1.01, P=0.182). It is also worth noting that in Brasky 
et al.’s case-control study44 it was found that aspirin had a reducing effect on breast cancer risk 
regardless of the subtype of cancer and, more interestingly, that ibuprofen was associated with an 
increased risk with many of the subtypes although that most of the analysis in both cases had no 
statistical significance.
13
As with prostate cancer, there is a lack of well-designed RCTs that focus on investigating the effects 
of prolonged exposure to NSAIDs on breast cancer to minimise the impact of confounding factors 
on the evidence. Cook et al. in their study18 within the Women’s Health Study RCT and their 
follow-up analysis19 however, found no statistically significant risk reduction of breast cancer with 
the long-term use of low-dose aspirin (alternate-day 100 mg). In the light of COX-2’s potential 
involvement in breast cancer development, this might be explained by the fact that aspirin is about 
160 times more selective to COX-1 than COX-2 at low doses (75-100 mg) and requires higher 
doses (≥1200 mg) to suppress COX-2 and produce the anti-inflammatory effect.45,46 
1.1.4. Kidney cancer
Renal cell carcinoma is perhaps the only type of cancer that has shown evidence of being positively 
correlated with the prolonged use of some NSAIDs. A meta-analysis by Choueiri et al.47 of 18 
case-control and cohort studies found that the use of non-aspirin NSAIDs was correlated with 
an increased risk of renal cell carcinoma (RR: 1.25, 95% CI: 1.06–1.46) but did not find that 
association with the use of aspirin (RR: 1.10, 95% CI: 0.95–1.28) except when the five non-US 
studies were pooled together (RR: 1.17, 95% CI: 1.04–1.33). Cho et al.’s analysis48 of the large 
prospective Nurses’ Health Study49 (about 127,000 subjects with a follow-up period of 20 years) 
arrived at a similar conclusion of an increased risk of kidney cancer with the use of non-aspirin 
NSAIDs (RR: 1.51, 95% CI: 1.12-2.04). 
Although neither analysis could provide an explanation for this finding, it might be related to the 
effects of NSAIDs on the renal homeostasis and kidney function50 that will be discussed more in 
detail later, although this does not explain why this is observed with non-aspirin NSAIDs but not 
with aspirin.
1.1.5. Other cancers and metastasis
A meta-analysis by Wang et al.51 that mostly included case-control studies on the effect of NSAID 
use on gastric cancer incidence found that aspirin users had a lower risk of non-cardia gastric 
cancer (OR: 0.73, 95% CI: 0.63-0.86) as did non-aspirin NSAID users (OR: 0.74, 95% CI: 0.55-
1.00). When stratifying patients into regular vs irregular users, the risk reduction was found to be 
statistically significant with the regular NSAID use (OR: 0.57, 95% CI: 0.44-0.74) as opposed to 
irregular use (OR: 0.84, 95% CI: 0.66-1.07).
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An analysis of 12 case-control studies by Trabert et al.52 also found that the regular use of aspirin 
inversely correlated with ovarian cancer risk (OR: 0.91, 95% CI: 0.84-0.99, I2 = 5.2%) but was 
statistically insignificant with non-aspirin NSAIDs (OR: 0.90, 95% CI: 0.77-1.05, I2 = 73.2%).
As for metastasis, a meta-analysis by Zhao et al.53 of related reports in the literature found that 
patients who were exposed to NSAIDs had a lower risk of distant metastasis whether this exposure 
was pre-diagnostic (RR 0.708, 95% CI 0.586–0.856) or post-diagnostic (RR: 0.484, 95% CI: 
0.393–0.595), and that this reduction was significant for prostatic cancer (pre-diagnosis 22.6%, 
post-diagnostic 51.8%), and breast cancer (pre-diagnosis 33.6%, post-diagnostic 52.5%) but less 
pronounced (only 5.1%) with pre-diagnostic use in lymph node metastasis.
Despite all the promising evidence, regulatory bodies and practitioners are still reluctant to make 
strong recommendations regarding the use of NSAIDs for the prevention of cancer. For example, 
the highly-regarded U.S. Preventive Services Task Force, who provides evidence-based clinical 
guidelines on preventative medicine that are followed by practitioners in the US and worldwide, 
cautiously advised in its latest recommendations54 to prescribe aspirin as a chemopreventative 
against CRCs only in patients beyond a certain age who are at a low risk of bleeding and who are 
willing to take low-dose aspirin daily for at least 10 years. 
Clinical guidelines, in general, are based on balancing the risks and benefits of any particular 
treatment. The same pharmacological effects through which therapeutic benefits manifest in the 
body can determine the potential side effects that can be induced by the treatment and the pre-
existing contra-indications that can prevent from using it. Below we discuss the pharmacological 
actions exerted by NSAIDs that could potentially explain their chemotherapeutic effects as well as 
their common adverse reactions.
1.2. The pharmacological mechanisms of NSAIDs in cancer
There are multiple proposed pathways in which NSAIDs exert their chemotherapeutic activity; 
what follows is an overview of these pathways:
1.2.1. The COX-dependent pathway
Many physiological processes are moderated by prostaglandins (PGs), a subgroup of bioactive, 
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hormone-like lipids called eicosanoids. They exist in most human tissues and are responsible for 
a wide array of biological regulatory processes such as maintaining homeostasis and mediating 
inflammatory responses.55 It has been long proposed that many PGs might be responsible for 
promoting cancer growth and metastasis.56,57 The pro-inflammatory prostaglandin E2 (PGE2), 
in particular, has been found to be overexpressed locally in many tumours such as colon,58 
breast,59 lung,60 and head and neck61 cancers and is suspected of playing a role in tumour growth, 
angiogenesis, cell adhesion, and metastasis.56 These findings encouraged researchers to suggest 
that suppressing PGE2 might carry a tremendous chemotherapeutic value.
Prostaglandins are synthesised in vivo from a 20-carbon chain fatty acid called arachidonic acid 
(AA) which is freed from the phospholipid layer of the plasma membrane by phospholipase A2 
and then further metabolised into prostaglandins by cyclooxygenases (COXs, also known as 
prostaglandin-endoperoxide synthases or PTGSs). The COX enzymes comprise of 2 isoforms; COX-
1 which mediates the synthesis of the “housekeeping” PGs (i.e. PGs responsible for blood clotting, 
stomach epithelial cytoprotection, and homeostasis), and COX-2 which mediates the synthesis 
of the inflammatory and proliferative prostaglandins, including PGE2.
55,57 The overexpression of 
PGE2 is thought to promote the proliferation of colon cancer by activating the RAS-ERK signalling 
pathway62 as it does in lung cancer.63 It is also believed to upregulate the aromatase production 
and the subsequent synthesis of oestrogen in the adipose stroma surrounding breast cancer tissue, 
thus promoting its growth.64 Figure 1.3 illustrates the COX synthesis pathway and the effects of 
the major prostaglandins.
NSAIDs exert their anti-inflammatory effects through the inhibition of COX enzymes, although 
they vary in terms of the extent and selectivity of this inhibition. While aspirin is the only 
NSAID capable of irreversibly deactivating both isoenzymes through modifying their structure 
by acetylation, thus requiring the synthesis of new molecules to restore their activity, all other 
NSAIDs reversibly bind to the COX enzymes. Furthermore, aspirin is more selective to COX-1 
at low doses and it becomes non-selective at higher doses. In contrast, other NSAIDs such as 
ibuprofen are inherently non-selective, and others like celecoxib are entirely selective to COX-
2 (hence collectively called COX-2 selective inhibitors or COXIBs).45,46,65 PGE2 synthesis, among 
other PGs, is mediated through COX-2 and the inhibition of the latter and hence the subsequent 
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production of PGE2 is believed to be the main mechanism by which NSAIDs produce their anti-
tumour activity.57 It has also been suggested that COX-1 might promote the progression of some 
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Fig 1.3. The cyclooxygenase pathway adapted from [55]. COX: cyclooxygenase, NSAIDs: non-steroidal 





The antiplatelet effect of aspirin, which is achieved through the irreversible suppression of COX-
1 and the subsequent inhibition of the production of the eicosanoid thromboxane A2 (TXA2) 
that is responsible for platelet aggregation,67 is also believed to play a role in the growth and 
spread of tumours. It has been speculated that activating platelet aggregation might facilitate 
the metastasis of cancer cells while reducing aggregation could reduce the tumour burden, at 
least in animal tumour models.68,69 Aspirin also could possess the capability not only to suppress 
platelet aggregation but also to change the profile of many proteins secreted from platelets upon 
their activation (collectively known as the platelet releasate), such as interleukin 7 (IL-7), vascular 
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endothelial growth factor (VEGF), angioprotein-1, and fibroblast growth factor (FGF) among 
others,70,71 all of which are pro-inflammatory factors and are suspected of playing a part in the 
promotion of angiogenesis and metastasis.72 It has also been suggested that some component of 
releasate, especially VEGF and FGF, induce COX-2 production and the subsequent rise in the 
production of PGE 2 and other COX-2-mediated inflammatory factors.
73 Finally, TXA2 itself is 
a suspect of possessing a supportive role in inducing the production of local COX-2 and in the 
angiogenesis and metastasis processes, and suppressing its synthesis by aspirin might prove to be 
beneficial.74,75 
1.2.2.  COX-independent pathways
Although the COX-dependent mechanisms of NSAIDs as chemopreventive are the most prominent 
and the most studied, there are other suggested mechanisms by which NSAIDs exert such effects.
Eluding apoptosis (i.e. the naturally-programmed cell death) is a hallmark of cancerous cells, and 
reactivating the kill switch in these cells is the target for many anti-tumour drugs.76 NSAIDs are 
believed to induce apoptosis through modulating the effects of Bcl-2, a family of genes responsible 
for encoding the proteins that either inhibit or induce apoptosis mainly through controlling cell 
membrane potential and its permeability for apoptotic elements.77 Aspirin was found to decrease 
the expression of the anti-apoptotic Bcl-2 gene and increase the expression of the pro-apoptotic Bax 
gene in lung and ovarian cancer cells.78 Naproxen and sulindac showed similar effects in bladder79 
and colon80 cancer cells, respectively, while celecoxib is believed to amplify the expression of p53 
anti-tumour proteins in colorectal cancer cells.81
Aspirin has also been found to increase the production of intracellular reactive oxygen species 
(ROS) that induces cell apoptosis through increased oxidative stress, as well as disrupt the activity 
of mitochondrial respiratory enzymes and the related energy production, subsequently promoting 
cell death in liver cancer.82
Other mechanisms by which NSAIDs potentially induce apoptosis include:
- the inhibition of cyclic guanosine monophosphate phosphodiesterases (cGMP PDEs) that 
inactivates cGMP which is otherwise responsible for normal apoptosis.83
- Modulating peroxisome proliferator-activated receptors (PPAR) α, γ, and δ.84,85
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- Inhibition of the transcriptional signalling of nuclear factor NF-κB which mediates several anti-
apoptotic and cell survival-promoting pathways.86
In addition to promoting apoptosis, the inhibitory role of NSAIDs of other tumour-related 
activities, i.e. angiogenesis and metastasis, might also be explained through COX-independent 
pathways. Since cGMP plays an active role in tumour angiogenesis, it might be possible that 
this process is inhibited by NISADs via the suppression of cGMP PDEs as well as the previously 
discussed COX-mediated suppression of VEGF.87 Matrix metalloproteases (MMPs), a family 
of proteinases that exist in most solid tumours and are responsible for the degradation of the 
extracellular matrix (ECM) thus facilitating metastasis, are also thought to be inhibited by 
NSAIDs, more specifically, MMP2 and MMP9.88
1.2.3. The side effects of NSAIDs
Even though NSAIDs have a wide therapeutic window and many of them are available over-the-
counter (OTC), they are still not free of side effects that can be serious in some cases. Those side 
effects are generally linked to the pharmacological effects, mainly the ones related to the COX 
pathways discussed above.
As previously mentioned, many of the prostaglandins whose synthesis is catalysed by the COX 
isoenzymes have homeostatic effects throughout the body. Some prostaglandins, especially PGE2 
and PGI2 (also known as prostacyclin), for example, mediate the gastric acid and mucus secretions. 
These prostaglandins maintain the balance between gastric acid production and inducing the 
secretion of the stomach mucosal layer, hence maintaining the integrity of the stomach lining 
and protecting it from being digested by its acidic content.89 Non-selective NSAIDs suppress PGI2 
resulting in the most prominent side effect to these NSAIDs, i.e. peptic and duodenal ulcers.90 In 
the presence of risk factors, such as old age or prolonged use of NSAIDs, these ulcers can develop 
into bleeding lesions leading to anaemia, or even perforate the stomach into the abdominal cavity 
leading yet to more serious complications.91,92 This bleeding complication is observed mainly 
with aspirin due to its irreversible antiplatelet effect that lessens the body’s ability to produce 
thrombosis in the bleeding gastric tissue.93 This irreversible antiplatelet effect is also the reason 
why the prolonged use of aspirin is associated with an increased risk of intracranial bleeding and 
haemorrhagic strokes.94
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Although COXIBs, by being inherently selective to COX-2, help reduce the production of the COX-
2-mediated pain and inflammation PGs while being far less harmful to the stomach, this does not 
come without a price. COXIBs inhibit the production of prostacyclin, a dominant vasodilator, in 
blood vessels while leaving the constrictive and pro-aggregation effects of the COX-1-mediated 
TXA2 unopposed. This pro-thrombotic imbalance carries the risk of serious cardiovascular (CV) 
events (such as angina pectoris or myocardial infarction) should any predisposing risk factors 
exist.95,96
In a similar fashion, by suppressing prostacyclin synthesis in the renal afferent arteriole, both 
selective and non-selective NSAIDs affect the renal function and can lead to reversible acute renal 
failure that can develop to a chronic state if the injury was prolonged. In brief, suppressing the 
vasodilating effect of prostacyclin causes a constricted renal arteriole to let less blood into the 
kidney leading to poor renal perfusion and a subsequent reduction in glomerular filtration rate 
and renal ischemia might eventually develop. This effect could also lead to an elevation of blood 
pressure and the formation of oedemas, which pose an added risk to patients with hypertension 
and heart failure.97,98
Prostaglandins, especially PGE2, play a significant role in maintaining the muscle tone of the 
respiratory system. PGE2  controls the tone of the bronchi through binding to different subtypes 
of receptors, mainly EP 1 receptors that promote bronchoconstriction and EP2 that causes 
bronchodilation. Suppressing the production of PGE2 causes imbalance in this system leading to 
bronchospasm.99 PGE 2  is also believed to be a major stabiliser of mast cells, the immune cells 
whose activation is responsible for the release of histamine and other pro-inflammatory and 
broncho-constricting agents from the leukotriene (LT) family. It is through the inhibition of the 
PGE2 synthesis and the subsequent destabilisation of mast cells and the release of inflammatory 
LTs that aspirin and other NSAIDs cause aspirin-exacerbated respiratory disease (AERD) or 
aspirin-induced asthma (AIA) in susceptible patients and making this class of drugs altogether 
contra-indicated in asthma patients.100
From what has been discussed above, it is clear how the mechanisms by which NSAIDs produce 
their response immensely affect the delicate risks/benefits balance and can vary largely from one 
patient to another furtherly complicating the clinical practitioner’s decision and either robbing a 
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potential candidate from the NSAIDs’ chemotherapeutic gains or causing harmful, and sometimes 
lethal, effects to another. This has led us to consider exploiting a concept that has been extensively 
studied, and, to a lesser extent, commercially used to maximise the therapeutic benefits while 
minimising the risks, namely, nano-scale delivery systems.
1.3. Nanotherapy and its prospects in cancer
Since the beginning of the twentieth century when the German physician, scientist, and Nobel 
Laureate Paul Ehrlich envisioned a “magic bullet”101 that would target only pathogens, scientists 
have been trying to tailor therapeutics in a manner that would concentrate treatment in ailed organs 
while sparing healthy ones potential toxicity, and many advances have been made in this regard 
especially in the field of immunology. Targeted therapy started taking form in the 1980s primarily 
as antibody-drug conjugates (ADCs) where specific antibodies are linked to drug molecules which 
would only exert their pharmacological effect upon cells that have a corresponding antigen to the 
conjugated antibody.102 However, around the early 1990s, other targeted strategies were evolving 
from the emergent nanotechnology field that was conceptualised by pioneers like Richard 
Feynman a little over 30 years prior.103 The idea of building minute systems that can deliver high 
drug payloads only to the cite of action was quite appealing, and the field of nanomedicine started 
to take shape.
1.3.1. The definition of nanomedicine and nanotherapeutics
As the name suggests, the term nanomedicine came to be when nanotechnology converged with 
medicine. The prefix “nano-“ (from the Greek word “nanos”, meaning “dwarf ”) pertains objects 
and processes that are happening on the nanometre scale, i.e. one billionth of a metre.104 Because 
the size factor can be unfairly limiting to the definition of the vast discipline of nanomedicine in 
which chemistry, biology, physics, and engineering are involved, the National Institute of Health 
(NIH) gave a broader definition105 to the practices involved in nanomedicine as:
1. studies that use nanotechnology tools and concepts to study biology;
2. the engineering of biological molecules toward functions very different from those they have 
in nature; or
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3. manipulation of biological systems by methods more precise than can be done by standard 
molecular biological, synthetic chemical or biochemical approaches. 
Based on this definition, the term nanodrugs can be applied to particles on the nanoscale that can 
be used for the diagnosis, prevention, and treatment of disease, yet variations in nomenclature 
can be used to further identify nanotherapeutics whose primary purpose is the prevention and 
treatment and nanotheranostics which can also aid in diagnosing diseases. Although these names 
entail that the described entities can fall somewhere between 1 nm and 1000 nm, in the biomedical 
and pharmaceutical contexts, it is particles that are mainly under 200 nm that might be more 
clinically-relevant.104 Figure 1.4 compares the size of nanotherapeutics to biological components.
Fig 1.4. A scale bar showing the size of nanotherapeutics in comparison to biological systems.
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Nanotherapeutics have offered a promising alternative to conventional therapy. In the case of cancer, 
for example, cytotoxic drugs that are used conventionally to suppress the abnormal proliferation 
of cancer cells can also inhibit normal cells which have rapid growth rates such as those in hair 
follicles, bone marrow, and gastrointestinal tract giving rise to the common side effects associated 
with those drugs.106 The unique physicochemical characteristics of nanocarriers can help reduce 
the systemic effects of cytotoxic drugs by delivering them almost exclusively to the targeted sites 
and at the same time accumulate higher payloads at those sites in a way that conventional therapy 
cannot achieve. Moreover, nanocarriers provide another advantage over conventional therapy and 
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other forms of targeted therapy related to the antibodies and antibody-drug conjugates (ADCs) 
and that is enhancing the pharmacokinetic profile of the drug payload. Nanocarriers can prevent or 
slow down the degradation of their payload by blood enzymes as well as reduce its renal clearance 
resulting in prolonging the drug half-life and enhancing its bioavailability. Thus formulating drugs 
into nanocarriers can also resolve issues related to drug solubility as well as allow control over their 
release kinetics for added therapeutic benefits.106–108
Although nanotherapeutics has many potential clinical applications including cancer, pain 
management, and the treatment of infectious disease,109 we will look at the mechanisms, advantages, 
and utilisation from the cancer perspective, as it is the one related to the work at hand as well as 
being the one most-extensively researched.
1.3.2. Tumour microenvironment
In his “seed and soil” hypothesis, Stephen Paget proposed in the late 19th century that cancer “seeds” 
(that we now call metastases) can only grow when embedded in a suitable “soil” that provides 
protection and nutrients.110 Clinical and experimental studies in the past decades have confirmed 
that the “soil” concept applies to the cellular environment in which solid tumours grow, proliferate, 
and from which they metastasise. The non-malignant components of a tumour are collectively 
termed the tumour microenvironment (TME), and it is the exploitation of its uniqueness and 
contrast with healthy tissues that constitutes the most important aspect of targeted nanotherapy.111
TME is majorly composed of a (a) stromal scaffold that consists mainly of cancer-associated 
fibroblasts (CAFs), (b) the extracellular matrix (ECM) which is a conglomerate of macromolecules 
such as collagen and proteoglycans, (c) immune cells and other bone marrow-derived cells, and 
(d) a chaotic network of blood vasculature, each having a part in cancer growth and metastasis.112 
CAFs are previously normal fibroblasts, cells that normally promote wound healing, that have been 
activated through various carcinogenic conditions and turned into perpetually-activated immortal 
cells that resist apoptosis and boost tumorigenic activity.113 Upon their activation, CAFs form the 
framework that supports solid cancer cells. They also help generate the ECM that further define 
the physical characteristics of the tumour.114 CAFs also induces the epithelial-to-mesenchymal 
transition (EMT) process which gives rise to mesenchymal cells that do not provide the tumour 
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with the same structural integrity that epithelial cell layers have in normal tissues thus encouraging 
cancer cell invasion and metastasis.115,116 CAFs are also implicated in releasing multiple growth 
factors such as the vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and 
platelet-derived growth factor (PDGF), all of which aid in tumoural angiogenesis and the growth 
and proliferation of cancer cells.115 
The ECM also has a supportive role in the physical structure of solid tumours. It consists of the 
non-cellular components of the microenvironment, mainly the fibrous proteins like collagen, 
elastin, and fibronectin as well as the proteoglycans chondroitin sulphate, heparin sulphate, 
keratin sulphate, and hyaluronic acid, all of which help define the mechanical characteristics 
such as stiffness and deformability of solid tumours and help guide cancer cell invasion and 
metastasis.117,118 Collagen, in particular, is responsible for the stiffness of the tumour mass. While 
the stiffness of normal stroma is typically around 150 Pa, the presence of high levels of crosslinked 
collagen in the ECM of tumours causes the stiffness of tumour stroma to be about 400 Pa.119 It is 
also suspected of making structural conduits that aid in cancer cell migration.120  
In addition to the supportive role, the proteoglycan components of the ECM, especially heparin 
and heparan sulphate, are also suspected of facilitating tumour growth and metastasis by 
binding growth factors such as VEGF, PDGF, and EGF (epidermal growth factor) and acting 
as reservoirs that release those factors upon activation via growth signalling.121 It is also worth 
noting that hyaluronic acid raises the interstitial fluid pressure in the tumour mass causing an 
outward movement of fluids that prevent drugs in the main bloodstream from diffusing into the 
tumour.120,122
Other major components of the TME are immune cells that have been recruited into the location 
of cancer as a response to the inflammatory process. These cells include mast cells, neutrophils, 
natural killer (NK) cells, and most importantly, macrophages.112 Macrophages found in solid 
tumours, doped tumour-associated macrophages (TAMs), are the most prominent immune cells 
found in tumours and they can be distinguished into two phenotypes; M1 macrophages that 
are part of the normal inflammatory response of the host to the tumour, i.e. the destruction and 
phagocytosis of cancer cells, and M2 macrophages that are involved in pro-tumourigenic processes 
that encourage angiogenesis and metastasis.112,122 In invasive cancer, there is a high polarisation of 
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M1 to M2 TAMs, and it is the latter that produces growth factors and inflammatory cytokines such 
as IL-10 and prostaglandin E2 (PGE2).
112 It is also believed that those cells might be involved in 
promoting the development of the premetastatic niches thus priming the “soil” for the migrating 
cancer cells invade and form new metastatic foci.123
From all discussed above, it can be clear that growth factors are excessively produced by many 
components of the TME. This is due to the fact that those factors, among others, mediate the 
regulation of the processes that vascularise tumour tissues.112 The rapidly-growing tumour mass 
possesses a high oxygen demand that the existing vasculature continuously fails to fulfil and, as 
a result, chronic hypoxia ensues especially in the deep layers of the tumour where the oxygen 
concentration is believed to be in the range of 1-2% as opposed to 3-6% in normal tissues.122 
This leads to the activation of signalling pathways that promote angiogenesis (i.e. the formation 
of new blood vessels through branching out from pre-existing ones) and vasculogenesis (i.e. the 
formation of new blood vessels through recruiting circulating endothelial cells).124 However, due 
to the high metabolism rate of cancer cells, the resulting branching is often chaotic leading to an 
uneven lumen and a highly-fenestrated, thus leaky, endothelium causing irregular blood flow and 
a further increase in the interstitial fluid pressure (IFP) which can be 10-40 folds of that of normal 
tissues.125 All of this worsens the hypoxia and promotes the tumour development.111,126 Figure 1.5 
illustrates the composition of a solid cancer tissue.
It is also noteworthy that, due to this hypoxic state, the abnormally metabolic cancer cells depend 
on oxygen-independent glycolysis (known as the Warburg effect) to obtain energy as opposed to 
the oxidative phosphorylation that happens in normal cells. This causes the excessive production 
of lactate and carbon dioxide and the subsequent increase in proton ions concentration. The result 
is an acidic extracellular pH in the tumour (pHe = 6.5-6.9) compared to the normal physiological 
pH (7.2-7.4).127,128
These unique characteristics of the TME separate it from normal tissues, and exploiting this 
uniqueness has been an appealing catalyst for creating more effective and safer therapies. However, 
while many targeted therapy strategies fall within the field of molecular biology, i.e. the development 
and use of monoclonal antibodies that target specific components of the TME such as those that 
target growth factors, TAMs, or any of the factors that modulate the signalling pathways involved 
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in tumourigenic activities,112 we will focus on the approach related to the project at hand, namely, 
targeted nanotherapy. This approach entails formulating existing conventional therapeutic agents 
into nanocarriers that take advantage of some of the unique characteristics of the TME discussed 
above to maximise the delivery of those therapeutics to cancer foci while sparing healthy tissues 





Fig 1.5. A schematic demonstrating the differences between healthy and tumourous tissues, 
especially in regards to the enhanced permeability and retention (EPR) by which nanoparticles are 
able to extravasate into tumour tissues (B) mainly due to the fenestrations and gaps in vasculature, 
unlike healthy tissues (A) where the tight junctions between epithelial cells allow only small 
molecules to pass through.
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1.3.3. Types of targeting in nanotherapy
1.3.3.1. Passive targeting
As discussed earlier, the tumour vasculature can be contrasted with that of healthy tissue in the rate 
and manner of formation. Normally, when new capillary blood vessels form through controlled 
angiogenesis in tissues like muscles, skin, lung, heart, and the central nervous system (CNS) the 
resulting lumen wall is lined with tightly-packed endothelial cells. Those cells are held together 
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by junction proteins and thus help maintain the integrity of the epithelial walls while the tight 
junctions allow only small molecules to bypass into the surrounding tissues.129 However, the chaotic 
angiogenesis process in tumours along with the absence of the junction proteins in the tumour’s 
periphery result in large gaps within the epithelial walls that usually range in size between 380-780 
nm130 but can reach up to 1.5 µm.129 The tumour epithelial cells also noticeably have intercellular 
fenestrae (pores) that can reach up to 0.5 µm in diameters, and although some organs like the 
endocrine glands and the kidney peritubular plexus do have fenestrae within their epithelial 
cells (60-80 nm), they are still sealed by a non-membranous diaphragm (basal membrane) that 
regulates the movement of fluids and solutes without allowing big molecules to pass through, 
whereas a similar seal is lacking in the epithelial cells of tumours.129 This leakiness of the epithelial 
walls within the TME allows particles that are smaller than the gaps and fenestrae within the walls 
to permeate into the cancer tissue, and because of their size, nanocarriers circulating through the 
bloodstream can inherently escape through these openings.
Moreover, the lymphatic system that is normally responsible for clearing large particles from the 
interstitial space is also functionally impaired in the tumour microenvironment allowing the 
infiltrating nanocarriers to linger further within the tumour tissue. The combined phenomena of 
leaky vasculature and poor lymphatic drainage are termed the “enhanced permeability and retention” 
(EPR) effect.131 This effect is what gives nanoparticles their preference to accumulate in tumours 
minimising penetration to normal tissues, and it constitutes the golden standard when designing 
nanocarriers for targeted cancer therapy and, because it depends solely on the pathophysiological 
properties of the TME, this type of targeting is considered as “passive” by nature.131–133
It should be noted, nonetheless, that there is significant heterogeneity in the EPR effect within 
and between tumours, since there are differences in the pore dimensions and the structure of 
the vasculature depending on the type of the tumour and its location (primary vs metastases).134 
Furthermore, heterogeneity in the density of ECM and the different cellular components as well 
as in the coagulation and clotting in tumour vessels are some of the factors that limit the ability to 
effectively translate the EPR effect, and nanomedicine in general into the clinic.135 Some have even 
suggested that the entry of nanoparticles to solid tumours happens via active trans-endothelial 
pathways rather than through the inter-endothelial gaps.136
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1.3.3.2. Active targeting
Since all nanocarriers have some degree of passive EPR effect, active targeting cannot be separated 
from the passive targeting aspects but provides an added advantage that enhances the chances of 
nanotherapeutics to be successful in their selective targeting to cancer tissue. This can be achieved 
by using targeting ligands such as antibodies or peptides that can be recognised by cancer tissue 
cells, thus increasing their binding to and uptake by those cells.137 Two types of active targeting 
can be recognised:
1. Active targeting to cancer cells: in this type, nanoparticles can be conjugated with ligands 
that are over-expressed on cancer cells themselves. This is especially useful to enhance the 
internalisation of therapeutics into cancer cell rather than increasing the accumulation of 
nanoparticles in the tumour tissue.133 Multiple potential targets exist for this purpose, the 
most important of which are:
a) Transferrin receptors. Transferrin is a glycoprotein responsible for binding and 
transporting iron and plays an essential role in cell growth. The expression of its receptors 
in cancer cells are up to a hundred-fold higher than that of normal cells, thus conjugating 
transferrin to drug-loaded nanoparticles can boost their uptake into cancer cells by to a 
great extent.132
b) Folate receptors. Folate (vitamin B9) is essential for the synthesis of nucleotide bases and 
the subsequent synthesis and replication of DNA. Since this is crucial for cell growth and 
proliferation, folate receptors are overly expressed in most cancer cells, and thus folate has 
been widely used as a conjugate to nanocarriers to enhance their targeting capabilities.106
c) Epidermal growth factor receptors (EGFR). EGFR  has a crucial role in angiogenesis and 
the growth, proliferation, and metastasis of tumours. Antibodies that can selectively bind 
to its receptors are attractive candidates for use in the active targeting of tumours.132
d) Other specific targets. Via the use of aptamers, which are short single-stranded DNA or 
RNA sequences that can bind to specific corresponding targets on the surface of cancer 
cells.137
2. Active targeting to tumour endothelium: Nanocarriers can encounter some barriers between 
the epithelium of the blood microvessels and the deep layers of tumour cells, such as the 
presence of pericytes, smooth muscle cells or simply multiple layers of cancer cells. Conjugating 
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these nanocarriers with ligands that correspond with target receptors on endothelial cells 
enhances their chances of being internalised by the tumour.135 Not only can this increase the 
chances of nanocarriers reaching their target, but the nanoparticles can also be designed to 
release their drug load within the endothelial layer upon being taken up by its cells which can 
cause the released low-weight molecules to penetrate further within the tumour.133 Some of 
the most prominent examples of this approach are ligands that bind to the VEGF receptors in 
the epithelial cells and those that bind to the matrix metalloproteinases (MMPs).138
1.3.3.3. Stimuli-responsive (triggered) targeting 
Stimuli-responsive targeting adds more control over the delivery of therapeutics from loaded 
nanoparticles in either of their forms, the passively or actively targeted. This type of nanocarriers 
are designed to either take advantage of the unique internal features of TME like enzymatic 
composition or pH, or respond to an external stimulus like heat or a magnetic field.139
1.3.3.3.1. Internal stimuli
As mentioned before, because of the Warburg effect where excessive amounts of lactic acid are 
produced within the TME, the extracellular pH is more acidic (6.5-6.9) than normal tissues (7.2-
7.4) which has led to designing many strategies that take advantage of this difference in pH. One 
strategy depends on the hydrophobic-hydrophilic transition of materials depending on their 
protonation state.  Bae et al. used the pH-dependent reversible transition of poly-L-histidine 
(polyHis) and created stable micelles by mixing polyHis-b-PEG copolymer with poly(L-lactic 
acid)-b-PEG at a pH above 7.4 and proved that the micelles have destabilised gradually below a 
pH of 7.0.140 Other strategies include the use of polymer-drug conjugates with acid-labile bonds,141 
and the fabrication of NPs with zwitterionic features.142,143
Another internal stimulus that can be exploited to trigger the release of therapeutics is the 
enzymatic composition of the TME, which shows high selectivity to specific substrates. For 
example, Mansour et al. developed an albumin-doxorubicin prodrug that is joined together with 
a sequence-specific peptide linker that can be cleaved by matrix metalloproteinase 2 (MMP2) that 
is overexpressed in most tumours.144
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The redox potential can also be used as a trigger for drug release. The most researched in this area 
is glutathione (GSH), which is a tripeptide responsible for the reduction of disulfide linkages and 
has an intracellular concentration that is 100-1000 higher than that in the blood.145 Furthermore, 
its concentration in cancer tissues is at least 4 times that of normal ones.146 Ma et al., for example, 
exploited this by creating doxorubicin-loaded micelles from an amphiphilic block copolymer 
that had a long side alkyl chain conjugated via a disulfide group. When the micelles reached the 
tumour, the high levels of GSH cleaved the disulfide group causing a hydrophobic to hydrophilic 
transition in one of the main-chain polymers which lead to the disassembly of the micelles and 
the release of the drug.147
1.3.3.3.2. External stimuli
Many therapeutics depend on external stimuli instead of internal ones to induce the change in the 
structure of the particles that prompt the release or activation of the loaded therapeutic molecules. 
Temperature is the most typical example of such stimuli. Drug-loaded liposomes prepared using 
lipids that are rigid at normal body temperature and have higher solid-gel transition temperatures 
(usually, lipids such as dipalmitoylphosphatidylcholine that have a transition temperature of 
about 41 °C are preferred) can accumulate in the tumour after their injection into the body. Then 
an external clinically-controlled hyperthermia using water baths, electromagnets, or focused 
ultrasound is applied to the tumour site to induce the transition of the lipid bilayer and increase 
its permeation to the drug load prompting its release.148,149 Another widely used example of 
temperature-responsive nanomaterials are conjugates of poly(N-isopropylacrylamide) (PNIPAM) 
which changes from the hydrophilic coil confirmation to the hydrophobic globule conformation 
when the temperature is raised above its lower critical solution temperature (LCST) causing the 
structure of the nanocarrier to be damaged and the drug released.150
Magnetically-sensitive materials have also been extensively studied as externally-stimulated 
delivery systems. Superparamagnetic iron oxide nanoparticles (SPIONs) are a family of tiny 
magnetic nanoparticles (about 10 nm in diameters) with good biocompatibility that can be used 
as contrast agents to increase the sensitivity of magnetic resonance imaging (MRI)151 but can also 
be co-loaded into other drug nanoparticles to increase their concentration at the desired site using 
external magnetic guidance.152 SPIONs can also be used with a focused alternating magnetic field 
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to create localised heat that would help induce apoptosis to eradicate the tumour, a process termed 
“magnetic thermal ablation.”153
Light has also been used as an external trigger for the release of drugs from photo-sensitive 
nanomaterials. For example, azobenzene-incorporated DNA double strands have been 
used as switchable caps for the pores of drug-loaded mesoporous silica nanoparticles. The 
photoisomerisation of the azobenzene from trans to cis under UV and visible lights respectively 
causes the DNA double strands to hybridise/dehybridise, making the pores open and close 
on command.154 Another example is the use of UV light-triggered spiropyran-merocyanine 
isomerisation in PEGylated lipid nanoparticles to shrink their size to more than a third of the 
original size in order to allow deeper tissue penetration.155 However, these systems are limited by 
the poor skin penetration of short-wavelength light, and other systems that use near-IR with better 
penetration have been developed.156,157
1.3.4. Design considerations and biological barriers
From what has been discussed so far, it is clear that nanoparticle-based therapy offers a promising 
alternative to conventional therapy in terms of effectiveness and safety by exploiting the unique 
attributes of the TME and by the versatility of the tools that can be employed to take advantage of 
those attributes fully. Ideally, an effective nanocarrier should meet the following requirements:158
1. Formulation with biocompatible and/or biodegradable materials that in themselves and their 
by-products are harmless to the body.
2. Possess high loading capacity for the drug intended for delivery to maximise the exposure of 
the tumour and reduce the need for frequent administration.
3. Site-specific delivery mechanism of the loaded cargo to minimise normal tissue exposure.
4. Negligible or no premature release of the drug load.
Controlled release mechanism that allows precise control over the delivery of the drug to target 
tissues.Since biological systems are complex and their interaction with injected particles involves 
an array of factors that would complicate the efficacy and safety of the NPs, some considerations 
should be taken into account when designing NPs for theranostic purposes:
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1.3.4.1. Particle size
The particle size plays a significant role in the fate of nanocarriers. While small NPs (<5 nm) get 
rapidly cleared from the bloodstream through the kidneys,159 particles in the micrometre range 
(2-5 µm) readily accumulate in the pulmonary capillaries making them good candidates for the 
use in targeting metastatic tumours in the lungs.107 
Moreover, While the majority of microcapillaries in the body are lined with a discrete layer 
of endothelial cells and a basal membrane that prevents the penetration of large particles 
as mentioned earlier, the liver and spleen are an exception. The blood capillaries in these two 
organs have sinusoidal gaps that allow the spleen to filter out blood cells and the liver to take up 
chylomicrons, the lipoproteins that transport nutritional fat.129 These gaps measure about 200-500 
nm in the former and about 0.1-1 µm in the latter,160 which makes these two organs responsible for 
the nonspecific retention of particles that are >200 nm in size.
All together combined, it has been postulated that NPs with the average size of 100-200 nm could 
be good candidates as drug carriers to prolong its circulation half-life and enhance the chances of 
its accumulation in most solid tumours.107,161
1.3.4.2. Particle shape
Conventional nanocarriers used in clinical and pre-clinical settings are typically spherical, but the 
shape of NPs have been found to influence their uptake and accumulation in tumour tissues. It 
has been observed that discoid and rod-like particles are more likely to penetrate tumours,107,125,162 
and this might be determined by haemorheological factors and how NPs flow within blood 
vessels, mainly through what is known as margination dynamics. Margination is the lateral drift 
of particles towards the area (which is called the cell-free layer) near the vessel walls as opposed 
to the core of the blood vessel where red blood cells move. It is believed that spherical NPs have a 
poor lateral drift and thus have less contact with blood vessel walls and less chance to encounter 
the fenestration through which they can extravasate or encounter a vascular marker to which they 
would bind in case of active targeted NPs, unlike discoid or rod-like NPs that show a more complex 
movement that involves tumbling and rolling which causes their lateral drifting and increases the 
possibility of tumour penetration.163
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The shape also massively affect the circulation half-life of NPs. Discher et al. demonstrated that 
filamentous polymer micelles (filomicelles) had circulation lifetimes of over one week compared 
to their spherical counterparts that could be detected in the blood for only 2-3 days, which was 
attributed to the tendency of filomicelles to align with blood flow.164
1.3.4.3. Particle surface charge
The surface charge of NPs is a double-edged sword. On the one hand, it was found that neutral 
and negative surface charges reduce the adsorption of serum proteins onto the particles, thus 
increasing their circulation half-life.165 On the other hand, positively charged particles demonstrate 
better uptake by tumour endothelial cells when they come in close contact with their negatively 
charged membranes.166,167 
This can be exploited through a charge-conversion strategy by making stimuli-responsive 
zwitterionic nanoparticles that would have prolonged circulation because of their net-zero 
charge, and that would shed the anionic component upon extravasating into the low-pH 
microenvironment resulting in an accelerated uptake by the endothelial cells. For example, some 
research groups developed polymer-based NPs with both amine and carboxylate surface groups 
that give the particle its overall zero-charge. However, the carboxylate groups are linked via acid-
labile amide bonds that break in acidic conditions similar to that of the TME giving the NPs a 
positive charge that increases their interaction with the cell membrane and thus enhancing their 
cellular uptake.142,143
1.3.4.4. Mononuclear phagocytic system (MPS)
Also known as the reticuloendothelial system (RES), MPS is a collective term for the leukocytic 
cells responsible for the taking up (or “phagocytising”) and clearance of large insoluble materials 
such as cellular debris, bacteria, or nanoparticles.168 These phagocytes can be either tissue-resident 
macrophages in filtration organs such as the red pulp macrophages and Kupffer macrophages 
lining the endothelium of the spleen and the liver, respectively, or blood-circulating monocytes 
that can extravasate into any tissue and differentiate into macrophages.169
Macrophages are a significant hurdle for effective nanotherapy. When NPs enter the blood 
circulation, a wide array of plasma proteins including serum albumin, apolipoproteins, and 
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immunoglobulins (especially opsonins) adsorb on the surface of the NPs forming a protein “corona” 
that alters the physicochemical and biological characteristics of the particles and accelerates the 
opsonisation process;170 Opsonins help phagocytes recognise the attached NPs which in turn get 
phagocytised and fused with lysosomes where they undergo degradation.171
The prevalent strategy used to overcome this issue is to “stealth” NPs via PEGylation where 
polyethylene glycol (PEG) is grafted on the surface of the particles so it would form a hydration 
layer in the blood that shields the NPs from the adsorption of proteins and the subsequent 
opsonisation.172 Other common strategies involve coating the particles with CD47-derived ‘self ’ 
peptides that act as a ‘don’t eat me’ signal,173 incorporating a coating derived from the membrane 
red blood cells,174 or a leuko-like coating (derived from leukocyte membranes).175
1.3.4.5. Other barriers
Another factor that proves to be challenging is elevated IFP. In contrast to the EPR effect, high 
interstitial pressure drives fluids in an outward movement away from the tumour tissue reducing 
the ability of NPs to extravasate into it.107 One possible strategy to overcome this obstacle was 
proposed by Jain et al. -  the co-administration of the angiotensin II receptor antagonist losartan to 
enhance the accumulation of NPs in tumours by reducing the IFP via suppressing the production 
of collagen, owing to the anti-fibrotic properties of losartan.176
Another barrier worthy of note is the protein corona that forms around NPs in the bloodstream as 
it might mask targeting ligands thus reducing the efficacy of actively targeted NPs.177
1.3.5. Types of nanotherapeutics 
Many nanocarriers used to target the delivery of cytotoxic drugs can be recognised both in clinical 
practice and preclinical studies. What follows is a quick overview of the most common types of 
nanocarriers that have potentials for clinical applications and their general characteristics.
1.3.5.1. Polymer-based nanocarriers
Polymer-based NPs are a versatile and highly-tuneable form of targeted nanoparticles. They often 
offer higher in vivo stability, bioavailability, loading capacities, and more control over their release 
profiles than other nanotherapeutics.106
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1.3.5.1.1. Polymeric micelles
Polymeric micelles consist of amphiphilic block copolymers that self-assemble in aqueous solutions 
into structures comprising of a hydrophobic core and a hydrophilic shell. The hydrophobic core 
can be used to incorporate the poorly-soluble drugs while the outer shell improves the solubility 
of the micelles, thus enhancing the bioavailability of the drug and making it more suitable for 
intravenous injection.178 Self-assembled micelles typically range in size between tens and a few 
hundred nanometres making them good candidates for the targeted delivery to tumours.179 One of 
the most preferred and widely used hydrophilic polymers to form the outer shell (or the corona) is 
PEG. As well as its stealthing effect that hinders opsonisation by the MPS, PEG is highly tolerated 
by the body due to its high biocompatibility and hydrophilicity, although there has been some 
concerns regarding its possible immunogenicity in susceptible individuals.180–182 Nonetheless, 
other polymers have also been studied such as poly(vinyl alcohol) (PVP), polyethylenimine (PEI), 
and poly(N-vinyl-2-pyrrolidone) (PVP) as the hydrophilic shell, as well as poly(D,L-lactic acid) 
(PLA), poly(D,L-lactic-co-glycolic acid) (PLGA), and poly(ε-caprolactone) (PCL) for making the 
hydrophobic core of the micelles.181 Polysaccharides has also been of interest as stealthing agents 
because of their biocompatibility and the ease of chemical manipulation.183
In addition to that, polymeric micelles are very versatile systems the size and morphology of which 
are highly modifiable. Although the most common type is spherical micelles, different architectures, 
like filamentous (worm-like), rods, and disc-like micelles, can be produced depending on the 
number, ratios, and structure of the copolymers used and the method of micellisation.184
Polymeric micelles still have some drawbacks that limit their clinical applications, most prevalently, 
their instability and dissociation upon dilution.185
1.3.5.1.2. Polymeric nanoparticles
Polymeric NPs are biodegradable colloidal systems that can be either nanospheres where the drug 
intended for delivery is dispersed within the polymeric matrix, or nanocapsules where the drug 
is confined within a cavity surrounded by a polymeric membrane.186 Depending on the intended 
purpose for the NPs different approaches can be considered in their design; (a) drug molecules can 
be attached to the polymer to get a polymer-drug conjugate that can increase the bioavailability 
and prolong the half-life of the drug, (b) the drug is dissolved in an aqueous or an oily medium 
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within the cavity of the nanocapsule to increase its solubility, or (c) the drug can be incorporated 
within the biodegradable polymer matrix of the nanosphere to achieve better control over its 
release.187,188 Compared to other NPs such as polymeric micelles and liposomes, polymeric NPs 
provide better stability and more homogeneous size distribution as well as better control over 
the release profile especially in the case of nanospheres where the drug is released via diffusion 
through or the erosion of the polymeric matrix.106,189 The FDA-approved polymers that have good 
biocompatibility and biodegradability include synthetic polymers such as polyglycolic acid (PGA), 
poly(D-L-lactide-co-glycolic) acid (PLGA), polyethylene glycol (PEG), polylactic acid (PLA), and 
polycaprolactine (PCL), and naturally-occurring polymers such as chitosan, collagen, heparin, 
alginate, heparin, albumin, and dextran.190 
Abraxane® is an FDA-approved albumin-bound paclitaxel indicated for the treatment of breast, 
pancreatic, and non-small cell lung cancers. The 130 nm formulation improves the solubility of 
paclitaxel and enhances its delivery to tumours.188
1.3.5.1.3. Dendrimers
Dendrimers (from the Greek word dendron for “tree”) are highly-branched macromolecules 
consisting of polymeric chains stemming from a central core and are synthesised in a stepwise 
manner allowing a high level of control over their molecular weight, size, shape, and physicochemical 
properties.191 These particles can be used as drug carriers by either non-covalently entrapping the 
drug molecules or by chemically conjugating the drug to their structures during or after the synthesis 
of the dendrimers.192 Small drug molecules are usually encapsulated within the dendrimer’s void 
spaces while it is preferable to adsorb large molecules onto their surface.193 dendrimers show high 
promise in nanotherapy because of their controlled, step-wise synthesis that results in uniformly 
distributed particles with low polydispersity and well-defined peripheral groups.187 They are also 
highly tuneable which allows adding multifunctionality, such as incorporating different drug 
molecules, adding targeted moieties, or PEGylation to enhance solubility, dendrimers show high 
promise in nanotherapy.193
1.3.5.2. Lipid-based nanocarriers
These carriers consist mainly of lipids that are similar in composition to many physiological 
compounds, hence they are well-tolerated and very biocompatible, and they normally break down 
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to non-toxic components, which makes them very desirable means of targeted therapy.194
1.3.5.2.1. Liposomes
Liposomes have been described since the 1960s as nanovesicles consisting of at least one 
phospholipid bilayer entrapping an aqueous compartment.195 The size of the vesicles is defined 
by the manufacturing process as is the number of lipid bilayers, forming either small unilamellar 
vesicles (SUV), large unilamellar vesicles (LUV), or concentrically arranged multilamellar vesicles 
(MLV).196 Because of their biphasic nature, liposomes can be loaded with either hydrophilic drugs 
in their aqueous phase or hydrophobic drugs within their lipid lamellae, or both, offering better 
bioavailability for both sorts of drugs and showing high biodegradability and biocompatibility 
and practically no immunogenicity due to their similarity to cellular composition.187 Liposomes 
can also be modified by integrating targeting ligands or PEG into their structures enhancing their 
targeting abilities and bioavailability even further.188 The relatively easy manufacturing process 
and high modifiability made liposomes quickly find their way into clinical practice. A classic 
example is Doxil®, the first FDA-approved nanoparticle formulation in 1995 for the anticancer 
drug doxorubicin (DOX).197 This PEGylated liposomal formulation of DOX has been found to 
reduce the cardiotoxicity of the free drug as well as enhancing its availability at the cancer site by 
4-16 folds.198 
1.3.5.2.2. Lipid nanocarriers (LNs)
Solid lipid nanocarriers (SLNs) were the first generation developed of LNs. They are comprised of 
glycerides that have high melting points and are rigid at both room and body temperatures, and 
because they mimic those that are naturally found in the body, they are highly biocompatible and 
biodegradable.199 They are considered good carriers for drugs that are highly lipophilic to enhance 
their bioavailability and, because of their rigidity they offer better control over drug release.200 
They do, however, have a low drug loading capacity and they might show drug expulsion from 
the carrier during storage due to the polymorphic transformation of the lipids over time which is 
more pronounced with pure lipids as opposed to lipid mixtures which leads to instability of the 
particles and the loss of the release control advantage.201
The second generation of LNs was developed to overcome these limitations. Nanostructured lipid 
carriers (NLCs) are made of a mixture of solid and liquid lipids to create controlled structures. 
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The imperfections between the two lipids provide a space for accommodating the drug instead of 
the rigid matrix of the SLNs, which maximises the loading capacity.202
1.3.5.3. Carbon-based nanocarriers
Carbon nanotubes (CNT) are single- or multi-walled tubular networks of carbon atoms that can 
be only a few nanometres in diameters and reach up to 100 µm in length.203 CNTs are considered 
a versatile medium for biomedical applications such as drug delivery, imaging, and stimuli-
responsive therapy because of their structural, mechanical, electrical, and optical properties and 
their extensive surface area.204 CNTs can both carry the drug load in the entrapped volume within 
their walls, and they can have their surfaces functionalised for various purposes and, biologically, 
they can be taken up into cells either by endocytosis or needle-like penetration of membranes.205 
Nonetheless, because of their insolubility, they have raised toxicity concerns as they have been 
found to accumulate in the liver, spleen, and lungs of test animals.206
Carbon dots (CDs) in contrast, potentially have lower toxicity as they are less than 10 nm in all 
dimensions and thus are quickly filtered out of the blood by the kidneys and excreted into urine 
and show very little accumulation in the lungs and liver,207 and they are more biocompatible than 
conventional semiconductor quantum dots (QDs) that are based on heavy metals.208 CDs show 
potential for having applications in biosensing, imaging, and drug delivery.209
1.3.5.4. Inorganic nanocarriers
As well as QDs that are limited by their toxicity, this category includes gold-based nanocarriers 
whose plasmonic characteristics can be used for the purposes of biosensing and imaging.210 
However, even though gold was used in the past for the treatment of arthritis, there are no gold-
based NPs currently approved for clinical practice because toxicity is still an issue.188
Other particles include silica-based NPs such as Cornell dots (C-dots) are undergoing clinical 
trials as potential theranostic tools.211 Nanothem™, a formulation of superparamagnetic iron oxide 
nanoparticles (SPION) discussed elsewhere, is also undergoing clinical trials to investigate its 
efficacy and safety in the magnetic hyperthermia therapy of glioblastoma.212
38
1.3.6. NSAID-based nanocarriers
Many of the NSAID-based nanocarriers that exist in the literature focus on the making of lipid-
based formulations to enhance the skin penetration of topical NSAIDs for the management of 
pain and other inflammatory disorders.213,214 However, there are other formulations that involve 
developing NSAID nanocarrier for systemic administration, some of which are aimed at the 
management of inflammatory diseases but other also focused on cancer.
Of these systemic formulations, lipid nanocarriers are the most common. For example, Lopes-de-
Araújo et al. created oxaprozin-loaded NLCs intended for oral administration for the management 
of inflammation. The particles were also functionalised with folic acid for enhanced uptake.215 B. 
Lee et al. synthesised nano-emulsions of the NSAID flufenamic acid that produced an inhibitory 
effects on human glioma cells.216 The ketoprofen-loaded liposomes prepared by Tarţaŭ et al. 
produced a longer analgesic effect in mice than free ketoprofen, indicating that a liposomal drug 
might produce a more sustained release of the drug.217
The versatility of polymeric NPs has also allowed for the creation of different kinds of NSAID-
loaded carrier. For instance, S. Lee et al. produced a naproxen-loaded dextran NPs. In this drug-
polymer conjugate, naproxen was loaded on dextran via a boronic ester linker that is sensitive 
to the reactive oxygen species (ROS) similar to those found in inflammatory tissues.218  Zeng et 
al. used atom transfer radical polymerisation (ATRP) to build a pH-responsive amphiphilic co-
polymer in which mPEG was the hydrophilic chain while the hydrophobic chain carried ibuprofen 
molecules via ester bonds. During self-assembly, the cytotoxic drug doxorubicin was loaded in the 
core of the micelles. These NPs showed an inhibitory effect against a melanoma cell line in vitro 
comparable to free doxorubicin, and prevented also prevented metastasis to the lung in vivo.219 
Shehata et al. also developed a norbornene-derived PEG-Ibuprofen copolymers via ring-opening 
metathesis polymerisation (ROMP) for tumour targeting.220 Figure 1.6 shows the structure of 
these three polymeric systems.
NSAID-loaded magnetic NPs have also been developed for a more controlled delivery of these 
drugs. Giannousi et al. functionalized aspirin, mefenamic acid, and naproxen on manganese ferrite 
NPs and obtained different release profiles from the 10-nm NPs via PEGylation.221 Gronczewska et 
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Fig 1.6. Examples from the literature of NSAID-loaded polymers intended for targeted delievery.
1.4. Conclusion
It can be clear that nanotherapeutics demonstrate great potentials to be versatile and dynamic 
systems that would serve as alternatives to conventional therapy not only to enhance the 
bioavailability of the hydrophobic drugs and concentrate higher doses at the target tissue but also 
to widen the therapeutic window of the cytotoxic drugs and make them more tolerable and less 
harmful to healthy tissues and organs. However, even though this concept has been around for 
decades, only a handful of nanoformulations are approved for clinical use, although many more are 
undergoing pre-clinical studies to determine their safety and pharmacokinetic/pharmacodynamic 
profiles.223 An analysis done by Wilhelm et al. to determine the efficacy of NPs in published in 
literature found, after analysing 232 published data sets between 2005 and 2015, that only a median 
of 0.7% of the injected dose of NP preparations found its way to the tumour,125 which shows that 
we still have a long way to go in order to understand how nanotherapeutics interact with the 
human body so we can learn how to accurately shoot those “magic bullets” and hit the bull’s eye.
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2.1. Salicylic acid-pased polymer (polysalicylate)*
2.1.1. Introduction
In 1895, the German company Bayer tasked the young chemist Felix Hoffman with enhancing 
the efficacy and safety of the already successful salicylic acid (SA) that was being widely used as 
an analgesic and antipyretic. Hoffman, also driven by his concern for his father who could no 
longer take SA without feeling nauseous, put forth a method to acetylate the hydroxyl group on 
the molecule. Aspirin was hence born, and after two years of testing it was released to the public 
to become the most popular drug in the world.1
After its administration, aspirin is rapidly hydrolysed into acetate and salicylic acid. It is 
estimated that about 40% of an oral dose of aspirin is hydrolysed during the first-pass by hepatic 
carboxylesterases while the circulating aspirin is metabolised by the plasma cholinesterases and 
possess the half-life of about 13-20 minutes.2–4
The primary metabolite, salicylic acid, has a half-life of approximately 3-5 hours and is eliminated 
through urine and bile after being converted to its metabolites, mainly salicyluric acid (its glycine 
conjugate which constitutes about 75% of all metabolites), salicylphenolic glucuronide, salicylacyl 
glucuronide, and gentisic acid, while about 10% of salicylic acid is renally excreted without 
change.5–7 Of all metabolites, gentisic acid is the only one that is pharmacologically active.8 The 
half-life can, however, increase by up to three-folds as the plasma albumin that normally binds the 
free drug becomes saturated with repeated doses.6,9 Figure 2.1 illustrates the main metabolites of 
aspirin after its hydrolysis to salicylic acid.
Even though the pharmacological effects of aspirin are mainly attributed to the transfer of its acetyl 
group to the serine residue in the active sites of COX enzymes, thus irreversibly inactivating them, 
its longer-circulating hydrolysis by-product, i.e. salicylic acid, still exhibits anti-inflammatory 
activity through COX-dependent and -independent pathways.10,11 Moreover, it has been speculated 
that fruit, vegetable, spices and herbs that are naturally rich with salicylate might be responsible for 
the lower cancer rate in certain demographies.12,13
*Parts of this work were peer-reviwed and published in Macromolecular Rapid Communications.31
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In addition to having therapeutic properties similar to those of its parent drug, salicylic acid is a 
simple molecule with two functional groups which makes it an attractive candidate for the design 





























































Fig 2.1. Aspirin metabolites. (1) Salicylacyl glucuronide, (2) Salicylphenol glucuronide, (3) 
2,3-Dihydroxybenzoic acid, (4) Gentisic acid, (5) 2,3,5-Trihydroxybenzoic acid, (6) Salicyluric acid, 
(7) Gentisuric acid, (8) Salicyluric phenolic glucuronide. Adapted from [7]
Kathryn Uhrich and her group have developed biodegradable salicylic acid-derived poly(anhydride-
esters). These polymers, collectively patented as PolyAspirin™ (Figure 2.2a), incorporated salicylic 
acid (SA) within their backbone and were intended to be polymeric prodrugs for the use with 
diseases such as inflammatory-bowl disease and with drug-releasing bone implants.14,15 One of 
their earliest polymers was synthesised by melt condensation polymerisation of an SA-sebacic 
acid diester. The final polymer had a high loading capacity of the drug (62 wt%) and showed 
a slow in vitro degradation profile to salicylic acid and the biocompatible sebacic acid. The 
degradation rate varied depending on the pH of the medium used and took about 90 days to fully 
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degrade at pH=7 as opposed to 38 hours at pH=10 with insignificant degradation at pH=3.5.16 
Using solution polymerisation method instead of melt condensation yielded a polymer with 
similar characteristics.17 This polymer [poly(1,10-bis(o-carboxyphenoxy)decanoate) or poly-
CPD], however, had a transition temperature (Tg) of 27 °C making the polymer softer at body 
temperature and limiting its stability in biomedical devices. In order to solve this issue, the group 
co-polymerised poly-CPD with a similar one [poly(1,6-bis(p-carboxyphenoxy)hexane) or poly-
p-CPH] at different ratios through melt condensation. The resulting copolymers had higher Tg 
values than the original homopolymers (33-38 °C) but significantly lower drug loading (6-31 
wt% inversely correlated with Tg).
18 The group also experimented with changing the linker from 
sebacic acid to adipic and suberic acids and showed that it slightly affected the release profile 
of SA (100% release after 7, 6, and 10 days with sebacate, suberate, and adipate, respectively).19 
Microspheres (2 to 34 µm) prepared from similar polymers with different linkers in the polymer 
backbone showed release profiles that varied significantly. 100% of the SA was released in 20 days 
from microspheres of polymers with a linear aliphatic linker as opposed to 100% release in just 3 
days with a heteroaromatic linker, while a branched aliphatic linker caused a lag period of 10 days 
after which only 20% of SA was released in 20 days.20
Chandorkar et al. synthesised a very similar polymer (Figure 2.2b) through the melt-condensation 
of the same SA-sebacic acid monomer but with mannitol molecules instead of the end acetyl 
groups. The mannitol served as a cross-linker and resulted in an even more prolonged release of 
SA. The non-cured polymer showed an in vitro release of about 30% after 4 months at a pH=7.4 
and 37 °C while the cured version of the polymer showed a release of 3.5% in 4 months under 
the same conditions. Even though the potential application of the polymer in cancer therapy was 
suggested by the authors, only some cytocompatibility tests were conducted that proved that the 
polymer was compatible with certain murine myoblasts.21 
The Tg of these polymers, however, was 1 °C and 17 °C for the non-cured and cured polymers, 
respectively (as a result of the difference in the degree of cross-linking). Because these temperatures 
are much lower than that of the body temperature, these polymers would have high chain mobility 
at the body temperature and therefore higher degradation rate. They would, however, have high 
elasticity at temperatures above Tg and could still be useful in the development of elastomeric 
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biomaterials.22,23 Also, the addition of mannitol to the monomer decreased the loading capacity 
of the polymer almost by half (35 wt%). Nonetheless, the group has demonstrated that implants 
made of the cured polymer reduced the inflammatory response in mice over a period of 16 weeks.24
Dasgupta et al. developed a polymer similar to the last except that they used adipic acid instead 
of sebacic acid and they substituted mannitol with xylitol as the cross-linker (figure 2.2c). Using 
different ratios of the diacid and the cross-linker resulted in Tg values ranging between 17-33 
°C and hydrolytic degradation rates ranging between 4-65% in 7 days. The release rate of SA 
was affected, however, by the curing of the polymer where the non-cured polymer exhibited a 
release rate of 35% of SA as opposed to 10% of the cured polymer in 7 days at 37 °C and pH=7.4. 



























































In contrast, Cai et al. wanted to develop a polymer that not only have a higher drug loading but 
that would also degrade at a faster rate in the distal intestinal conditions so it would be useful 
in the local delivery of SA to the colon (Figure 2.2d). Their poly[bi(o-carboxyphenyl)adipate-
polyethylene glycol] anhydrides, or shortly P(BOCA-PEG), had a loading capacity ranging 
between 43.5-71.3% and exhibited an in vitro release rate of 15% in 21 hours in a medium that 
simulated the beginning of the large intestine, while less than 0.2% was released in 21 hours in 
simulated gastric conditions.26
Other attempts to create SA-based polymers for the localised and/or controlled delivery include 
incorporating SA into dendrimers,27 and creating polymer-drug conjugates such as SA-poly(vinyl 
alcohol) ester.28
While all the previous work focused on creating SA-loaded polymers that can be used for 
elastomeric biomaterials such as drug-eluting stent coatings,29 as anti-biofilm urological catheter 
coatings,30 or for the localised delivery of SA in inflammatory bowel disease and colon cancer,16 
no systemically-administered, SA-based nanocarriers for the purpose of targeting solid tumours 
were identified in the literature.
This chapter presents the work31 carried out to create amphiphilic copolymers with high payload 
and sustained release profile of SA that self-assemble into nanostructures. These nanoparticles 
(NPs) could potentially be administered intravenously as carriers for the delivery of SA into 
solid tumours, regardless of their location, by taking advantage of the uniqueness of the tumour 
microenvironment (TME) and the enhanced permeability and retention (EPR) effect as discussed 
in Chapter 1.
2.1.2. Materials and instrumentation
Polysalicylate (PSA) and PSA-b-mPEG. Salicylic acid, acetic anhydride, thionyl chloride, and 
N, N-diisopropylethylamine (DIPEA), were obtained from Acros Organics. Polyethylene glycol 
monomethyl ether was obtained from Alfa Aesar. 4-dimethylaminopyridine (DMAP) was 
obtained from Fluorochem.  
NMR spectra were obtained on a Bruker AV2 400 MHz spectrometer and were calibrated to the 
centre of the set solvent peak and chemical shifts were reported in parts per million (ppm). 
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Gel permeation chromatography (GPC) was conducted using PL-GPC 50 Plus system by Varian 
Inc. The separation media consisted of two Agilent (300x 7.5 mm) 5µm MIXED-C columns in 
series in a 40 °C oven. Refractive index (RI) detection was used and THF, stabilised with 250 ppm 
BHT, was the eluent. The flow rate was set at 1 mL/min and the sample run time was 25 minutes.
TGA-DSC was carried out in a Netzsch STA 409 PC/PG. The samples were heated from 25 °C to 
600 °C at 10 °C/min. 
FTIR spectra were recorded on a Shimadzu IRAffinity-1S with and ATR gate. A sweep of 500-4000 
cm-1 with a resolution of 2 cm-1 and 64 scans was performed.
Self-assembly. Visking dialysis tubing was obtained from Medicell Membranes Ltd. 
Dynamic light scattering (DLS) measurements were performed using Zeta Sizer Nano-ZS by 
Malvern Instruments Limited. Measurements were conducted using a glass cuvette at 25 °C. The 
refractive index RI of the dispersant (water) was set to 1.33 with the viscosity of 0.8872 cP while 
the RI for the material measured was set to 1.45. 
Zeta-potential measurements were performed in Litesizer 500 by Anton Paar GmbH using a zeta-
potential cell at 25 °C.
Transmission electron microscopy (TEM) was performed on a Jeol 1230, operating at an 
accelerating voltage of 80 kV and the images were recorded with a Gatan Multiscan 790 digital 
camera. 
Degradation. Gibco® phosphate-buffered saline and HyClone™ foetal bovine serum were obtained 
from Thermo Fisher Scientific. Lyophilised esterase from porcine liver was obtained from Sigma-
Aldrich.
Degradation studies were carried out in Mastercycler™ Pro PCR System by Eppendorf.





PSA was prepared in two steps. In the first step, SA was refluxed with 1.1-2 equivalents of acetic 
anhydride under nitrogen at temperatures ranging between 150-200 °C for varying durations of 
time (6-20 hours). In stage two, a distillation head was installed and the temperature was raised 
to 250-300 °C as vacuum was applied to remove the excess acetic anhydride and the acetic acid 
by-product over periods of time ranging between 1 and 36 hours. As the reaction vessel was 
left to cool down, a glassy amber solid formed and spontaneously cracked as it was reaching 
room temperature and was then extracted from the flask. The resulting polymer was soluble in 
dichloromethane (DCM), chloroform, tetrahydrofuran (THF), and dimethyl sulfoxide (DMSO). 
Long-chain forms of the PSA were partially soluble in acetone while the short-chain ones had 
a better solubility. PSA was practically insoluble in water, methanol (MeOH), ethanol (EtOH), 
dimethyl formamide, diethyl ether, and hexane. 
To remove residual monomers and other reactants, the polymer was dissolved in DCM and was 
then precipitated in MeOH. The precipitate was centrifuged and washed three times with MeOH 
and then dissolved again in DCM and reduced to dryness again using the rotating evaporator 
under vacuum. Further drying was achieved using high vacuum overnight.
The pure products had an amorphous brittle cotton-candy-like structure that had a white to 
yellowish colour. Yields ranged between 72 and 87%.
1H NMR (400 MHz, CDCl3) δ (ppm): 8.13 (b, n1H, ArH), 7.29 (b, n1H, ArH), 7.03 (b, n2H, ArH), 
2.17 (s, 3H, CH3), where n corresponds with the degree of polymerisation.
2.1.3.2. Polysalicylate-block-methoxy polyethylene glycol (PSA-b-mPEG)
PSA with nine repeating units of the monomer (PSA9) was conjugated with methoxy polyethylene 
glycol 1900 (mPEG-1900). An acyl chloride of PSA9 (Mn  = 668) was first obtained by refluxing 
the polymer with thionyl chloride at 65 °C overnight with a catalytic amount (5-10 mol%) of 
4-dimethylaminopyridine (DMAP). The excess of thionyl chloride was removed using the rotary 
evaporator under vacuum. The polysalicyloyl chloride was then dissolved in DCM and 2 molar 
equivalents of N,N-diisopropylethylamine (DIPEA) and 3 molar equivalents of mPEG (nominal 
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Mn = 1900) were added. The reaction was then left stirring at room temperature overnight. The 
reaction mixture was then transferred to a separation funnel and washed with 10% solution of HCl 
to remove the DIPEA and DMAP, then three times with de-ionised water and once with brine. 
The organic layer was reduced to dryness and then re-dissolved in a 1:1.5 mixture of DCM/diethyl 
ether and washed multiple times with de-ionised water and brine to remove the excess mPEG. 
The purpose of the DCM/ether mixture is to make the mPEG less soluble in the organic layer, 
resulting in its partition to the aqueous phase. The organic layer was then dried over magnesium 
sulphate and the solvent evaporated. The resulting product was dried further under high vacuum 
overnight. The resulting product was an amorphous white solid and the yield was 61%. 
 1H-NMR (400 MHz, CDCl3) δ (ppm):  8.13 (b, 9H, ArH), 7.29 (b, 9H, ArH), 7.03 (b, 9H, ArH), 
3.57 (b, 168H, CH 2CH2), 3.32 (s, 3H, CH3), 2.17 (s, 3H, CH3). 
2.1.3.3. PSA-b-mPEG self-assembly
The co-solvent method was used for the self-assembly of NPs where two sets of solutions of the 
BCP in two common solvents (THF and acetone) were prepared with two concentrations each 
(1 and 10 wt%) in separate round-bottom flasks. As the solutions were being stirred, de-ionised 
water was added dropwise in a uniform manner using a micropipette until a tenfold dilution was 
achieved. Suspensions prepared from acetone were left stirring for a few hours to remove the 
solvent while the ones prepared from THF were dialysed using Visking dialysis membrane with 
a molecular weight cut-off of 12-14 kDa. Volumes were measured before and after removing the 
solvent to keep track of and adjust concentrations accordingly.
2.1.3.3.1. Stability of vesicles
Zeta-potential (z-potential) measurement for the vesicle preparation with the final concentration 
of 1 wt% was conducted at 25 °C.
DLS measurements of the same sample were taken at different time points over a month. 
Measurements at each time point were done in triplicates and then averaged. 
2.1.3.4. Degradation of PSA
Five different media were prepared for the degradation studies; de-ionised water (pH =7-8), 
sodium hydroxide 2 mol.dm-3 (pH ≈14), phosphate-buffered saline (PBS, pH ≈7.4), 10% foetal 
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bovine serum (FBS) in PBS (pH ≈7.4), and a 36 units.mL-1 solution of porcine liver esterase (PLE) 
in PBS (pH ≈7.4). Equal volumes of degradation media were added to Eppendorf vials containing 
accurately-weighed equal amounts of PSA9. Five sets of vials were prepared in this manner for 
the five time points intended for measurement. Another five sets were also prepared but only 
contained the degradation media for blanks. This way each sample in a specific medium had a 
corresponding blank with the same medium and ran for the same amount of time. The vials were 
placed in the thermal cycler, and the temperature was fixed at 40 °C and was held at that point 
for the entirety of the experiment. At each predefined time point (2, 4, 8, 24, and 96 hours), a set 
was removed from the thermal cycler and the samples were analysed using UV spectroscopy in 
the wavelength range of 200-360 nm. Readings were carried out using the Nanodrop and each 
measurement was performed against its corresponding blank. The quantitative comparison was 
conducted by contrasting the absorbance value at the wavelength of 296 nm from the PSA samples 
with solutions of SA in the respective media corresponding to a 100% degradation of the polymer. 
The experiment was repeated at 70 and 90 °C.
2.1.4. Discussion of results
Given the potential benefits of aspirin for the chemoprevention and treatment of cancer as 
discussed in Chapter 1, the aim of this work was synthesising a polymeric prodrug based on the 
hydrolysis by-product of aspirin, salicylic acid, which also possesses similar anti-inflammatory 
properties and a much longer half-life. 
The SA-based polymers for biomedical applications that are already existing in the literature 
mainly focus on the use of such polymers in biocompatible implants for the anti-inflammatory, 
analgesic, and antiseptic effects of SA. Hence, a polymer patented by White et al.32 re-purposed to 
create a delivery system that has the following advantages over the existing polymers:
1- A higher capacity of SA, at least theoretically, since the polymer is made up entirely of the 
therapeutic molecule.
2- The ability to conjugate the polymer with another that is hydrophilic and biocompatible, such 
as PEG, to create an amphiphilic BCP which is capable of self-assembly into entities that could 
be useful for targeted therapy, especially for solid tumours.
3- A higher Tg that would delay biodegradation and provide a prolonged release of SA. 
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2.1.4.1. Polysalicylate (PSA)
The synthesis of polysalicylate (PSA) (Figure 2.3) was based on a patent by White et al.32 that 
aimed at synthesising this polymer as a capping agent for other polymers, such as polyphenylene 
ethers, with side hydroxyl groups. The author proposed that extreme conditions, such as high 
temperature in the presence of oxygen, can cause discolouration and brittleness of these other 
polymers. Inactivating such groups using polymers with high glass transition temperatures can 







Fig 2.3. The proposed structure of polysalicylate (PSA).
Herein, PSA is re-purposed to be used in a nanoparticle-based formulation since this polymer was 
solely comprised of repeating units of salicylic acid (SA) thus eliminating the need for polymeric 
backbones that would otherwise occupy the bulk of the particle. This will eventually lead to an 
increase in the drug payload of the nanocarriers. Another advantage of this polymer would be that 
SA units are exclusively linked by ester bonds that are potentially hydrolytically and enzymatically 
biodegradable.33 It is speculated that the slow hydrolytic degradation would offer relative long-term 
stability in an enzyme-free medium, i.e. during the storage of NPs, while it becomes accelerated by 
endogenous enzymes upon delivery to target tumours.
Even though the patent followed for making the PSA had adequate details about synthesis, the 
information about the structure is somewhat vague. The reaction mechanism is not discussed but 
it is indicated in the document that the specified conditions result mainly in linear polymers with 
one end acetyl group for each 15-50 repeating units of salicylate. Nonetheless, by comparison with 
similar polymers in the literature16–18 the reaction mechanism can be speculated. 
Figures 2.4 illustrates the possible reaction scheme. During the first stage of the reaction, refluxing 
salicylic acid with acetic anhydride at high temperatures yields acetylation on the hydroxyl and 
the carboxyl groups depending on the reaction stoichiometry. In the second stage, heating the 
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reaction mixture at temperatures above 200 °C under reduced atmospheric pressure initiates melt 
condensation polymerisation through anhydride elimination. If the acetic anhydride is used in 
excess during the first stage of the reaction, the yield would be mainly compound (a), i.e. methyl 
o-acetoxybenzoate, and the resulting polymer (c) would have an acetyl group at both ends. 
However, because only 1.1 to 2 equivalents are used, the yield is likely to be a mixture of compounds 
(b), i.e. aspirin, and (a) since acetylation happens favourably on the phenolic hydroxyl first. As a 
result, polymerisation of the two monomers is more likely to yield a polymer (e) that has acetyl on 
one terminal and a carboxyl on the other. It is also worth noting that very high temperatures can 
result in cyclic polymer species (d).






































Moreover, the reaction may go through another pathway as the salicylate–anhydride (f) resulting 
from monomer (b) undergoes rearrangement driven by the energy from the high temperature to 
form a more thermodynamically-stable ester (g).17 Figure 2.5 illustrates the possible mechanism 
of the rearrangement.
It might also be worth mentioning that acetic anhydride is necessary for the production of 
monomer (a) and as a reaction medium. An attempt was made to polymerise aspirin by heating 
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it to high temperatures. Aspirin did not polymerise but instead it sublimed and condensed again 
at the neck of the flask.











































Gel permeation chromatography (GPC)/size exclusion chromatography (SEC) and 1H-NMR were 
used to characterise the synthesised polymers. 
The average molecular weights and the polydispersity values of the polymers were determined 
using GPC. Results were reported mainly using number average molecular weight (Mn), weight 
average molecular weight (Mw) and dispersity (Ð).
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Mn is defined as the sum of the molecular weight of all species by their mole fractions:
M n Mn i i
Where ni is the mole fraction (or number of molecules) of the species i that has a molecular weight 
of Mi.
Mw is defined as the sum of the molecular weight of all species by their weight fractions:
M w Mw i i
Where wi is the weight fraction of the species i that has a molecular weight of Mi.
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1H-NMR was also used to characterise the synthesised polymers. The spectra showed broadening 
of the peaks of the aromatic region (6.9-8.3 ppm) indicative of polymerisation. The integration of 
the peak centred at 8.13 ppm, belonging to the protons on the ortho position to the carboxyl group 
on the aromatic rings in the polymeric chain, with the protons of the end acetyl group at 2.17 ppm 

















Fig 2.6. The 1H-NMR spectrum of polysalicylate
Typically, two DP values can be obtained from GPC data; the number average DP (DPn = Mn/M0) 
and the weight average DP (DPw = Mw/M0) where M0 is the molecular weight of the monomer. In 
contrast, 1H-NMR can provide information only about Mn since the areas under the resonance 
peaks in the spectra are proportional to the molar concentration of the species in the analysed 
sample.35 Table 2.1 exhibits some of the polymers obtained by varying reaction temperatures and 
summarises the data obtained from 1H-NMR and GPC for each polymer.
Since GPC depends on separating polymer species based on their hydrodynamic volume rather 
than their molecular weight, and due to the difference in nature between the analysed polymers 
(PSA) and the standard polymers used for calibration (polystyrene), this method is prone to 
significant errors.35 This can be seen in the differences in the reported degree of polymerisation 
between those obtained from GPC measurement and their counterparts that are calculated from 
1H-NMR integrals in Table 2.1. The trends, however, are still comparable, and while 1H-NMR 
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integrations are better for calculating the average number molecular weight of the polymers, GPC 
remains the main tool for determining their dispersity.
# PSAn Reaction temp Mn Mw Ð DPn
1 PSA9
140 °C – 3h
668 1055 1.58 5
220 °C – 3h
2 PSA17
140 °C – 3h
1767 2752 1.56 13
220 °C – 6h
3 PSA22
140 °C – 6h
2344 3444 1.47 17
250 °C – 36h
4 PSA11
150 °C – 6h
1063 1597 1.50 8
250 °C – 18h
5 PSA29
200 °C – 20h
1962 3053 1.56 14
250 °C – 26h
6 PSA15
200 °C – 20h
1876 2701 1.44 13
250 °C – 24h
7 PSA18
280 °C – 12h
3339 4927 1.47 24
280 °C – 1h
8 PSA19
220 °C – 12h
1504 2436 1.62 11
220 °C – 1h
n: the number of SA units (degree of polymerisation) calculated via 1H-NMR integrals.
DPn: degree of polymerisation calculated from Mn obtained by GPC.
Table 2.1. Different polymers obtained by varying reaction temperatures at both stages of the 
polymerisation reaction.
Nonetheless, it should be noted that using NMR integration to calculate the degree of 
polymerisation of the desired PSA, has its drawback in the case of PSA since these calculations 
might be complicated by the formation of species other than the linear PSA with an acetyl group 
on one end and a carboxyl on the other, such as the bi-acetylated chains, cyclic chains, or even 
poly-anhydride (as opposed to the polyester) species.
The data in Table 2.1 demonstrate that the overall temperature and reaction time are directly 
correlated with the length of the resulting polymers (especially when looking at DPs calculated 
from NMR analyses which, as discussed above, is more representative of Mn  and DP than data 
obtained from GPC). This is in agreement with the literature.32 Additionally, a few observations 
can be made when comparing reaction conditions between phase A (the formation of acetylated 
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monomers) and phase 2 (polycondensation). At moderate temperatures (140-150 °C) in phase A, 
the polymer length appears to be mainly determined in phase B, such is the case with polymers 1, 
2, and 3 where increasing the reaction time and temperature in phase B accelerated chain growth 
and resulted in longer polymer chains. However, increasing the reaction time and temperature of 
phase A to around 200-280 °C,  produced long polymer chains regardless of reaction time in phase 
B, such as in the case of polymers 7 and 8. This could be due to the fact that increasing reaction 
time and temperature in phase A produced more acetylated species (Figure 2.4 a and b) which 
expedited polycondensation in phase B.
The significant variation between DP obtained from 1H-NMR and GPC for some of the synthesised 
polymers could be explained by the formation of species other than the target polymer. In polymer 
5, for example, the prolonged reaction times at high temperature might have produced more 
cyclic polymer species than the linear one which resulted in a weaker acetyl signal in the 1H-NMR 
spectrum leading to false integration. On the other hand, the difference in DP between polymers 
7 and 8 as determined by GPC despite the similarity in DP determined by 1H-NMR could be a 
result of the presence of linear species with two end acetyl groups (one on each end), which causes 
a stronger acetyl signal in the 1H-NMR spectrum and another false integration but in the opposite 
direction to the one from the previous example.
Finally, it is worth noting that very high temperatures do not only result in cyclic chains, but they 
can also cause reversible thermal depolymerisation.17 This could explain the difficulty in attaining 
longer polymer chains even with prolonged reaction times, such as the case in polymers 3, 5, and 
6, for example.
2.1.4.2. PSA-mPEG BCP
Besides its function as the hydrophilic segment of the BCP that is essential for self-assembly, 
mPEG complements the assembled morphologies with added therapeutic advantages. The 
PEGylation of NPs enhances their pharmacokinetic profile by increasing their solubility, reducing 
their renal clearance due to the increase in size, and protecting them from being eliminated from 
the bloodstream via the reticuloendothelial system (RES).36,37
Since PEG is a non-biodegradable polyether, some issues have lately been raised concerning its 
safety. There are some concerns about the possible accumulation in cells and tissues upon repeated 
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administration of PEG-containing NPs and the possible immunogenicity in susceptible individuals, 
yet no clinical evidence is so far available to support such concerns.38,39 However, PEG remains the 
gold standard for increasing the biocompatibility and half-life of nanopharmaceutics and it has 
been widely used in clinically-approved formulations since the early 1990s.40 PEG clearance is 
mainly renal for PEGs that are less than 30 kDa, while higher chains primarily undergo biliary 
excretion.41
In this work, it was speculated that the presence of an end carboxyl group on the PSA would enable 
the production of PEGylated NPs without the need for a linker molecule. Conjugating mPEG with 
the PSA through esterification would create the amphiphilic chain necessary for self-assembly 
while connecting the therapeutic element with its shield via an ester bond that is cleavable by 
esterases that are widespread throughout the body. 
To preserve the ester groups of the polymer, a mild approach for esterification was necessary for 
making the PSA-mPEG conjugate. Steglich esterification, a common method for making such 
esters using a carbodiimide, was first adopted but failed after many attempts. After some tweaking, 
the method that worked involved converting the carboxylic acid to its more reactive species, acyl 
chloride, and then using DIPEA as the hydrogen chloride scavenger to make the ester. Figure 2.7 
summarises the reaction scheme for the preparation of the block copolymer (BCP).
Fig 2.7. Reaction scheme for making the BCP. Step (1) involves making the acyl chloride. Step (2) is 


















(2) mPEG / DIPEA
DCM
The formation of the BCP was always first investigated using GPC via comparing the differential 
molecular weight distributions (DMWDs) of the BCP with those of the individual homopolymers. 
DMWD describes the contribution of different polymer species to the overall molecular weight of 
the polymer and is expressed by plotting the weight fractions (dwt/dLogMi) of polymers having 
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the molecular weight of Mi (where i is the number of the repeating units in any given species) as a 
function of LogMi.




Polymer Mn Mw Ð
PSA 668 1055 1.58
mPEG-1900 2344 2490 1.06
BCP 2998 3315 1.11
Fig 2.8. Differntial molecular weight distributions (DMWDs) of polysalicylate (PSA), methoxy 
polyethylene glycol (mPEG), and the block co-polymer (BCP).
When comparing the DMWDs of the BCP and the individual homopolymers a shift in the curve 
of the BCP on the x axis is noted due to the emergence of new polymer chains that are longer 
than those in both PSA and PEG, which indicates a successful copolymerisation. The Mn of the 
copolymer was 2998, Mw was 3315, and Ð was 1.11. 
1H-NMR was also used to characterise the BCP (Figure 2.9). Integrating peak 5 that belongs to the 
salicylate chain with the PEG peak yielded a ratio of 1:1.3 suggesting a successful PEGylation with 
some residual PEG that could not be removed from the final product with the washing mixture.




































Conjugation was also confirmed by comparing the FTIR spectra of the homopolymer and the 
BCP (Figure 2.10). The broad weak peak at ~3050 cm-1 corresponding to the carboxylic acid O-H 
stretch of PSA was replaced by the intense peak at ~2890 cm-1, arising due to C-H stretches in the 
mPEG chain.
Fig 2.10. FTIR spectra of PSA and PSA-mPEG
Thermal analysis was also performed for the homopolymer and the BCP (Figure 2.11). The 
DSC calorigram of the PSA shows the glass transition temperature (Tg) at around 100 °C. The 
endothermic peak that follows indicates the melting temperature (Tm) to be around 225 °C and 
the exothermic peak of decomposition starting around 450 °C. For the BCP, an endothermic peak 
at the beginning of the calorigram indicated the melting point of the residual mPEG. Tg and Tm 
for the BCP were hard to identify because their peaks were complicated by the exothermic peak 
of cold crystallisation. An exothermic decomposition peak similar to that of the PSA could also 
be identified.
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Fig 2.11. Thermal analysis (DSC and TGA) of PSA and the BCP
The drug loading capacity (LC) of the BCP is defined by the percentage of the drug in the polymer 






Where md is the mass of the drug in the polymer, and mtot is the weight of the whole polymer.
As discussed before, the PSA used for the synthesis of the BCP consisted of 9 units with the molar 
mass of the monomer being 138.121 mg.mol-1. The mass of the BCP calculated from its structure 
is about 3145 mg.mol-1. Therefore, the approximate LC of SA of the synthesised BCP is:
LC x x(%) . %9 138
3145
100 39 5
Numerous attempts were made to create BCPs with higher SA payloads by using longer PSA 
chains and shorter PEGs (PEG-550 and PEG-750). The conjugation, however, was not always 
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straightforward regardless of the esterification and purification methods used. Figure 2.12 shows 
some of the attempts to make BCPs with higher loading of SA.
Fig 2.12. DMWDs for some of the BCPs synthesised with different PEG chains.
A
B
In Figure 2.12A, for instance, BCPs with either PEG-1900 or PEG-750 could be made, as shown 
by the shift in the DMWDs, but the shoulders on the peaks indicate that there is still some 
residual PSA that could not be esterified and neither could it be removed from the BCP using the 
conventional purification techniques. The presence of the homopolymer complicate self-assembly 
as it precipitates in aqueous solutions. Figure 2.12B shows a PSA sample that could hardly be 
esterified with any chain length of PEG in spite of long reaction times (days).
A possible explanation for the incomplete or unsuccessful copolymerisation is the steric hindrance 
to the carboxyl group by the bulk of the polymer, which was the reason for the use of the acyl 
chloride form of the polymer.
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Another possible cause is that some of the prepared polymers are either cyclic or have their both 
ends capped by acetyl groups. In retrospect, by examining the 13C-NMR spectrum of one PSA 


















Fig 2.13. 13C- and 1H-NMR spectra of a possible cyclic PSA.
2.1.4.3. Self-assembly
Dynamic light scattering (DLS) was used for the size analysis of the self-assembled particles. 
Measurement was done in triplicate and then averaged. Samples prepared from the THF solutions 
showed a mean particle size ranging between 250-300 nm, while the ones prepared from the 
acetone solutions were about 25 nm in size. Figure 2.14 shows the size distribution of NPs in all 
four samples by intensity, number, and volume.
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Fig 2.14. DLS size distribution of the four preparations and their corresponding correlograms


















The concentrations used for both solvents had no apparent effect on the self-assembly. The results 
from the four samples can be summarised in Table 2.2.
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Preparation Z-average (d.nm) PdI
Size distribution (d.nm)
Intensity Std dev Number Std dev Volume Std dev
A 291.4 0.137 338.5 132.8 243.1 104.3 396.0 160.9
B 236.0 0.139 303.0 107.4 229.8 87.67 340.0 127.8
C 23.19 0.247 22.71 6.537 15.48 3.774 18.25 5.311
D 26.88 0.366 21.87 5.812 15.61 3.648 18.11 4.975
Table 2.2. Summery of size distribution data from DLS for the four self-assembly preparations.
Self-assembled morphologies were also examined using transmission electron microscopy 
(TEM). Samples were deposited on Formvar-coated copper grids and left to dry, and then they 
were negatively stained with 1% uranyl acetate for better contrasting. Figures 2.15 and 2.16 exhibit 
TEM images for the morphologies self-assembled in THF/water and acetone/water, respectively.
Fig 2.15. TEM images of self-assembled morphologies in THF/water.
n=30
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Fig 2.16. TEM images of self-assembled morphologies in acetone/water.
n=30
The morphologies resulting from the self-assembly of BCPs is theoretically governed by many 
factors, mainly the degree of polymerisation, Flory-Huggins interaction parameters (χ), and the 
volume fraction (f) of polymers relative to one another.45,46
Flory-Huggins parameter (χ) describes free energy and phase behaviour of polymer mixtures in 
the solutions and can be experimentally and mathematically calculated but its complexity increases 
as the number of the components in the system.47 Self-assembly of (A-B) copolymer in a solvent-
nonsolvent (S-N) mixture, for example, involves six χ parameters; χAB, χAS, χAN, χBS, χBN, and χSN, 
where each parameter determines the compatibility of one of the components with each of the 
other components in terms of solubility, miscibility, swelling, and molecular interactions. These, 
however, are challenging to measure and model.45,47
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A more practical approach to explain the self-assembly behaviour is via the packing parameter 






where v is the volume of the hydrophobic chain, a0 is the optimal area of the head group, and lc is 
the length of the hydrophobic tail.48 Adjusting the factors that affect p, such as the composition and 
concentration of the BCP, the common solvent, water content, and additives can result in different 









⅓ ≤ p ≤ ½
Low curveture
½ ≤ p ≤ 1
A
B
Volume fraction of polymer A (fA) increases
Fig 2.17. Packing parameter (p) and its effect on the self-assembly behaviour. Multiple factors affect the 
volume fraction of the core polymer A (fA) and, subsequently, the packing paramater. Low values lead to 
sperical morphologies (1). As p value goes up, other morphologies like rods (2) then vesicles and lamellae 
(3) emerge. Adapted from [37].
In this work, self-assembly of the synthesised di-BCP was investigated in two solvent-nonsolvent 
systems, THF and acetone, each at two different concentrations, 1 and 10 wt%, of the BCP. The 
reasoning behind choosing these two common solvents is their differences in dissolving PSA 
(THF which was a good solvent for all chains versus acetone that dissolves only low chains) as well 
as having two different dielectric constants (ε = 7.5 for THF and 21 for acetone). It has also been 
demonstrated that these two solvents might produce different particle sizes on self-assembly of 
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BCPs depending on the chain length of each polymer.49 In terms of concentrations used, the two 
points were chosen on the basis of preserving the potential therapeutic value of the NPs by not 
going below 0.1 wt% (after dilution during self-assembly) and avoiding high concentrations that 
would complicate self-assembly through possible precipitation. 
While concentration did not have a role in the structure of the formed particles in the same solvent 
system, changing the common solvent resulted in a significant change in the size and morphology 
of the particles. DLS data shows a hydrodynamic diameter of around 25 nm for particles self-
assembled in acetone/water versus 250-300 nm for those self-assembled in THF/water, both 
with Gaussian distribution. This was corroborated with TEM imaging with negative staining that 
showed spherical particles with similar diameters to those observed by DLS.
The differences in these morphologies can be explained in relation to the packing parameter (p) 
which is controlled by a force balance between three factors; the stretching of the hydrophobic 
polymer in the core, the surface tension between the core and the outside solvent, and the repulsion 
among the corona chains. Since the mPEG chains that constitute the corona of the particle are 
relatively long, its effect will be stronger than the other forces and it could be the main determinant 
of the morphology of the assembled particles.
In the case of the acetone/water system, acetone has a relatively high dielectric constant which 
causes the PEG chains to be relatively charged increasing the repulsion forces among these chains. 
This, in turn, increases the volume of the corona domain leading to more curvature upon self-
assembly and the formation of spherical micelles (Figure 2.17). Since the corona chains are much 
longer than the core chains, the formed morphologies are “star-like” micelles as opposed to “crew-
cut” micelles that would result from a configuration in which the hydrophobic chain is longer than 
the hydrophilic one.50 
On the other hand, using a common solvent with a lower dielectric constant, like THF, reduces 
the inter-chain repulsion in the corona which decreases the effective volume of the corona and 
increases the volume fraction of the core polymer. The results in reducing curvature and causes the 
formation of bigger morphologies such as rods and, in this case, vesicles.45
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Dissolution of the core polymer in the common solvent also plays a role in the morphologies 
resulting from self-assembly. During the addition of water, the solvent is still present in the 
hydrophobic domain, and if the core polymer has good solubility in this solvent, the core polymer 
chains will still have high mobility which leads to increased stretching and therefore and increased 
volume fraction of the core chains. Also, because of the high mobility of the chains in THF, the 
window between the critical water content (CWC, i.e. the amount of water corresponding with 
the critical micelle concentration, CMC), and the point at which morphologies become frozen is 
broad, which increases the chance for morphologies to change from spheres to rods and vesicles 
before the structures are frozen.51 However, to better understand the relationship between the core 
polymer and the solvent and its effect on the self-assembly behaviour, the solubility parameter of 
PSA needs to be identified and compared in different solvents.
The vesicular nature of the morphologies formed in the THF/water system can be furtherly 
affirmed by the deformations that appear on some of the particles. In fact, it is common to 
encounter deformities such as slight indentations on the vesicles, or the vesicles appearing as 
stomatocytes or “kippah” structures. During preparation, the increase in water content, especially 
during quenching, causes an increase in water concentration outside the vesicles as opposed to 
their inside. This causes the diffusion of the solvent to the exterior of the vesicle and the water to its 
interior, but since the diffusion of the solvent through the hydrophobic portion of the wall is faster 
than that of the water, this creates a negative pressure inside the vesicle leading to indentations or 
the formation of stomatocytes. By the time the pressure has stabilised, the Tg of the hydrophobic 
part of the wall would have reached a level sufficient to preserve the vesicle in its deformed state.52 
Kippah deformations are especially encountered when vesicles are subjected to high vacuum 
without freezing, as the case in traditional TEM.53 Figure 2.18 shows some of the deformations 
encountered with the synthesised vesicles.
Given their size and structure, the self-assembled vesicles seemed to be fitting for the main 
objective of the project for multiple reasons; firstly, the mean size of the vesicles is around the 
preferable size for particles that are intended for passive drug delivery to solid tumours through 
the EPR effect. Secondly, the particles have a PEG shell that would provide a hydration shield in 
biological fluids that would enhance the half-life of the particles. And finally, the internal phase of 
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the vesicles can be re-purposed to obtain added benefits from the particles such as entrapping the 
monomer in the internal phase to increase the payload of SA, loading another therapeutic agent 
as a combination therapy, adding a diagnostic agent so the NPs would serve a theranostic tool, 
or a combination of the above. This, of course, requires further investigation as any additional 
components in the solvent/nonsolvent system could influence the self-assembly process and 
produce different morphologies or affect the size of the vesicles.
Fig 2.18. Some deformations observed on the vesicles. The images at the top 
showing indented and collapsed vesicles, while the images at the bottom show 
stomatocyte-like deformations.
Vesicles were hence the focus of the biological studies in Chapter 4, and for this reason, their 
stability was monitored over time. z-potential of the colloidal suspension was close to zero (-2.58 
mV) which indicated poor colloidal stability.54 The low charge in this buffer is expected since the 
outer shell of the corona consists manly of methoxy groups and the pH of the dispersant was close 
to 7. Nonetheless, DLS measurements of the same sample were consistent over the period of one 
month at room temperature and no change in size was recorded, which dismisses aggregation. 
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Only fine sedimentation was noted and simple reconstitution was all that was required before 
measurements. This could be explained by the robustness of the vesicular wall due to the high Tg 
of the PSA as well as the relatively high melting point of the mPEG used (52 °C) which helped 
preserve the structure of the particles. Figure 2.19 illustrate the z-potential of the vesicles and their 
size distribution change over time.
Fig 2.19. (A) zeta-potential measurement of vesicles prepared from THF/water. (B) Size distribution 
change over time as a function of intensity.
A B
2.1.4.4. Degradation studies
Degradation of the PSA was investigated in biological and non-biological conditions. Water was 
used as a simple medium, 2 M NaOH as a strong alkaline hydrolysis agent, PBS as a simple buffer 
resembling that of biological fluids without their enzymatic components, FBS that mimics blood 
serum with its protein components, and PLE as a pure biological esterase.
Degradation was first investigated at 40 °C, close to normal average body temperature. In all media, 
except for NaOH, degradation was negligible. In the alkaline medium, SA release was noted in 
the early stages of the experiment with about 15%. More than half was released after 8 hours and 
degradation was complete after 24 hours. Figure 2.20 shows PSA degradation UV spectra in all 
media at 40° C.
To accelerate release from other media, the experiment was repeated at 70 °C. Degradation was 
again negligible in all media except for NaOH. This time, nearly half of SA was released after 2 
hours and degradation was almost complete after 8 hours. Figure 2.21 shows PSA degradation UV 







Fig 2.20. PSA degradation in different media at 40 °C. PBS: phosphate-buffered saline, FBS: foetal 







Fig 2.21. PSA degradation in different media at 70 °C. PBS: phosphate-buffered saline, FBS: foetal 
bovine serum, PLE: porcine liver esterase.
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A third experiment was conducted at 90 °C. This time, a mediocre release of no more than 5% and 
11% in water and PBS, respectively, was noted by the end of the experiment while the degradation 
was complete in NaOH after the first two hours. Figure 2.22 shows PSA degradation UV spectra 
in all media at 90° C.
What is worthy of note is that the polymer degraded by almost half in both FBS and PLE even 
though it would be expected that temperature would render hydrolytic enzymes inactive through 
denaturation. Nonetheless, it has been demonstrated that denaturing might have complicated 
pressure-dependent kinetics and that moderate pressure could prevent the inactivation of 
enzymes.55 Since degradation experiments took place in the thermal cycler where there was a 
certain degree of increased pressure within the test vials, it is possible that similar kinetics preserved 
the enzymatic activity although it was not practically possible to measure it.
Furthermore, a possible explanation for why high temperature boosted the release of SA from the 
polymer is that polymers with high Tg have restricted chain mobility.
22 Increasing the temperature 
near to the Tg of PSA, which is around 100 °C, increased the chain mobility and accelerated the 
hydrolysis kinetics which promoted the release of SA.
Even though degradation was only possible in extreme conditions within the timeframe of the 
experiment, it might still be an indication that SA release could happen sustainably. This could be 
clinically beneficial if the PSA-loaded NPs were to reach solid tumours and be trapped within for 
prolonged periods of time through the EPR effect.
With the successful synthesis and characterisation of PSA-based NPs, this part of the project came 
to an end in order to allow time for the exploration of other possible polymeric nanodelivery 
systems; polyphosphoesters. Nonetheless, both PSA and the PSA-mPEG self-assembled NPs 








Fig 2.22. PSA degradation in different media at 90 °C. PBS: phosphate-buffered saline, FBS: foetal 




Natural polyphosphoesters (PPEs) exist in all life forms since they constitute the structural 
backbone of the genetic material and they have a crucial role in the storage and release of energy 
in the biology.56
In contrast with other degradable linking groups, such as carboxylic acid esters, phosphoesters are 
the nature’s selection when it comes to groups that are generally stable in physiological conditions 
yet degradable on demand. For example, genetic material needs to have stable enough linkage 
to preserve the genetic code throughout the life of the organism yet hydrolysable in a controlled 
manner when needed, and this is what is observed with phosphoester linker in living cells.57 DNA 
and RNA, which are natural PPEs, owe their stability in their aqueous environment mainly to 
their phosphoester backbone. The negative charge of the phosphate groups makes the ester more 
resistant to hydrolysis.58 The phosphate groups also help DNA bind to positively charged proteins 
called histones which stack together and ultimately coil into chromatin fibres. This process helps 
pack two metres of double-strand DNA inside the nucleus of the human cell.59 
Natural phosphorus anhydrides are crucial for energy transfer and in metabolism. Adenosine 
triphosphate (ATP), a phosphorus anhydride conjugate, is considered the energy currency of the 
cell. Energy is reserved in the covalent bond between the phosphate groups, i.e. the pyrophosphate 
group, and is released when the bond is hydrolysed and ATP is converted to ADP, the diphosphate 
form. Likewise, the cell store energy by converting ADP to ATP.60 Phosphate is also a part of 
the structure of the nicotinamide adenine dinucleotide (NAD+/NADH) redox system that has an 
important role in metabolism.61 Compared to carboxylic anhydrides, the negative charge on the 
phosphorus anhydrides gives them kinetic stability by slowing down the hydrolytic attack of water 
and other nucleophiles, yet they are thermodynamically unstable which, in the presence of proper 
catalysts (i.e. enzymes like phosphatases) drives chemical processes to completion.58
It is also worth mentioning that phosphate and its corresponding acids are an important part of 
the biological buffer system, and that inorganic polyphosphate is potentially involved in essential 
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blood coagulation and bone formation processes, hence phosphate is regarded as biologically 
benign, and in a degradable polymer system would be ‘traceless’. 62,63 Figure 2.23 illustrates some of 
the important phosphorus-containing biomolecules.
Fig 2.20. Prevalent natural PPEs that are essential for biological functions. RNA: ribonucleic acid; 
DNA: deoxyribonucleic acid, NADH/NAD+: nicotinamide adenine dinucleotide redox pair. ATP: 




























































































































































The prevalence of phosphate and its derivatives, phosphoric acid esters in particular, in humans 
gives synthetic PPEs a potential therapeutic value in terms of creating polymeric prodrugs that 
are biodegradable with low toxicity profile. Since phosphorous in phosphoric acid can form three 
stable divergent groups, it is possible to not only form stable polyesters but also functionalise the 
PPE with other moieties through side-chain modification. In this case, the moieties of interest are 
therapeutic agents.
Historically, PPEs are used as industrial flame-retardant additives to plastics but in recent years 
there has been an increasing academic interest in these polymers for biomedical applications. 
PPEs can be synthesised via multiple methods, the most important of which are:56,57,64
1- Polycondensation: The most widely used method to prepare general-purpose PPEs. It 
usually involves reacting phosphoric or phosphonic acid or their dihalide derivatives with 
a diol. However, the side reactions and the formation of cyclic polymers reduce the yield 
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and the molecular weight of the desired polymers. Incorporating functional groups post-
polymerisation is also challenging.
2- Polyaddition: Typically, by reacting phosphoric acid dichlorides with bisepoxides or bisoxetans 
using onium salts as catalysts. This method results in PPEs with reactive chloromethyl 
pendant groups. However, the limitations of the starting materials make this method less 
popular compared to other methods.
3- Ring-opening polymerisation (ROP): Starting from a cyclic phosphate monomer, a catalysed 
ring-opening polymerisation can produce PPEs that differ in their hydrophilicity profiles 
depending on the pendant groups. The development of controlled (living) polymerisation 
mechanisms has allowed the production of not just linear, but branched, hyperbranched and 
cross-linked PPEs.
Because of their biocompatibility, degradability, and potentially-low toxicity, PPEs have been 
considered as a promising platform to overcome some of the challenges related to pharmacological 
therapy such as solubility, drug bioavailability, and targeted delivery. In fact, Wurm and his group 
demonstrated that nanocarriers coated with polyphosphoesters, specifically poly(ethyl ethylene 
phosphate) or PEEP, exhibit a stealth effect similar to that observed with PEG through the 
hydration shell that forms around the nanocarriers. This novel ‘PPEylation’ technique might prove 
superior to PEGylation in terms of safety since PPEs are degradable, unlike PEGs.65,66
The research regarding the synthesis of PPE-based therapeutics using the conventional 
polycondensation method is limited since, as discussed above, it could yield different side reaction 
and cyclic product. Conjugating drug molecules with the PPE backbone post-polymerisation 
is also difficult and requires certain conditions. Bogomilova et al. (Figure 2.24a), for example, 
managed to conjugate the anti-cancer drug melphalan to a PPE backbone under Atherton-Todd 
reaction conditions. The resulting PPE-melphalan conjugate had better water solubility and 
reduced toxicity while the drug’s therapeutic efficacy was preserved.67 
On the other hand, the literature is full of examples relating to ROP as it remains the preferred 
method in the synthesis of PPE-based biomaterials due to the ease of conjugating active moieties 
and the high structural control it allows as well as yielding polymers with high molecular weights 
and low polydispersities.56 
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Fig 2.24. Some examples from the literature of PPEs in therapeutics. Only (a) is made via post-
polymerisation modification and its purpose is to increase the solubility of the conjugated drug, 
melphalan. All the other examples are synthesised via ROP and they self-assemble to make NPs for 
the purposes of targeted therapy. In (b) and (c), the drug is part of the amphiphilic chain, while (d) 




































































































Using this method, a wide array of drug-loaded NPs have been synthesised. For example, Zhang et 
al. (Figure 2.24b) used the anti-tumour drug, paclitaxel (PAX), as the initiator for the ROP reaction 
to create a PAX-PEEP conjugate that could then self-assemble into polymeric micelles with the 
drug being at the core of the micelles.68 Wang and his group had different approaches in designing 
delivery systems for anti-cancer drugs. On the one hand, they created a PEG-PEEP copolymer 
via ROP then conjugated the cytotoxic drug, doxorubicin, on the pendant groups through labile 
hydrazone bonds (Figure 2.24c). The BCP was amphiphilic and could self-assemble into micelles.69 
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On the other hand, they also used ROP to make BCPs that did not have the therapeutic moiety 
in the polymer structure (Figure 2.24d). Instead, the BCPs comprised of poly(ethylene glycol)-b-
poly(ε-caprolactone)-b-poly(2-aminoethyl ethylene phosphate). This PEG-PLC-PPEEA cationic 
amphiphilic triblock copolymer self-assembled into micelles that had a positive surface charge 
that could be used to load anti-cancer small interfering RNA (siRNA) after the self-assembly.70 The 
group also used the same method to create multifunctional micelles that are capable of delivering 
both siRNA and PAX, the latter being loaded in the micelles’ core during self-assembly.71 ROP has 
also been used to create non-ionic, anionic, cationic, and zwitterionic micelles by manipulating 
the pendant groups on the phosphorus atom of the cyclic phospholane monomer precursor.72
The only example that could be found in the literature related to the use of PPE-based NPs for the 
delivery of NSAIDs was of a ROP-synthesised PPE amphiphilic copolymer that self-assembles 
in aqueous conditions into micelles that are used to encapsulate the NSAID naproxen (Figure 
2.24e).73 
In this section of the project, the prospect of using ROP to make a PPE that has ibuprofen (IBU) 
linked to it through pendant ester groups for the targeted delivery of the NSAID was explored.
2.2.2. Materials and instrumentation
4-Isobutyl-α-methylphenylacetic acid (ibuprofen), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 
and 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC HCl) were obtained 
from Alfa Aesar. Solketal, benzyl alcohol, and phosphorus oxychloride were obtained from Acros 
Organics. 4-dimethylaminopyridine (DMAP) was obtained from Fluorochem. 
NMR spectra were obtained on a Bruker AV2 400 MHz spectrometer and were calibrated to the 
centre of the set solvent peak and chemical shifts were reported in parts per million (ppm). 
Gel permeation chromatography (GPC) was conducted using PL-GPC 50 Plus system by Varian 
Inc. The separation media consisted of two Agilent (300x 7.5 mm) 5µm MIXED-C columns in 
series in a 40 °C oven. Refractive index was used for the detector and THF, stabilised with 250 ppm 




2 equivalents EDC in dry DCM was added to a well-stirred solution of  IBU in dry DCM in an ice 
bath. 2 equivalents of DMAP was added to the reaction mixture and then 3 equivalents of solketal 
was added as well. The reaction was left stirring overnight. The solvent was then removed and the 
mixture was re-dissolved in di-ethyl ether and washed with 2M HCl, then three times with water 
and once with brine. The organic layer was dried over magnesium sulphate, filtered, and dried in 
vacuo to leave a colourless viscous liquid (97% yield). 1H NMR (400 MHz, CDCl3) δ (ppm): 7.20 
(d, J = 8.1 Hz, 2H), 7.09 (d, J = 8.4 Hz, 2H), 4.24 (m, 1H), 4.12 (m, 2H), 3.95 (m, 1H), 3.73 (qd, J 
= 7.2, 1.1 Hz, 1H), 3.63 (m, 1H), 2.44 (d, J = 7.2 Hz, 2H), 1.84 (dt, J = 13.5, 6.8 Hz, 1H), 1.50 (d, 
J = 7.2 Hz, 3H), 1.35 (d, J = 12.6 Hz, 6H), 0.89 (d, J = 6.6 Hz, 6H). 13C NMR (100 MHz, CDCl3) 
δ (ppm): 174.62, 140.75, 137.60, 129.46, 127.26, 109.81, 73.60, 66.30, 64.85, 45.12, 30.29, 26.71, 
25.52, 22.48, 18.54.
2.2.3.2. Deprotection (glyceryl ibuprofen)
The product from the previous step was mixed with 30 mL of 80% acetic acid for 20 min. The 
formation of the diol was tracked using a TLC plate. After the conversion was complete, di-ethyl 
ether was added and the mixture was moved to a separation funnel. The organic layer was washed 
with saturated potassium carbonate solution, water, and brine. The organic layer was dried over 
magnesium sulphate, filtered, and dried in vacuo to leave a colourless viscous liquid (89.9% yield). 
1H NMR (400 MHz, CDCl3) δ (ppm): 7.19 (d, J = 8.1 Hz, 2H), 7.10 (d, J = 8.2 Hz, 2H), 4.12 (m, 
2H), 3.82 (m, 1H), 3.73 (q, J = 7.2 Hz, 1H), 3.55 (m, 1H), 3.43 (m, 1H), 2.51 (s, 2H), 2.44 (d, J = 7.2 
Hz, 2H), 1.83 (dt, J = 13.5, 6.8 Hz, 1H), 1.49 (d, J = 7.2 Hz, 3H), 0.89 (d, J = 6.7 Hz, 6H). 13C NMR 
(100 MHz, CDCl3) δ (ppm): 175.24, 140.86, 137.41, 129.49, 127.10, 70.07, 65.41, 63.18, 45.03, 
30.21, 22.39, 18.32.
2.2.3.3. Cyclic phosphate-ibuprofen ester monomer
In a flame-dried, three-neck round-bottom flask, 15 mL of dry toluene was stirred under an influx 
of nitrogen and the reaction flask was cooled to around -10 °C using an ice/salt bath. Glyceryl 
ibuprofen (1 mmol) in 5 mL of dry toluene was added slowly and simultaneously with phosphorus 
oxychloride (1 mmol) in 5 mL of dry toluene to the flask and was then left stirring for 4 hours. The 
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reaction was then quenched with about 50 mL of dry MeOH and stirred overnight. The solvent 
was then evaporated and the product was further dried in vacuo to leave a yellowish transparent 
viscous liquid. 1H NMR (400 MHz, CDCl3) δ (ppm): 7.17 (m, 2H), 7.09 (m, 2H), 4.16 (m, 1H), 
4.02 (m, 2H), 3.74 (m, 5H), 3.50 (m, 1H), 2.44 (m, 2H), 1.83 (dt, J = 13.4, 6.7, 3.1 Hz, 1H), 1.49 (m, 
3H), 0.89 (m, 6H). 13C NMR (100 MHz, CDCl3) δ (ppm): 175.34, 141.00, 137.54, 129.62, 127.26, 
70.19, 65.58, 63.27, 54.57, 52.16, 45.12, 30.33, 22.50, 18.76. 31P NMR (160 MHz, CDCl3) δ (ppm): 
2.48.
2.2.3.4. ROP of the cyclic monomer
In a flame-dried round-bottom flask, the cyclic monomer (280 mmol) was dissolved in 10 mL of 
dry DCM and stirred. The flask was cooled to 0 °C in an ice bath, and then benzyl alcohol (2.8 
mmol) in dry DCM and DBU (4.2 mmol) in dry DCM were added to the flask and left to stir for 
6 hours.
2.2.4. Results and discussion
2.2.4.1. Ibuprofen-solketal ester
The proposed polymer comprised of phosphoester polymer with IBU linked to the phosphate 
groups of the chain through pendant ester groups. Since ROP provides the possibility of attaching 
the therapeutic molecule to the monomer through the prospective pendant groups, it was logical 
to have this as a starting point rather than making the PPE then doing a post-polymerisation 
modification. 
Two main things had to be considered towards the making of the monomer that will be used for 
polymerisation. Firstly, a simple diol carbon chain whose hydroxyl groups are separated by two 
or three carbons in order to make the five- or six-member cyclic phosphate needed for the ROP. 
Secondly, the chain must also have a functional group to attach the IBU through a bond cleavable 
in biological conditions. Since IBU has one functional group which is a carboxyl group, an ester 
linker was believed to be the most suitable for this purpose, especially that the ester group is 
inherently biocompatible and could degrade through hydrolysis to release the drug under certain 
biological conditions. Therefore, glycerol seemed to be the most appropriate choice for making the 
molecule that linked IBU to the cyclic phosphate. Glycerol is also naturally-occurring and is used 
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by many tissues for the biosynthesis of triglycerides (or triacylglycerols), the major energy storage 
form, and by the liver for the gluconeogenesis, i.e. the production of glucose.74,75
Hence, the final degradation products of the proposed polymer would be the drug and two benign 
components, phosphate and glycerol, which is optimal for a drug delivery system.
Since esterification was required on one hydroxy group while the other two were supposed to 
be preserved for making the cyclic phosphate, it was necessary to temporarily protect two of the 
groups before esterification. This was attempted by converting glycerol to solketal (2,2-dimethyl-4-
hydroxymethyl-1,3-dioxolane) via the condensation of glycerol with the readily available acetone.
Glycerol was refluxed with an excess of acetone and p-toluenesulfonic acid was used as a catalyst. 
To push the reversible reaction towards the favourable direction, the reaction was done in toluene 
with a Dean-Stark apparatus attached to continuously remove water from the reaction medium. 
Purification was then attempted via fractional distillation (boiling points are 189 °C and 290 °C for 
solketal and glycerol, respectively) and multiple attempts failed to separate the solketal.
It was then found to be more efficient to use the commercially available solketal. Esterification of 
solketal with IBU was straightforward and it was achieved via Steglich esterification using EDC 
and DMAP (Figure 2.25).











Esterification was investigated using 1H-NMR of the final product after purification. Integrating 
the peak at 1.35 ppm belonging to the two methyl groups on the solketal end with either the side 
methyl at 1.49 ppm or end methyl groups at 0.89 ppm belonging to the ibuprofen showed an 
coupling of 1:1.05 indicative of a highly pure product. Figures 2.26 and 2.27 exhibit the 1H-NMR 
and 13C-NMR spectra of the ester, respectively.
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Acid hydrolysis was used to obtain the diol after the esterification of IBU. Different agents in 
different conditions were investigated to achieve complete deprotection of the hydroxyl groups and 
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progress was tracked using TLC plates. At first, the compound was stirred at room temperature for 
a few hours with different concentrations of hydrochloric acid (1, 2, and 3 M) but the deprotection 
was incomplete in all three cases. Increasing the temperature to 50 °C did not give better results. 
Fearing that increasing the temperature any further with HCl will cause the hydrolysis of the IBU 
ester, acetic acid was used instead. At room temperature, mixing the compound with 80% acetic 
acid yielded barely any noticeable deprotection, but refluxing the mixture at 130 °C for 20-30 
minutes resulted in the full deprotection of the diol (Figure 2.28).











1H-NMR analysis of the pure product exhibited the complete disappearance of the peak at 1.35 
ppm of the two methyl groups that belonged to the solketal and the emergence of a single peak at 
2.51 ppm representing the deprotected hydroxyl groups. The integration of the this peak with the 
end methyl groups of the ibuprofen was approximately 1:3 indicating the presence of two hydroxyl 
protons and, therefore, complete deprotection. Figures 2.29 and 2.30 illustrate the 1H-NMR and 
13C-NMR spectra of glyceryl ibuprofen, respectively.










































































The best candidates to use as monomers for ROP when making PPEs are five- and six-member 
strained cyclic phosphoesters, and although both tri- and pentavalent phosphorus can be used, 
it is worth noting that trivalent monomers can only be polymerised using cationic initiators 
while pentavalent ones are polymerisable by a wider array of mechanisms (anionic, cationic, 
organocatalysis, metallic catalysis).57
The cyclic phosphoester polymer (CPM) was synthesised by reacting the glyceryl ibuprofen diol 
with phosphoryl chloride using equimolar concentrations while slowly adding the two compounds 
simultaneously at a slow rate to a cold flask to ensure that the end product is a cyclic phosphoester 
rather than a linear di-phosphoester (Figure 2.31). 
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Since the remaining chloride on the cyclic phosphoester was not needed for making pendant 
groups with any specific function in the final PPE, the pendant arm was capped with a methoxy 
group that would presumably have a minimal effect on the PPE solubility.76 A bulkier group 
would also hinder the accessibility to the ester groups which delays hydrolysis and the subsequent 
drug release. Typically, this reaction is done using methanol with the presence of a base such as 
triethylamine or pyridine,77 but due to the sensitive nature of the ester bond that attaches the 
IBU to the cyclic phosphoester, the reaction was only quenched with methanol and left to stir for 
several hours.
1H-NMR analysis of the CPM exhibited the appearance of a new peak around 3.7 ppm corresponding 
to the methoxy group. Since it was difficult to isolate the methoxy peak from other surrounding 
peaks, integration was calculated for the whole region between 3.30 and 4.21 ppm which contains, 
in theory, the peaks of nine protons. Integration value was 8.27 (Figure 2.32). 13C-NMR spectrum 
exhibited peaks corresponding with the target CPM molecule (Figure 2.33).


































31P{1H}-NMR analysis, on the other hand, was not indicative to any specific phosphate species as 
the spectrum showed a single peak at 2.48 ppm (Figure 2.34). Compared with the literature, the 
chemical shift for a cyclic phosphate with a pentavalent phosphorus is around 20 ppm, although 
these examples are of simple cyclic phosphate molecules.78,79







































The synthesis of PPE through ROP was pioneered by Penczek and co-workers in the 1970s 
through different anionic, cationic, and enzymatic pathways, but it was not until later that well-
defined polymers with controlled molecular weights could be achieved through metallic catalysis 
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and organocatalysis.77 Since a metal catalyst is not favourable for the synthesis of PPE intended for 
biomedical applications, an organocatalyst, DBU, is used instead. This kind of catalysis also allows 
good control over the molecular weight and polydispersity of the polymers.80
A simple alcohol is used as an initiator for the ROP. The organocatalyst acts as an acceptor to 
the hydroxyl proton of the alcohol. The nucleophilic oxygen will, in turn, attack the P=O double 
bond followed by the breaking of one of the single P-O bonds and the opening of the ring. The 
newly-formed nucleophilic oxygen at the end of the chain will then propagate the polymerisation 
reaction on other cyclic monomers and the reaction can be eventually terminated by the addition 
of an acid.81
In this work, benzyl alcohol was used as the initiator, and the reaction was done with the molar 
ratio of 100/1/1.5 for CPM/DBU/Benzyl alcohol (Figure 2.35). The reaction was monitored using 
GPC, 1H-NMR, and 31P-NMR.





















Even after several hours of running the reaction, no peaks could be detected when analysing the 
reaction mixture by GPC. NMR spectra did not show any significant changes either. It would 
be expected, if polymerisation was successful, that the 1H-NMR spectrum would exhibit peak 
broadening and the 31P-NMR would show new peaks indicative of the presence of PPE as such 
polymers usually show resonances at δ < 0.00.77
The most probable explanation for the failure of the polymerisation is that the synthesised 
monomer is not a cyclic phosphate. In fact, the 31P-NMR peak of the monomer spectrum falls in 
a range that could include other phosphorous species of which that is of relevance are dichloro- 
phosphoester, i.e. O=P(OR)X2, and chloro- diphosophoester, i.e. O=P(OR2)X.
104
Having low yields and impure cyclic monomers with the method used here (with phosphorus 
oxychloride) is indeed mentioned in the literature as a common issue. This is why the often used 
method in making CPMs is via using phosphorus trichloride for ring closure and the subsequent 
oxidation via heating in benzene with oxygen influx.57,77 This method was not followed for safety 
concerns. Another explanation for the possible absence of a CPM is the poor stability of the highly 
strained five-membered CPMs which requires cautious handling.79 The time limit of the project 
did not allow for further attempts to optimise the polymerisation reaction.
2.3. Conclusion
Based on the potential role of salicylic acid as a chemopreventive and chemotherapeutic agent, 
the synthesis of polymeric prodrugs that have high payloads of the active moiety was investigated. 
An already existing salicylic acid polymer was re-purposed in a manner that was not tried before. 
An amphiphilic BCP (PSA-mPEG) was synthesised and could self-assemble in water to create 
different morphologies with different sizes. The assembled NPs were within the desired size range 
for the targeted therapy of solid tumours through the EPR effect. They also possessed a PEG shield 
that would prolong their circulation half-life and enhance the pharmacokinetic profile of the active 
drug. The polymeric core proved to be degradable in different biological and non-biological media 
in accelerated conditions. This suggests that degradation in vivo might happen at a much slower 
rate, which is favourable for the sustained release of the drug in tumours leading to even lower 
toxicity, less frequent administration, and a better preventive role against metastasis.83
The loading capacity of the synthesised NPs for SA could still be possibly improved by using longer 
homopolymer chains. The main barrier against making BCPs with longer polysalicylate chains 
was possibly the formation of cyclic chains or double-capped chains that prevented conjugation. It 
was implied in the patent adopted to make the polymer that temperature was the main parameter 
that determined the characteristics of the desired polymer, but it appears that the stoichiometry of 
the reaction might be quite as important.
Nonetheless, the synthesised NPs still possess a potential therapeutic value and some of the 
structures made, namely vesicles, can be probably exploited to load more of the monomer or in 
other approaches such as combination therapies and theranostics.
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An attempt was also made to synthesise a polyphosphoester loaded with ibuprofen through 
pendant ester groups. It was believed that such a polymer would make a good delivery vehicle 
for ibuprofen since PPEs are a promising tool for targeted therapy due to their characteristics 
that makes them very biocompatible and highly modifiable especially when synthesised via ring-
opening polymerisation. The first steps making the monomer for polymerisation were optimised to 
produce pure products with high yields but, unfortunately, making the cyclic monomer necessary 
for ROP requires special conditions and cautious handling. Due to time limitations, this part of the 
project could not be advanced further.
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Chapter




Liposomes are spherical vesicles comprising of one or more concentric lipid bilayers that entrap 
one or more aqueous compartments. They were first described in the 1960s and have been gaining 
an increasing interest as drug delivery vehicles, especially in cancer therapy, due to their unique 
physicochemical characteristics.1 They can be used for the delivery of hydrophilic and/or lipophilic 
agents and they can range in size from tens of nanometres to several micrometres. However, only 
those with sizes within the range of 50-450 nm have an actual medical use, and with over 20 
commercialised liposomal formulations and many more in clinical trials they are considered the 
most successful nano-delivery system to date.2,3
The lipid layers of liposomes are comprised of amphiphilic phospholipids. Each phospholipid 
molecule is composed of a glycerol backbone with one of its hydroxyl groups phosphorylated and the 
other two esterified with long-chain fatty acids that can be saturated or unsaturated. The phosphate 
is also esterified on one of its other oxygens with a variety of molecules such as ethanolamine, 
glycerol, choline, serine, or inositol, to get different phospholipids; phosphatidylethanolamine, 
phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, and phosphatidylinositol, 
respectively. The glycerol backbone and the attached phosphoester form the hydrophilic head of 
the phospholipid, while the fatty acids form the lipophilic tail (Figure 3.1).4,5
In aqueous solutions, the phospholipid molecules assemble as bilayer membranes in which the 
hydrophilic heads are facing outwards while the hydrophobic chains face each other to create 
the inner compartment of the membrane. These membranes then form closed structures. The 
architecture is held together and stabilised mainly via two types of interactions; the first is the 
van der Waals forces between the tail chains, and the second is the hydrogen bonds and polar 
interactions between the aqueous environment and the hydrophilic heads of the phospholipids.2,6
The composition of liposomes, especially when natural lipids are used, makes them non-toxic 
and biodegradable with a very low chance of inducing immunogenicity, in turn making them 
among the most biocompatible nano-delivery systems.7 They are also among the most versatile 
systems due to their dual nature since they allow the loading of hydrophilic drugs in their aqueous 
compartment and the embedding of hydrophobic drugs in their lipid membrane. They can also be 
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loaded with different types of molecules at the same time for combination therapy or theranostic 
purposes.8,9 Liposome-NP hybrids have also been developed where other types of NPs such as 
iron oxide NPs, quantum dots, and polymer-based NPs have been incorporated in liposomes to 
















Fig 3.1. The basic anatomy of a liposome. The phospholipid shown, as an example, is 
dipalmitoylphosphatidylcholine (DPPC) comprising of phosphatidylcholine esterified with two 
palmitate groups.
Traditional (plain) liposomes are inherently passively-targeted at solid tumours via the EPR effect 
discussed in Chapter 1 due to their size and they can be used as-is for targeted therapy. However, 
various modifications have been introduced to liposomes to enhance their bioavailability as well as 
make them more actively targeted and/or responsive to internal or external stimuli to obtain better 
therapeutic outcomes. This can be achieved either by modifying the head group of the lipid, using 
different combinations of lipids, incorporating certain materials in the lipid layer or the aqueous 
compartment, or a combination of the above.11 
For example, liposomes can be grafted with PEG to provide a hydration shield against opsonisation 
proteins and stealth them from the RES to enhance their circulation half-life, which is the case 
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of many liposomal formulations that are available in the market.4,12 For more active targeting, 
transferrin- or folate-coupled liposomes might accumulate more preferentially in tumours where 
transferrin or folate receptors are overexpressed.13,14 Antibodies can also be either bound to or 
anchored into the lipid membrane to create immunoliposomes that have a higher selectivity 
in targeting towards cells with the corresponding antigen.11 For an externally-guided approach 
in targeting, magnetic liposomes (loaded with magnetite in addition to the therapeutic agent) 
demonstrated better accumulation in tumour tissues where a magnetic field is applied.15 Finally, 
stimuli-responsive liposomes have also been developed by incorporating stimuli-sensitive (mainly 
pH-sensitive) materials in the liposomal formulation.16 Figure 3.2 illustrated the different types of 
modifications that can be used with liposomes.
Fig 3.2. Some of the different types of liposomes that has been developed. Water-soluble drugs 
(a) can be loaded in the aqueous phase of the liposome while hydrophobic molecules (b) 
can be embedded in the lipid bilayer. Liposomes can also be used for the delivery of DNA by 
either entrapping it within the liposome (c) or anchoring it to the surface by using positively-
charged phospholipids (d). Diagnostic labelling agents can also be either encapsulated within 
the liposomes (e) or conjugated to its surface (f). The circulation half-life of liposomes can be 
extended by stealthing them with a polymer like PEG (g) and they be more actively targeted by 
conjugating specific ligands (h) like folate or transferrin, or by attaching specific antibodies to the 
liposome (i). Further control on the behaviour of liposomes can be exerted by the incorporation 
of stimuli-responsive materials such as thermoresponsive lipids or polymers (j) or the addition of 










The versatility and biocompatibility of liposomal formulations attracted much attention as excellent 
candidates to increase the bioavailability of poorly soluble drugs, reduce the toxicity of drugs with 
a narrow therapeutic index, and develop a targeted approach in therapy, especially in cancer. The 
very first NP-based formulation approved by the FDA for clinical use was Doxil®, a PEGylated 
liposomal intravenous formulation of the cytotoxic drug, doxorubicin, for the treatment of Kaposi’s 
sarcoma and ovarian and breast cancers. This formulation was associated with a significant increase 
in the accumulation of doxorubicin in tumour tissues compared to the conventional free drug as 
well as a decrease in cardiotoxicity, the main adverse effect of doxorubicin.17
Cytotoxic drugs are not the only class of drugs that have been incorporated into liposomes 
and neither is the intravenous route the only method by which liposomes can be used. For 
example, AmBisome® is a liposomal amphotericin B that is used for the treatment of invasive 
fungal infection while reducing the renal toxicity of the drug.18 Epaxal® and Inflexal® are two 
intramuscular ‘virosomal’ formulations in which liposomes are used as more tolerable adjuvants 
than aluminium hydroxide that is used in their conventional counterparts for the vaccination 
against hepatitis A and influenza, respectively.19,20 Depodur™ is a third example where liposomes 
loaded with morphine sulphate are injected epidurally providing an extended release of the drug 
for a more controlled approach to pain management.21
Nonetheless, with all the advantages that liposomal formulations have, there are a few drawbacks. 
These include the low colloidal stability of such formulations, especially on long-term storage, 
causing the leakage of the active materials or the fusion of liposomes to form larger vesicles, the 
oxidative damage that phospholipids might undergo under certain conditions, the high cost of 
production, and the challenging large-scale manufacturing of such formulations.22,23
There is a multitude of methods by which liposomes are prepared. What follows is a brief outline 
of the most common preparation methods:2,5,22–24
1. The film hydration method. Also known as “Bangham method” which is the first and one of the 
still widely used methods for the preparation of liposomes. It involves the hydration of a thin lipid 
film with aqueous media. However, it produces large and nonhomogeneous multilamellar vesicles 
(MLVs) that require post-processing to obtain liposomes with the desired attributes.
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2. The reverse-phase evaporation. This method involves two steps; first, the aqueous medium 
is slowly introduced to an excess of an organic solvent that contains the lipid followed by 
sonication to produce inverted micelles. In the second phase, the organic solvent is removed 
under vacuum and the micelles come together to form a gel-like matrix that, at a critical point, 
collapses as some of the micelles are disrupted and their components rearrange around the intact 
micelles to form liposomes. This method yields a better encapsulation efficacy than the film-
hydration method, but it is not suitable for organic solvent-sensitive materials, such as peptides. 
3. The solvent-injection method. In this method, the organic phase which contains the lipid is 
injected in excess of the aqueous phase, then the solvent is removed via evaporation. This method 
has similar advantages and disadvantages to the reverse-phase evaporation method.
4. The detergent-depletion method. In this method, a lipid film is hydrated with a detergent to 
form micelles. The detergent is then removed, and at a critical lipid-to-detergent ratio, liposomes 
are formed. This method effectively produces unilamellar liposomes, but it is rarely used because 
of its low encapsulation efficacy.
5. The microfluidic-based method. Which is a relatively new method that uses microfluidic 
channels to allow a highly controlled mixing of phases to obtain the desired vesicles.
It should be noted that most of the methods mentioned above produce vesicles with different 
sizes and lamellarity, such as large unilamellar vesicles (LUVs) and multilamellar vesicles (MLVs) 
and post-formation processing, such as sonication and membrane extrusion, is required to obtain 
liposomes with specific size, homogeneity, and lamellarity.2 It is also worth noting that although 
that the most common technique to load drugs into liposomes involves dissolving them in either 
phase prior to preparation (i.e. direct loading), empty liposomes can also be prepared with drugs 
then being remotely loaded into them.25,26
There are plenty of examples in literature in which liposomes are used for the encapsulation of 
NSAIDs. However, the purpose of most of these formulations is either to enhance the penetration 
of the drug through the skin when used topically, or to enhance the bioavailability and provide 
a sustained release of the drug when given orally or injected locally, such as the formulations 
intended for intra-articular injection for the management of osteoarthritis.27–30 Fewer formulations 
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that are intended for systemic application to take advantage of the EPR effect could be identified. 
These included liposomal formulation of diclofenac, flurbiprofen, and celecoxib.31–33
Regarding the salicylates group of NSAIDs, there exist in the literature multiple liposomal 
formulations for various purposes. For example, Bhalerao et al. made SA-containing liposomes 
to enhance SA penetration of the skin for the treatment of acne and dry skin conditions.34 Kwon 
et al. synthesised aspirin-containing liposomes to enhance skin penetration for the treatment of 
inflammatory conditions.35 They failed, however, to provide information regarding encapsulation 
efficacy or the release profile of the liposomes but instead used the liposomal suspension as-is 
after encapsulation for the in vitro studies. For cancer-targeting purposes, Park et al. developed 
liposomes loaded with metformin and sodium salicylate as a combination therapy. However, their 
work also was lacking in terms of liposome characterisation and stability studies and the focus was 
mainly on in vitro studies.36
Lichtenberger et al. recently made a formulation of aspirin (and another of indomethacin) with 
phosphatidylcholine (PC) and tested their anti-tumour activity.37,38 Interestingly, even though 
those formulations were prepared using the traditional film-hydration method, they were not 
deemed as liposomal, or at least lipid-based vesicular, nanocarriers. Instead, they were only named 
PC-NSAID preparations (and were even patented as such), and the anti-tumour activity was 
investigated directly after preparation (with no characterisation, release profile, etc.) in vitro and 
in vivo (orally) against colorectal cancer. 
Since salicylic acid was the focus in making a polymeric anti-cancer prodrug in Chapter 2, a 
conventional liposomal salicylic acid formulation was attempted in this chapter as another form 
of nano-delivery systems of the NSAID for comparison with the polymeric vesicles. 
3.2. Materials and methods
Salicylic acid (SA) and aspirin, were obtained from Acros Organics. Phosphatidylcholine (PC), 
cholesterol, and calcium acetate were obtained from Sigma Aldrich.  1,2-dipalmitoyl-sn-glycero-
3-phosphocholine (DPPC) was obtained from Avanti Lipids. Gibco® phosphate-buffered saline 
(PBS) and sodium sulphate were obtained from Fisher Scientific. Visking dialysis tubing was 
obtained from Medicell Membranes Ltd.
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Avestin Liposofast Extruder was used for vesicle extrusion. The polycarbonate membranes (pore 
size 100 nm) used in the device were obtained from Sigma Aldrich.
Dynamic light scattering (DLS) measurement were performed using Zeta Sizer Nano-ZS by 
Malvern Instruments Limited. Measurements were conducted using a glass cuvette at 25 °C. The 
refractive index (RI) of the dispersant (water) was set to 1.33 with the viscosity of 0.8872 cP while 
the RI for the material measured was set to 1.45. 
Zeta-potential (z-potential) measurement for the vesicle preparation with the final concentration 
of 1 wt% was conducted at 25 °C.
High-performance liquid chromatography (HPLC) measurements were conducted on a Dionex 
UltiMate 3000 system equipped with a C18 column in a 30 °C oven. The mobile phase was 
composed of 75% water, 25% acetonitrile, and 0.1% formic acid. The flow rate was set to 4 mL/min 
and the injection volume was 10 µL. UV detection was used at a wavelength of 234 nm.
3.3. Experimental
3.3.1. PC liposomes by direct loading (freeze/thawing)
A solution of the lipid in chloroform was added to a round-bottom flask and then dried using the 
rotary evaporator to create a thin film of the lipid. The film was further dried in vacuo for 24 hours. 
The film was then hydrated with a 2-3 mg/mL solution of SA in PBS to get a final concentration of 
about 25 mM of the lipid. The flask was then subjected to 5-7 cycles of freeze-thawing by moving 
it between a dry ice/acetone bath and warm water. The resulting suspension was passed back and 
forth an odd number of times (between 19-23) through two stacked polycarbonate membranes 
with a pore size of 100 nm using the extruding device. The suspension was dialysed using a Visking 
dialysis membrane with PBS as the dialysis medium. The medium was changed after 2 hours, 8 
hours, and 24 hours.
3.3.2. PC liposomes by direct loading (sonication)
The same procedure mentioned above was used to make the liposomes except that the hydration 
technique used was sonication for 30 minutes in an ultrasonic water bath instead of freeze/thawing.
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For the lipid:cholesterol (PC:chol) preparations, the film was prepared from a mixture of PC and 
cholesterol at a molar ratio of 70:30%.
3.3.3. DPPC liposomes by direct loading 
A solution of the lipid in chloroform was added to a round-bottom flask and then dried using the 
rotary evaporator to create a thin film of the lipid. The film was further dried in vacuo for 24 hours. 
The film was then hydrated with a 2-3 mg/mL solution of SA in PBS to get a final concentration 
of 15 mM of the lipid. The content of the flask was sonicated for 30 minutes in an ultrasonic water 
bath set at 50 °C. The resulting suspension was passed back and forth an odd number of times 
(between 19-23) through two stacked polycarbonate membranes with a pore size of 100 nm using 
the extruding device submerged in a water bath set at 50 °C. The suspension was dialysed using a 
Visking dialysis membrane with PBS as the dialysis medium at room temperature. The medium 
was changed after 2 hours, 8 hours, and 24 hours.
For the lipid:cholesterol (DPPC:chol) preparations, the film was prepared from a mixture of DPPC 
and cholesterol at a molar ratio of 70:30%.
3.3.4. DPPC liposomes by remote loading
A solution of the lipid in chloroform was added to a round-bottom flask and then dried using the 
rotary evaporator to create a thin film of the lipid. The film was further dried in vacuo for 24 hours. 
The film was then hydrated with 5 mL of a 120 mM solution of calcium acetate (pH = 7.47) to get 
a final concentration of 10 mM of the lipid. The content of the flask was sonicated for 30 minutes 
in an ultrasonic water bath set at 50 °C. The resulting suspension was then passed back and forth 
an odd number of times (between 19-23) through a stack of two polycarbonate membranes with 
a pore size of 100 nm using the extruding device submerged in a water bath set at 50 °C. The 
suspension was then brought to room temperature and then filtered using centrifugal filters. The 
filtrate was washed three times with a 120 mM solution of sodium sulphate (pH = 6) and then 
extracted from the filters. The filtrate was then resuspended in a 3 mg/mL solution of SA in 120 
mM sodium sulphate and was left stirring in a water bath at around 50 °C for 7 hours. Liposome 
were then washed with PBS using centrifugal filters.
For the lipid:cholesterol preparations, the film was prepared from a mixture of PC and cholesterol 
at a molar ratio of 70:30%.
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3.3.5. Sample preparation for HPLC analysis
To measure the liposomes’ content of SA, the samples were mixed with either a solution of 5% 
SDS or 10% triton-X then run through the centrifugal filters and the filtrate was used for the 
measurement. All other samples did not require further processing.
3.4. Results and discussion
The aim of this part of the project was to synthesise SA-loaded liposomes with the highest loading 
capacity possible while, at the same time, achieve maximum retention of the drug inside the 
liposomes in storage conditions, only to get a controlled release in biological conditions.
The hydration method, first described by Bangham et al. in 1965, was used for making the lipid 
vesicles since it is the most common and most straightforward method for entrapping drugs that 
are stable during the post-formation processing, i.e. sonication, freeze-thawing, and extrusion.39
The size of the round-bottom flask (i.e. the glass support) was proportional to the amount of the 
lipid used in a way that guarantees the formation of the thin phospholipid (PL) film upon drying 
from the organic solvent under nitrogen. Drying the lipid film under high vacuum for at least 24 
hours was also crucial since the presence of any residual organic solvent is not only a health hazard 
were these liposomes to be used in a clinical setting (and would affect prospective biological 
studies at the very least), but it can also affect the stability and permeability of the liposomes after 
formation. 
Upon hydration, the PL film swells and flakes start peeling off from the glass support (i.e., the 
round-bottom flask). To avoid the exposure of the lipid chains to the aqueous medium at the 
edges, the flakes tend to curve and seal themselves to create vesicles.6 Since the glass support is 
very smooth, surface properties would have no effect on the size and homogeneity of the resulting 
flakes. Instead, they are mainly determined by the crystal defects in the PL film. Nonetheless, 
Large flakes would result in the formation of multilamellar vesicles (MLVs), while smaller flakes 
would form large unilamellar vesicles (LUVs) and small unilamellar (SUVs).40 
To achieve a higher degree of homogeneity, agitation is used to disrupt and break the MLVs 
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which then re-assemble to form SUVs.40 Two different methods were used to produce such effects; 
sonication and repeated freeze-thawing. While sonication directly dissipates the energy required 
for the disruption of vesicles, freeze-thawing is believed to cause destabilisation and breaking of 
the lipid bilayers due to the expansion of the aqueous phase and the dehydration of the head 
groups during freezing, followed by the re-exposure of the hydrophobic chains to water during 
thawing causing them to fuse again, forming new vesicles.41
Further homogenisation and size control could be achieved by extruding the vesicles from the 
previous step through a polycarbonate membrane with specific pore size. Since the desirable size 
range for particles used in nanotherapy is 100-200 nm, as discussed in Chapter 1, the chosen pore 
size was 100 nm. 
Membrane extrusion was performed in an air-tight, hand-driven device developed by MacDonald 
et al. in 1990 as a method for small-volume extrusion using low pressure (Figure 3.3). One or two 
polycarbonate membranes are fitted between two membrane supports and the vesicle suspension 
is pushed back and forth through the membrane with two 500 µL Hamilton syringes equipped with 
Luer locks. A nylon mesh on both sides of the membrane support distributes the injected sample 
over the surface of the membrane. This back and forth movement maximises homogeneity while 
reducing the blockage of the membrane and the need to replace it while processing each patch.42 











In addition to the pore size of the membrane, the particle size distribution of the extruded particles 
is determined by the external pressure applied to the device and the viscosity of the formulation 
which is primarily controlled by temperature, namely the phase transition temperature (Tm).
42 
At Tm, the hydrocarbon chains of the phospholipids transform from their extended and tightly-
packed form, that gives phospholipids their rigid gel-like structure, to a randomly-oriented form, 
that causes phospholipids to have a liquid crystalline structure with more empty spaces between 
the phospholipids.43 For this reason, extrusion (and sonication where applicable) was performed 
above the Tm of the phospholipid. 
While vesicles with a size close to or below the pore size pass the membrane uninterrupted during 
extrusion, larger vesicles undergo expansion and shear forces that, in addition to interfacial 
tension effects and the steric hindrance between vesicles, cause them to break up and form smaller 
liposomes. After multiple cycles of extrusion, suspensions with a particle size distribution around 
the membrane pore size and with low polydispersity are achieved.44
Two different approaches were investigated to load the therapeutic agent, SA, into liposomes; the 
direct loading and the remote loading methods.
3.4.1. Liposomes prepared via the direct (passive) loading method
In this method, SA was dissolved at the highest concentration possible (2-3 mg/mL) (water 
solubility of SA is 2.48 g/L at 25 °C)45 in the aqueous phase used to hydrate the lipid film.
Egg L-α-phosphatidylcholine (PC, also called L-α-Lecithin) was first used for the lipid phase. Egg 
PC is a mixture of phosphoesters of saturated and unsaturated fatty acids, mainly palmitic (16:0), 
stearic (18:0), oleic (18:1), and linoleic (18:2) acids, and has a phase transition temperature that 
is below 0 °C (-5 to -15).46 Because of the low Tm of the phospholipid, synthesis processes like 
sonication and extrusion were performed at room temperature.
After film hydration with the SA solution, one of two homogenisation methods (sonication 
or freeze-thawing) was performed and then the suspension was extruded through the 100 nm 
membrane. DLS was used to determine particle size which ranged between 135-145 nm with 
PdI values ranging between 0.07 and 0.120. Figure 3.4 illustrates particle size distribution as 
determined by DLS.
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Drug entrapment could be quantified via the encapsulation efficiency (EE%) which represents 
the per cent fraction of the input drug that is loaded in the liposomes at a particular phospholipid 









Where Ctot is the total concentration used of the drug and Cf is the concentration of the free drug 
after encapsulation. Free (unentrapped) drug concentration was measured in the suspension 
medium after separating it from the liposomes using centrifugal filters (Figure 3.9).
The average EE was 47% for liposomes prepared via freeze-thawing and 60% for those prepared 
via sonication. 
Although the mechanism by which sonication reduces the size of the vesicles is not fully 
understood, it is speculated that the gas bubbles within the suspension oscillate in response to 
sonication creating localised pressure forces that draw towards the bubbles any particles that have 
densities higher than the surrounding liquid. The radii of the oscillating gas bubbles also expand 
and contract on the microsecond scale, creating a convective flow near the surface of the bubbles. 
It is believed that this convective flow subjects the liposomes that are attracted towards the bubble’s 
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surface, due to the aforementioned pressure, to high shear forces causing their division.49 On the 
other hand, the mechanism of size reduction in the freeze-thawing method, as discussed earlier, 
is thought to be due to the breaking of the lipid bilayer due to dehydration and the mechanical 
pressure caused by the growth of ice crystals during freezing followed by rehydration and the 
reassembly of vesicles upon thawing.50 In other words, freeze-thawing induces a system-wide 
breaking and reassembly of the lipid bilayer, causing SA to be released and re-entrapped. In 
contrast, sonication causes vesicles to divide and split with less pronounced loss of their content. It 
could be the more disruptive nature of the freeze-thawing method that causes it to result in lower 
EE than the sonication method.
It is worth noting that EE expresses the efficiency by which a specific method and/or phospholipid 
can entrap the input drug regardless of the amount of the drug used. This means that EE can be 
high even when low concentrations of the drug are used and vice versa. This is distinguishable 
from loading capacity (LC) which represents the maximum amount of the drug at a particular 
phospholipid concentration and is expressed as a per cent molar ratio of the entrapped drug to the 
lipid by the equation:33,48
LC Mol of encapsulated drug
Mol of lipid used
(%)  100
It is also referred to as a molar ratio (moles of drug per moles of lipid) which is called the drug-to-
lipid ratio, or D/L ratio.48
The LCs for the synthesised SA liposomes were 34% and 53% for the sonicated and the freeze-
thawed samples, respectively.
It is also worth noting that, assuming the resulting vesicles are unilamellar, the number of liposomes 
per mL of solution and their content of SA can be estimated. This depends on the type of lipid 
used, its final concentration, and the amount of the entrapped drug. The number of liposomes per 







Where N A is the Avogadro number, Mlipid is the molar concentration of the lipid, and Ntot is the total 































  is the surface area of a single liposome that has the diameter d, h is the thickness 
of the bilayer (5 nm in the case of egg PC), and a is the area of the lipid head group (0.71 nm2 for 
egg PC).51
By applying the previous formulae to the sonicated preparation, for example, the number of 
liposomes can be estimated to be around 86.7 x 1012 liposomes/mL. By dividing the concentration 
of entrapped SA on the number of liposomes per mL, it can be speculated that each liposome 
contains about 21.9 femtograms of SA.
The following step involved washing the liposome suspension to remove the unentrapped drug 
from the suspension. This was carried out via dialysing the suspension using Visking dialysis 
tubing with a molecular weight cut-off of 12-14 kDa. After 24 hours of dialysis, during which the 
dialysis medium was changed three times, the liposome suspension was investigated again for the 
free drug, and only a trace amount was detected by HPLC.
To investigate whether the liposomes’ content of SA corresponds with the entrapped amount, the 
liposomes suspensions were mixed with a known amount of a surfactant to lyse the liposomes and 
release the entrapped drug for measurement. Either a 10% solution of Triton-X or a 5% solution 
of sodium dodecyl sulphate (SDS) was used for lysis. However, only trace (negligible) amounts of 
SA was detected from any of the preparations. Figure 3.5 shows the chromatograms of SA during 
the different stages of the preparation process.
Upon further investigation, it was found that the whole amount of SA used to load the liposomes 
(i.e. both entrapped and free) was being lost in the dialysis medium during the first two hours of 
the dialysis process. The most probable explanation for this issue is that the lipid used to make the 
liposomes has a very low Tm  (-5 to -15 °C) at which the lipid exists in its liquid crystalline phase 
making liposomes more prone to leakage.52
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Fig 3.5.  HPLC chromatograms of SA at different 
stages of preparing egg PC liposomes. (A) is the the 
measurement for the SA solution used to prepare 
the liposomes. (B) is the measurement in the 
filtrate after encapsulation showing an EE of 47%. 
(C) is the measurement of SA in the liposomal 
suspension after dialysis, lysis with Triton-X, and 





The first approach that was explored to overcome this issue is by incorporating cholesterol in the 
lipid phase of the liposomes. Cholesterol, which is also an essential component of the membrane 
of biological cells, is known to decrease the permeability of the lipid bilayer and increase its 
rigidity possibly by increasing the packing of the phospholipid molecules and increasing the 
hydrophobicity of the membrane.53,54
The preferred molar ratio of lipid to cholesterol is about 2:1 (or 70:30%).53 Hence a new preparation 
of liposomes was synthesised from egg PC and cholesterol with that ratio. Film hydration followed 
by sonication and extrusion was henceforth used for liposome preparation since it yielded better 
encapsulation and was more straightforward than freeze-thawing. The addition of cholesterol had 
no effect on the size of the liposomes. EE was 66% and LC was 38%. Nonetheless, dialysing the 
suspension resulted in the same issue of leakage, and the liposomes lost their load of SA during 
the first two hours of dialysis. 
The lipid was changed to DPPC, a phosphatidylcholine ester with two palmitoyl saturated chains. 
The homogeneity of the lipid and the stronger van der Waals interactions observed with long acyl 
chains, as opposed to shorter ones, and the absence of kinks associated with the cis-double bonds 
in unsaturated chains raise the Tm of DPPC to 41 °C which makes it one of the preferable lipids in 
drug delivery since it is only a few degrees  above the body temperature.46,55
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The same method, film hydration followed by sonication then extrusion, was used to prepare the 
DPPC liposomes with the exception that all synthesis processes, i.e. hydration, sonication, and 
extrusion, were conducted above the Tm of DPPC.
The average EE was about 59% and LC of up to 71% could be achieved (depending on the 
concentration of DPPC used). However, the same leakage issue was encountered with the new 
lipid, and most of the SA load was being lost during the first two hours of washing even after 
incorporating cholesterol at a 70:30% molar ratio. Figure 3.6 shows the chromatograms of SA 





(E)Fig 3.6.  HPLC chromatograms of SA at different 
stages of preparing DPPC:Chol (70:30%) 
liposomes. (A) is the the measurement for the SA 
solution used to prepare the liposomes. (B) is the 
measurement in the filtrate after encapsulation 
showing an EE of 71%. (C) is the measurement of 
SA in the dialysis medium after 2 hours of dialysis. 
Here, around 87% of the original amount of SA is 
lost in the dyialysis medium. This is coming from 
both the unentrapped SA and the portion that is 
being released from the liposomes. (D) is the measurement of SA in the dialysis medium after 12 hours 
of dialysis. All of SA has been practically washed away at this stage. (E)is the measurement of SA in 
the liposomal suspension after dialysis, lysis with Triton-X, and filtration (dilution factors are x10 for 
A and B, approximately x41 for C and D, and x15 for C).
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This is comparable to what is found in the literature. For example, Bhalerao et al. synthesised 
SA liposomes for skin application via film hydration using soy lecithin which has a transition 
temperature of 40-50 °C. The liposomes were not washed to remove the unentrapped but rather 
just separated from the hydration medium via centrifugation, resuspended in fresh medium, and 
then immediately stored at 4 °C. The preparation suffered leakage even during the first hours of 
storage and it increased significantly when the temperature increased.34
Hagiwara et al. encountered a similar issue with their liposomal preparations of SA where they 
measured EE after dialysis and found it to be less than 1%. However, the focus of their study was 
not SA per se but rather the use of γ-Cyclodextrin to enhance entrapment, and SA was used as a 
model drug for the system.56 Nonetheless, the SA-γ-Cyclodextrin conjugate had an EE of about 8% 
which is still considered to be very low.
The loss of drug from liposomes could be explained by the fact that SA is a weak acid and it exists 
in aqueous solutions in equilibrium between the ionised (deprotonated) and neutral (protonated) 
states. Lipid bilayers are typically permeable to the non-ionised species, and after encapsulation, 
an osmotic equilibrium is reached between the inner and outer phases of the liposomes. When 
an osmotic perturbation occurs (in this case, dialysis), the permeant species of the acid (i.e., the 
neutral form) and water move across the membrane to establish diffusion equilibrium.57 Since 
SA is being depleted continuously from the outer phase via dialysis, the weak acid equilibrium 
shifts towards the formation of the neutral form of the acid which in turn permeates across the 
membrane until very little SA remains inside the liposomes.
The permeation of a molecule can be estimated from its lipophilicity expressed as partition 
coefficient (P), or its decimal logarithm LogP, which is determined experimentally in a polar/
non-polar system (usually octanol-water) where a higher value means higher lipophilicity and, 
subsequently, higher membrane permeability.58 
Because aspirin is less lipophilic than SA (LogP is 2.35 for SA and 1.14 for aspirin),59 an attempt 
was made to entrap aspirin instead of SA using the same direct loading method discussed above. 
However, the hydrolysis of aspirin to SA in the aqueous solution was very fast making the process 
inefficient. The rapid hydrolysis was identified by the appearance of two peaks in the HPLC 
chromatogram (Figure 3.7) of freshly prepared standard samples of aspirin.
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3.4.2. Liposomes prepared via the remote (active) loading method
To overcome the problems related to the retention of weak acids or basis inside lipid vesicles, a pH 
gradient approach has been successfully employed for the active loading of drugs. In this method, 
the difference in permeability between ionised and neutral forms of a drug is exploited via a 
transmembrane pH gradient. Empty liposomes are first prepared in a suspension that provides a 
difference in pH between the inside and the outside of liposomes. When the drug is added to the 
suspension, the neutral form permeates through the lipid membrane into the liposomes. The pH 
in the inner phase causes the drug to ionise and stay entrapped in the liposomes since the ionised 
form is impermeable through the membrane.26 A gradient of ammonium sulphate, for example, 
has been established as an effective method for the remote loading of weak bases, such as the anti-
tumour drug doxorubicin.60
For the remote loading of SA, calcium acetate was considered for the pH gradient method. This 
method (known in this case as the acetate gradient method) has been successfully used to entrap 
other weak acids, such as the antibacterial nalidixic acid and the NSAID diclofenac.61,62
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Calcium acetate is preferably used for the remote loading of weak acids because it has the following 
characteristics: (1) it is the water-soluble salt of an amphipathic weak acid at high concentrations, 
(2) the permeability coefficient of the weak acid is high enough to ensure a rapid transmembrane 
movement (on the scale of 10 milliseconds), (3) the cation (calcium) is practically impermeable, 
and (4) the cation, being divalent, facilitate the formation of intraliposomal salts of the loaded 
drug that could probably be insoluble, which enhances drug retention.62
Empty liposomes were prepared via the film hydration method. Two different preparations were 
made; one contained only the lipid DPPC, while the other was prepared from a mixture of DPPC 
and cholesterol (70:30 mol%). The lipid film was hydrated with a solution of calcium acetate 
and then washed with sodium sulphate to remove the calcium acetate from the outer phase and 
create the acetate gradient. Sodium sulphate was used as the external phase because of the poor 
permeability of both the sodium and sulphate ions.62 The external phase was prepared at the same 
concentration of the internal phase to preserve osmolarity.
After removing the calcium acetate from the external medium, internal acetic acid would permeate 
until an equilibrium of acetate concentration is reached between the inside and the outside. 
Through this movement, acetate acts as a proton shuttle and it causes the pH of the internal phase 
to rise with minimum effect on the pH of the external phase (since the volume of the external 
phase is much larger than the internal phase), thus a gradient in pH is created between the inside 
and outside of the liposomes. When another weak acid is added, SA in this case, the neutral form 
also starts to permeate through the lipid membrane, but with the higher pH inside the liposomes, 
SA would ionise and get trapped. This ionisation would also disturb the equilibrium of neutral 
SA between the two phases causing more SA to permeate through to the inner phase. Inside the 
liposomes, the salicylate ion possibly binds to the calcium ion and form salt complexes that might 
further precipitate providing even better retention and a slower release of the drug.62-64 Figure 3.8 
summarises the process of remote loading of a weak acid.
The EE of the preparations were 18% and 13% for the DPPC and the DPPC:chol liposomes, 
respectively. These results are much lower than expected EE values via the remote loading method 
which is considered much more effective than the direct loading method for ionisable drugs 
(efficiency is usually above 90%).63,64 
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Fig 3.8.  A summary of the remote loading (acetate gradient) method. (1) after loading the liposomes 
with calcium acetate and removing it from the outer phase, the acetate readily permeates to the outside 
of the liposome which raises the pH inside creating a transmembrane gradient. (2) When the weakly 
acidic drug (D-COOH) intended for loading is added, the neutral form permeates to the inside of the 
liposome. (3) because of the higher pH inside, the drug ionises and becomes entrapped due to the 
decreased permeability of the ionised form. (4) the calcium ion might form salts with the drug that 
have low solubility which could cause precipitation and further enhance drug retention. The depletion 
of the neutral form of the drug inside the liposome causes the transmembrane equilibrium of the drug 

















Nonetheless, after washing the liposomal preparations and then lysing them using Triton-X 
100, no SA was detected, indicating that again SA leaked out of the liposomes during washing 
even though washing was performed on a small scale using the centrifugal vials (by a few cycles 
of removing the washing medium, resuspension, and washing again) rather than dialysing the 
liposomal suspension for prolonged periods of time, as illustrated in Figure 3.9.
Supposing encapsulation was successful with the aforementioned efficiency, the most likely 
explanation for the poor EE and the leakage of SA during washing is that the lipid bilayer was 
compromised causing the liposomes to be unstable and leaky. This could be due to the possible 
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hydrolysis of the lipids constituting the bilayer membrane. Hydrolytic degeneration is a common 
stability issue with liposomes made from phospholipids with saturated hydrocarbon chains.65 
Fig 3.9.  Washing liposomes with centrifugal filters. (1) the freshly prepared Liposomal suspension is 
added in the filter compartment and centrifuged. (2) the solution containing the unentrapped drug 
passes through the membrane while the liposomes stay in the upper compartment. (3) the washing 
medium is added to the filter compartment and the liposomes are resuspended. (4) the sample is 
centrifuged again to remove the washing medium and the process is repeated a few times. (5) to recover 
the liposomes, the filter compartment is inverted and the sample is centrifuged. (6) after their recovery 
in the vial, the liposomes are suspended in fresh medium.
(1) (2) (3) (4) (5) (6)
The first stages of DPPC hydrolysis produce the lysophospholipid (a phospholipid with one fatty 
acyl chain) MPPC and the free fatty acid, palmitic acid. Further, slower hydrolysis of the lysolipid 
produces glycerol-3-phosphatidylcholine and glycerol-3-phosphoric acid, while the complete 
hydrolysis to glycerol and phosphoric acid is very slow and practically absent in pharmaceutically-
relevant conditions.65,66 Figure 3.10 shows the hydrolysis products of the phospholipid DPPC.
It has been determined that the presence of lysolipids and free fatty acids in the lipid bilayer could 
compromise its integrity and induce leakage, probably through the alteration of the pure lipid’s 
Tm.
67–69 This causes a collapse in the acetate gradient and the leakage of the calcium ions resulting 
in the failure of SA encapsulation.
Although hydrolysis usually occurs during the long-term storage of liposomes in their aqueous 
suspensions or at extreme pH levels or high temperatures, it is possible that such impurities 
already existed in the DPPC batch used to prepare the liposomes since it had already been in 
storage for almost two years at the time of the experiment. Furthermore, it has been suggested 
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that bubble cavitation during sonication could produce free radicals leading to the oxidation and 
hydrolysis of phospholipids. For this reason, it might be necessary to exert more control over 
mixture temperature during sonication and limit sonication time.70,71
Fig 3.10. The hydrolysis products of DPPC. The lysophospholipids 1-MPPC and 2-MPPC result 
from the hydrolysis of the carboxy esters at sn-2 and sn-1, respectively. In certain pH and buffer 
conditions, 2-MPPC is rapidly converted to the more stable 1-MPPC. The end product of hydrolysis 
is glycerophosphoric acid, while further hydrolysis to phosphoric acid and glycerol is not observed in 
pharmaceutically-relevant condition. The presence of any of these species in the phospholipid bilayer 
compromises its stability. 65
DPPC: 1,2-dipalmitoyl-sn-glycero-3-phosphocholine. 1-MPPC: 1-palmitoyl-2-hydroxy-sn-glycerol-
3-phosphatidylcholine, 2-MPPC: 2-palmitoyl-1-hydroxy-sn-glycerol-3-phosphatidylcholine. GPC: 








































The time limitation of the project did not allow for further investigation of the presence of 
lysolipids or any other possible changes in the structure of the phospholipid, nor did it allow to 
study the effect of sonication and other methods on the structure of the phospholipid during the 
preparation of liposomes.
It is also worth noting that the zeta potential values of liposomes prepared from DPPC are close 
to zero (between -0.03 and 0.69 mv), which is in agreement with the literature under similar 
experimental conditions (PBS).72 This might be due to the overall neutral charge of the head 
group at a pH of 7.4.73 These low values of zeta potential are of concern when it comes to the 
long-term stability since liposomes with such values tend to aggregate.74 This could be improved 
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by incorporating other charged lipids in the bilayer or decorating the surface with various 
polymers.75,76 However, the main priority was to achieve better retention of salicylic acid before 
investigating the long-term stability of the preparations.
Table 3.1 summarises the different SA liposomal preparations. As discussed above, egg PC was first 
used for the lipid membrane and one of two homogenisation methods, in addition to extrusion, 
was used. As preparation 2 shows, sonication yielded better EE than freeze/thawing probably due 
to the less aggressive splitting of vesicles associated with sonication. It was therefore used with all 
the subsequent preparations. Preparation 3 showed that the addition of cholesterol had a mild effect 
on EE but LC decreased due to the decrease in drug/lipid ratio after the addition of cholesterol. 
In preparation 4, DPPC was used instead of egg PC and yielded similar EE to the previous lipid. 
Adding cholesterol in preparation 5, however, increased EE probably via stabilising the liposomes 
and making them less leaking during the preparation process. Preparations 6 and 7 were done 
using the remote loading method without and with the addition of cholesterol, respectively. Low 
EE values are probably due to the collapse of the pH gradient that resulted from the compromised 
lipid membrane, most likely due to sonication. LC values follow EE values, again, due to a decrease 
in the drug/lipid ratio.




EE (%) LC (%)
1st 2nd
1 Egg PC 1:0 direct freeze/thawing extrusion 47% 34%
2 Egg PC 1:0 direct sonication extrusion 60% 53%
3 Egg PC 2:1 direct sonication extrusion 66% 38%
4 DPPC 1:0 direct sonication extrusion 46% 71%
5 DPPC 2:1 direct sonication extrusion 59% 67%
6 DPPC 1:0 remote sonication extrusion 18% 26%
7 DPPC 2:1 remote sonication extrusion 13% 19%
Table 3.1. Summary of the different salicylic acid liposomal preperations. 
PC: phosphatidylcholine. DPPC: Dipalmitoylphosphatidylcholine. Chol: cholesterol. EE: encapsulation 
efficiency. LC: loading capacity.
3.5. Conclusion
Attempt were made to synthesise SA-loaded liposomes as another nanodelivery medium for SA to 
compare it with the polymeric vesicles presented in Chapter 2. In early experiments, egg PC for the 
synthesis of the lipid vesicles which lead, inevitably, to the end product being leaky due to low gel 
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transition temperature of the lipid. The addition of cholesterol to the formulation did not influence 
the permeability of the liposomes.
DPPC was then used instead of egg PC. Being a favourite when it comes to the synthesis of lipid 
vesicles for drug delivery due to its transition temperature that is only a few degrees above normal 
body temperature, DPPC was expected to yield better results than its predecessor. However, the 
DPPC liposomes prepared with the conventional method of synthesising liposomes, i.e. the direct 
(passive) loading via film hydration, still lost their load of SA during purification, even with the 
integration of cholesterol, at a rate unsuitable for the purposes of targeted therapy. For this reason, 
another method that has been successfully used to load liposomes with weak acids and bases was 
investigated.
Theoretically, the remote (active) loading method was expected to increase the loading capacity 
of the liposomes and enhances the retention of SA via a transmembrane calcium acetate gradient 
that causes a difference in pH between the inner and outer phases of the liposomes. This difference 
in pH could drive the loading process by allowing the permeable species of SA to enter the empty 
liposomes, become ionised, and stay entrapped. 
Unfortunately, the liposomes synthesised by this method still failed the give satisfactory results. 
This might be attributed either to the degraded quality of the starting materials over time, or 
to ultrasonication that was used to homogenise the lipid vesicles since it has been found to 
compromise the integrity of the lipid bilayer via inducing hydrolysis. Nonetheless, it was not 
possible to further investigate these issues within the time frame of the project.
However, these findings raise some questions about similar formulations in the literature, since the 
stability and release profile of some of these formulations were not appropriately addressed. Even 
though this could be tolerated to a certain degree for topical application in semi-solid preparations, 
the issue of poor retention or leakage represents a major challenge if those liposomes were to be 
used systemically for targeted therapy. Some formulations made for this purpose were presented 
as novel lipid-associated NSAIDs even though their preparation method is identical to that used 
for the synthesis of conventional lipid vesicles. These formulations were used as-is and the focus 
was on the study of their pharmacological effects rather than their physicochemical properties.
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Creating liposomes with good encapsulation efficiencies and loading capacities for the purposes 
of targeted therapy via systemic administration represents a major challenge that is encountered 
throughout literature. This is especially the case with amphiphilic weak acids and bases, which is 
the case in the vast majority of drugs. Since the direct loading method has proven ineffective in 
many cases, as in the work discussed above, the remote loading method shows some promise, at 
least theoretically, in improving the retention of small-molecule weak acids, such as salicylic acid. 
Further examination of the quality of the lipid used and making sure that the storage conditions 
and the preparation method do not produce lysolipids that compromise the integrity of the lipid 
bilayer might prove useful in attaining liposomes that are stable enough to hold their load of 
salicylic acid in relevant biological conditions until they reach their target tissue.
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No matter how meticulously engineered, the biological response obtained from any given nano-
delivery system can be very hard to predict, and how nanoparticles interact with biological systems 
is still not fully understood.1
The pharmacokinetics and biodistribution of nanoparticles are different from their small-molecule 
counterparts. The drug delivery process using intravenously-injected nanocarriers can be divided 
into three phases: (1) systemic circulation and the interaction with the reticuloendothelial system 
(RES), (2) extravasation and tumour penetration, and (3) interaction with the target cells (i.e. 
uptake and intracellular trafficking) and drug release.2
Immediately after their systemic administration, injected nanoparticles encounter a wide array of 
blood proteins (e.g. immunoglobulin G, serum albumin, fibrinogen, apolipoproteins, complement 
components, etc.) that adsorb onto the surface of the particle, creating a “protein corona” that alters 
the physicochemical characteristics of the nanoparticle by changing its surface properties and 
helps shape its biological identity.3,4 Some of these proteins (especially the immunoglobulins and 
complement components), called “opsonins”, help the immune system identify the nanoparticles 
as foreign intruders and make them visible to the macrophages of the reticuloendothelial system 
(RES), especially in the liver and spleen, which in turn clear the particles from circulation via the 
endocytic process of phagocytosis.5
In addition to being phagocytised by Kupffer cells (the liver’s macrophages), particles smaller than 
50 nm entering hepatic circulation might extravasate through the vascular fenestration of the 
liver’s endothelium, causing them to accumulate in and interact with hepatocytes.6 As the size of 
the particles increases, hepatic clearance appears to decrease while the splenic capture increases.7 
It has been demonstrated that particles with a size of about 300 nm and above start to accumulate 
in the spleen in a size-dependant manner unrelated to the spleen’s phagocytic system.7,8 On the 
other hand, very small NPs that have the size of about 5 nm (or a molecular weight of about 40 
kDa) are rapidly cleared out by the kidneys via glomerular filtration.9,10 
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NPs can still reach the target tissues before encountering macrophages or can evade phagocytosis 
altogether either because of being PEGylated or due to the saturation of the endocytic capacity of 
the macrophages and/or the depletion of opsonins.11–13 When those NPs reach the microvessels of 
a solid tumour (in the case of its presence) they diffuse throughout the tissue after extravasating 
through the fenestrations in the walls of the blood vessels supplying the tumour to be taken up 
after that by cells via various forms of endocytosis.14
While the first form of endocytosis, phagocytosis “cellular eating”, is exclusive to phagocytes (i.e. 
macrophages, monocytes, and dendritic cells) and is observed to take place with large particles 
(>500 nm), the uptake of most of  NPs that have a size range between a few nanometres and a few 
hundred nanometres happen via pinocytosis “cellular drinking” which is the primary mechanism 
of uptake in all kinds of cells, including tumorous ones.15,16 Both types of endocytosis involve 
engulfing NPs in membrane invaginations, followed by their budding and pinching off on the 
intracellular side of the membrane. In phagocytosis, however, the phagocytic membrane is tightly 
apposed to the solid particle itself in contrast with pinocytosis where the cell engulfs a volume of 
the interstitial fluid that contains the NPs, hence the distinction between the ‘eating’ and ‘drinking’ 
processes.17
Pinocytosis can be further divided into four subtypes:1,15,18,19
1- Clathrin-mediated endocytosis (CME), which is the primary mechanism by which cells 
obtain their main nutrients and plasma membrane components such as iron and cholesterol. 
CME happens either via receptor-specific uptake or by nonspecific adsorptive uptake through 
the hydrophobic or electrostatic interactions between the NPs and the membrane of the cell. 
Clathrin is the protein that is considered the assembly unit that causes curvatures in the 
cellular wall forming pits that are about 100-150 nm in size that engulf the NPs then bud 
and pinch off to form the endocytic vesicles. Those vesicles usually end up fusing with the 
degradative lysosomes in the cytoplasm.
2- Caveolae-mediated endocytosis (CvME), which occurs in cells that contain caveolin, a protein 
that plays a role in cell signalling and the regulation of membrane proteins. The invaginations 
formed in this pathway are characterised by their flask-like shape that is around 50-80 nm 
in size. Since the resulting vesicles do not usually fuse with lysosomes, their content does 
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not typically undergo enzymatic degradation. Hence, this pathway is usually exploited by 
pathogens to avoid lysosomal enzymes and, for the same reason, there has been a growing 
interest in this pathway as a potential means to deliver NPs loaded with enzyme-sensitive 
materials such as proteins and peptides.
3- Clathrin- and caveolae- independent endocytosis, which happens in cells that lack both 
proteins. Cellular uptake of extracellular fluids, growth hormones, and interleukin-2 takes 
place via this pathway. Because folic acid is also internalised via this route, NPs that are 
functionalised with folate are usually taken up into cells through this route. Folate-conjugated 
particles are also not usually delivered to lysosomes, but instead are either retained in the 
endocytic compartments or released into the cytoplasm.
4- Macropinocytosis, which is a nonspecific uptake pathway in which the cytoskeleton rearranges 
to form large membrane extensions that engulf a large extracellular volume and then fuses 
back with the membrane forming large vesicles (0.2-5 µm), making it a good candidate for 
the uptake of large NPs.
Other entry mechanisms have been reported, such as passive diffusion and nanoscale hole 
formation via disruption of the lipid bilayer, as well as artificially-induced mechanisms, such as 
direct cytoplasmic microinjection and electroporation (inducing the formation of transient pores 
in the lipid bilayer through the application of external high-voltage electrical impulses).1
It is worth noting that the uptake mechanism depends on the type of target cells as well as the 
physicochemical characteristics of the NPs, such as the composition, shape, size, and surface 
charge.2,5 
After pinching off from the cell membrane, the internalised vesicles go through the process 
of intracellular trafficking that determines the final fate of the cargo. For vesicles destined for 
enzymatic degradation, they fuse with the membrane-bound “early endosomes” that act as 
temporary storage for the cargo before being sorted via the differentiation of the early liposomes 
to either “recycling endosomes”, that carry part of the cargo back to the cellular membrane and out 
to the exterior of the cell, or to “late endosomes” that fuse with lysosomes to form endolysosomes 
where the hydrolytic enzymes degrade its content, mediated by the acidic pH in the lysosomes.20,21
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Other vesicles, such as those formed via caveolae-dependent endocytosis, are delivered to other 
cellular components, such as the Golgi apparatus and the endoplasmic reticulum in order for their 
content to be utilised by the cell.22
It should be noted, however, that even if particles escape being delivered into lysosomes, they still 
might be cleared sometimes from the cytoplasm through autophagy, a process in which special 
endosomes (autophagosomes) appear around objects in the cytoplasm, engulf them, and deliver 


















Fig 4.1. A summary of the endocytotic process via different pathways. Numbers indicate pH levels in 
endosomes. Adapted from [1] and [17].
Nanoparticles Nanoparticles' degradation products
Clathrin Caveolin Enzymatic components
Finally, it should be noted that it is of great importance to factor the uptake mechanism and the 
biofate of nanomaterials engineered for therapeutic purposes into their design. To obtain effective 
nanodelivery system, it would be important, for example, to determine whether the delivered NPs 
are needed to be hydrolysed in the lysosome to release the active drug, or whether the cargo is 
sensitive to enzymatic degradation and should be designed to avoid meeting lysosomes altogether.2
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Attaining this kind of understanding of the possible biofate of the salicylic-acid-based NPs 
developed in work requires extensive research and is out of the scope of this project. However, in 
vitro work has been carried out to gauge how certain cancer cell lines react to being exposed to 
these particles and how that compares to their single-molecule counterparts.
4.2. Materials and instrumentation
The HCC1806 human breast cancer cell lines and the UKF-NB-3 human neuroblastoma cell line 
were provided by the Resistant Cancer Cell Line (RCCL) Collection established by the laboratories 
of Dr Jindrich Cinatl (Goethe University Frankfurt, Germany) and Dr Martin Michaelis (University 
of Kent, UK).
Iscove Modified Dulbecco Medium (IMDM) and foetal bovine serum (FBS) were obtained from 
Gibco. Phosphate-buffered saline (PBS) was obtained from Oxoid. Trypsin-EDTA and penicillin-
streptomycin (Pen Strep) were obtained from Invitrogen. Trypan Blue was obtained from Sigma-
Aldrich.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), sodium dodecyl sulphate 
(SDS), and dimethylformamide (DMF) were obtained from Fisher scientific. 
Paclitaxel, bleomycin, mitomycin, and temozolomide, and zeocin were sourced from Cayman 
Chemicals. Salicylic acid and aspirin were obtained from Acros Organics.
Cellstar® 96-well cell culture microplates were obtained from Greiner Bio-One. Dye intensity in 
the microplates was measured in PerkinElmer’s Victor X4 Multilabel Plate Reader at a wavelength 
of 600 nm.
4.3. Experimental
4.3.1. Maintenance of cell lines
All consumables used for cell culture such as cell culture flasks, pipette tips, and serological 
pipettes were either sterile as purchased or were sterilised in-house via autoclaving. All surfaces 
and implements were sprayed with 70% ethanol before being placed in class II biological safety 
cabinet in which all handling of cell cultures was carried out. 
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Cells were typically grown in Iscove’s Modified Dulbecco Medium supplemented with foetal 
bovine serum 10% v/v and penicillin/streptomycin 1% v/v. Cells were maintained in a humidified 
incubator at 37 °C under 5% CO2 at physiological pH (7.2-7.4).
At about 80% confluence, the culture’s medium was removed, and the cells were washed with 3 
mL of PBS. The cells were detached following incubation with 1 mL of trypsin/EDTA solution 
for 5 minutes at 37 °C.  The trypsin enzymatic reaction was terminated by the addition of 9 mL 
of complete medium to the cell culture flask. Cell passaging was usually done at a ratio of 1:10 by 
adding 1 mL of the newly suspended cell culture to 9 mL of complete medium in a new T25 flask.
For the paclitaxel-resistant cell line, 10 µL of paclitaxel in DMSO (20 µg/mL) was added to the new 
10-mL T25 flask to achieve a final concentration of 20 ng/mL of paclitaxel.
All solid waste was autoclaved, whilst liquid waste was aspirated into a flask containing a working 
concentration (1%) of Virkon disinfectant solution.
4.3.2. Cell counting
A haemocytometer was used to determine the number of cells per mL. Briefly, a small volume 
of the cell suspension was mixed with Trypan Blue at a known ratio (the dilution factor), then 
about 10 µL of that mixture was deposited between the haemocytometer counting chamber and a 
coverslip. The haemocytometer was placed under an inverted microscope and cells were counted 
in the four outer quadrants of the chamber (each quadrant has a volume of 10-4 mL) and then the 
number was averaged. The number of cells per mL was then calculated as follows:
Number of cells per mL = average number of counted cells x dilution factor x 104
4.3.3. Cell viability assay
4.3.3.1. Determination of the half-maximal inhibitory concentrations (IC50 )
After determining the number of cells per mL, about 5000 cells were seeded in each well of a 96-
well culture plate (in a volume of 50 µL of the medium in each well).
Drug solutions were prepared in 8-point serial dilution sets at a ratio of 1:4 then aliquots of 50 µL 
of the drug solutions were added to the cell plates. Each set was repeated on the plate in triplicate. 
The plates were then incubated for five days in the cell culture incubator at 37°C with 5% CO2. 
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After the incubation period, 25 µL of MTT was added to each well, and then the plates were 
incubated for a further 4 hours. 100 µL solution of SDS 20% (w/v) in a 1:1 mixture of DMF and 
de-ionised water (pH = 3.5-4.5) was added to each well, and the plates were left in the incubator 
overnight. The plates were read the next day in the plate reader at 600 nm. Viability changes upon 
treatment were determined as intensity percentages against control wells (untreated cells) after 
subtracting background values (blanks, medium only). Readings were normalised when possible 
and were then fit in a log(dose)-response model (in Prism GraphPad software) from which IC50 , 
the concentration of the compound that caused a 50% loss of metabolic activity, was calculated.
4.3.3.2. Drug comparison against different cell lines
After determining the IC50 for the different drugs, plates for different cell lines were prepared with 
around 5000 cells per well for each plate. Drugs, either individually or combinations, were added 
to the wells at their respective IC50s in triplicates. The same MTT assay procedure mentioned 
above was followed.
4.3.4. Preparation of self-assembled PSA-b-mPEG NPs for the in vitro study
The co-solvent method discussed in Chapter 2 was used to prepare PSA-b-mPEG NPs for the 
cell viability assay with the exception of using autoclaved PBS for the aqueous medium instead 
of de-ionised water. Briefly, 10 mg of the block co-polymer was dissolved in 1 mL of THF. As the 
solution was stirring in a round-bottom flask, autoclaved PBS solution was added dropwise in a 
uniform manner using a micropipette until a tenfold dilution was achieved. The suspension was 
then loaded in a Visking dialysis membrane and was dialysed using autoclaved PBS. The volume 
was measured before and after removing the solvent to keep track of and adjust the concentration 
accordingly. Implements were washed, when possible, with 70% ethanol prior to their use.
4.4. Results and discussion
The MTT assay was used to evaluate the response of selected cancer cells to PSA-PEG NPs, their 
active molecule, salicylic acid (SA), and its therapeutically-related molecule aspirin (acetylsalicylic 
acid, ASA). This assay is a sensitive indicator that can be used to quantitatively measure the effect of 
treatment on the metabolic activity on cells in vitro. After treating cells with a proposed treatment, 
the yellow water-soluble tetrazolium dye, MTT, is added to the cell culture. Depending on the 
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viability of the cells in the culture, MTT is converted to the purple-coloured formazan crystals, 
primarily by the mitochondrial dehydrogenases. After dissolving the crystals, in DMF or DMSO 
for example, the concentration of the formazan product is analysed spectrophotometrically and is 
compared against untreated cells to determine the viability of the treated ones.24 Figure 4.2 shows 
















Fig 4.2. Reduction of MTT dye. The mitochondrial dehydrogenase converts the water-soluble yellow 
MTT dye to the insoluble formazan crystals.
MTT Formazan
Experiments were mainly conducted on two breast cancer cell lines, the chemo-naïve (parental) 
HCC1806 and its paclitaxel-resistant subline, HCC1806rPCL20 (i.e. HCC1806 cell line adapted 
to 20 ng/mL of paclitaxel, PCL). HCC1806 is a triple-negative breast cancer (TNBC) cell line, 
meaning that it lakes tumour cells lack oestrogen and progesterone receptors as well as the absence 
of the overexpression of human epidermal growth factor receptor-2 (HER-2).25 Compared to the 
subtypes of breast cancer that express those receptors and respond well to hormonal and/or anti-
HER-2 antibodies, TNBCs are resistant to many treatments and is associated with poor prognosis.26 
Even though TNBCs usually respond to cytotoxic chemotherapy, they have high relapse rates and 
a poor overall clinical outcome.27 It was hypothesised that, if SA and its NP formulation could 
produce cell death in these cell lines, then this formulation would be a good candidate for the safe 
and effective management and prevention of TNBCs that would enhance patients’ survival rate 
and their overall quality of life.
The first step was to evaluate the cytotoxicity of SA and ASA against the chosen cell lines in order 
to compare their effects as molecules with their NP counterparts and with other anti-tumour 
drugs. 
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For the sake of simplicity, the parental cell line will henceforth be called HCC180 PTL and the 
paclitaxel-resistant one will be called HCC1806 PAX.
Different sets of serial dilutions of SA and ASA were tried on the two cell lines. Concentrations 
with a micromolar order of magnitude (which is usually used with anti-tumour drugs) did not 
give any cytotoxic effects. Hence, concentrations within the millimolar order of magnitude were 
used instead until a response was achieved.  Data was normalised and then plotted on a log(dose)-
response graph to give a sigmoidal dose-response relationship to determine the IC50 values. The 
experiments were repeated in triplicates.
The IC50 of ASA for HCC1806 PTL was 0.65 mM (95% CI: 0.46-0.90, r
2 = 0.94) and 0.7 mM for 
HCC1806 PAX (95% CI: 0.58-0.86, r2 = 0.97). The two cell lines were less sensitive to SA as its 
IC50 values were 0.99 mM (95% CI: 0.79-1.25, r
2 = 0.97) and 2.02 mM (95% CI: 1.60-2.56, r2 = 
0.96) for HCC1806 PTL and HCC1806 PAX, respectively. These concentrations are still within the 
clinically-relevant range as the therapeutic concentration after the administration of salicylates is 
typically between 1-2 mM.28,29 Figure 4.3 illustrates the normalised log(dose)-response curves of 
ASA and SA for both cell lines.
Fig 4.3. Normalised log(dose)-response curves of aspirin (ASA) and salicylic acid (SA) against the 
chemo-naïve (HCC1806 PTL) and the paclitaxil-resistant (HCC1806 PAX) breast cancer cell lines.
































These values are comparable to the findings of Bashir et al. who tested ASA and SA on a colorectal 
cancer cell line and found that the IC50 values were 1.8 mM for ASA and 2.6 mM for SA.
30 Castaño31 
et al. identified the IC50 for ASA at 5 mM for a human colon adenocarcinoma cell line while 
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Vejselova et al32 found the IC50 of SA to be 6 mM for a human lung adenocarcinoma cell line. Raza 
et al. also tested the inhibitory effect of ASA on a hepatoma cell but needed higher concentrations 
(5-10 mM).33 The IC50 was not calculated, however, and these concentrations were used to induce 
maximum inhibition.
Results from the in vitro studies in this project and from the work of others, such as Bashir et al. 
discussed above,30 show that the tested cancer cell lines are more sensitive to ASA than SA. From 
this, it could be inferred that the conversion of ASA to SA might not be as quick in vitro as it is 
in vivo, and that the two drugs might be interacting differently with cancer cells based on their 
lipophilicity.
As discussed in Chapter 2, the maximum circulation half-life of ASA in the body is about 20 minutes 
since it is rapidly hydrolysed to salicylic acid.29 However, this hydrolysis might be happening 
at a much slower rate in the in vitro experiments. ASA is thought to be mainly hydrolysed via 
butyrylcholinesterase, paraoxonase, and albumin in the plasma as well as the platelet-activating 
Factor Acetylhydrolase 1b2 (PAFAH1b2) in the platelets.34,35 However, the concentration of these 
hydrolases in the in vitro experiment would be very small, especially that the component of the 
growth medium that might contain these enzyme, i.e. FBS, is only used at a concentration of 
10%. These hydrolases, if existent in the growth medium, would be easily saturated with the 
concentration of ASA used. The non-enzymatic hydrolysis of ASA happens at a slower rate. For 
instance, Bakar et al. found that the hydrolysis half-life of aspirin at 37 °C increased from 0.21 
hours in complete blood, to 2.8 hours in plasma, to 15.4 hours in a phosphate buffer.36 
It is well established that the more lipophilic a drug is the more rapidly it moves across the cell 
membrane during passive transcellular transport, but it could also undergo higher retention in the 
membrane which might limit its internalisation.37,38 It could therefore be argued that, since SA is 
more lipophilic than ASA (LogP = 1.14 and 2.35 for ASA and SA, respectively),39 SA is retained in 
the cell membrane at a greater extent than ASA while the later gets internalised more easily leading 
to a greater pharmacological response.
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Determination of IC50 for polysalicylate (PSA) was not as straightforward. Because of its 
hydrophobic nature, the addition of PSA (dissolved in DMSO) to the culture medium caused it to 
precipitate immediately. The small volume of PSA (5 µL) added to the 995 µL of culture medium 
caused the formation of a rigid pellet that could not be dissolved upon agitation with the pipette, 
but instead broke down to small flakes. For this reason, the flake suspension was used as it is for 
seeding the polymer in the well plate with reconstitution upon each addition. Thus, the serial 
dilutions were of the flakes rather than PSA itself, making estimating the concentration of the 
polymer less accurate. Furthermore, The insoluble state of the polymer complicates interaction 
with the seeded cells. Nonetheless, Dasgupta et al. and Chandorkar et al. used discoid implants of 
their respective salicylic-acid-based polymers (discussed in Chapter 2) for their cytocompatibility 
studies, possibly due to similar solubility issues.40,41
Results were fitted in the same model as the small-molecule drugs (SA and ASA), but normalising 
data did not provide an accurate estimation of the IC50 of PSA (as could be inferred from the 
coefficient of determination, r2) since none of the concentrations produced full inhibition of 
cell growth. Figure 4.4 illustrates both, the normalised and non-normalised log(dose)-response 
curves of PSA for both cell lines. The trend is the same in both cases, and although it is difficult 
to determine the IC 50 with a good degree of confidence from the normalised curve in this 
case, the non-normalised curve provides better information about how much inhibition each 
concentration produced. For example, The highest concentration of the PSA suspension produced 
75% and 69% inhibition for the HCC1806 PTL and HCC1806 PAX respectively, while the lowest 
concentration produced only 9% and 14% inhibition for the parental and the paclitaxel-resistant 
cell lines, respectively.
Calculated IC50 values for the PSA suspensions as determined from the normalised curves were 
0.58 mM  (95% CI: 0.45-0.72, r2 = 0.84) [equivalent to 3.48 mM SA] and 0.49 mM (95% CI: 0.36-
0.66, r2 = 0.78) [equivalent to 2.94 mM SA] for HCC1806 PTL and HCC1806 PAX, respectively. 
Although expressing the inhibitory effect of PSA in this case by concentration is not truly 
representative both because of the solubility issue and the poorly-fitted graph, the data shows that 
PSA still exhibited some cytotoxic activity even in its non-dissolved state. Since both cell lines 
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are of the adherent type, cells were seeded and were left in the incubator for 24 hours before the 
addition of the PSA suspension, as opposed to seeding the cells and the drug flakes in the same 
settings. This was done to exclude the physical interference of the flakes with the adhesion of the 
cells. The results, however, were similar in both cases.
Fig 4.4. Normalised (top) and non-normalised (bottom) log(dose)-response curves of polysalicylate 
(PSA) against the chemo-naïve (HCC1806 PTL) and the paclitaxil-resistant (HCC1806 PAX) breast 
cancer cell lines.


























































Whether there is some sort of physical inhibition to cellular growth, or whether the PSA has 
inherent cytotoxic properties, or whether there is simply a slow release of SA from the polymer 
that induced some inhibition of cell growth over the incubation period of 5 days warrants further 
investigation.
Self-assembled PSA-PEG vesicles like those discussed in Chapter 2 were also prepared in 
autoclaved PBS and tested for their cytotoxic effect. The tested vesicles had a z-average diameter 
of 364 nm as determined by DLS (Figure 4.5). Because the synthesis method did not allow for 
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the use of high concentrations of the NPs without resulting in non-uniform precipitations during 
self-assembly, and because only a reasonable amount of the NP suspension could be added to 
the cell cultures without diluting the growth medium to the extent that would interfere in cell 
growth, the maximum concentration of the NP suspension that could be used was 0.25 mg/mL 
and, consequently, the serial dilutions for the cell viability assay were only performed at a ratio of 
1:2 to avoid exaggerated dilution.




Nonetheless, the highest concentrations still exhibited some cytotoxic activity for both cell lines. 
However, fitting and normalising data in the familiar log(dose)-response model to extrapolate the 
IC50  did not yield accurate results because, as in the case with PSA, none of the concentrations 
used fully inhibited cell growth. The calculated IC50 values were 0.07 mg/mL (95% CI: 0.04-0.12, 
r2 = 0.65) and 0.03 mg/mL (95% CI: 0.02-0.14, r2 = 0.83) for HCC1806 PTL and HCC1806 PAX, 
respectively (Figure 4.6).
Although IC50 values could not be inferred from the normalised data, the raw data shows that the 
highest concentration of the NP suspension still managed to kill about 45% and 30% of the culture 
for the HCC1806 PTL and HCC1806 PAX cell lines, respectively.
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Fig 4.6. Normalised (top) and non-normalised (bottom) log(dose)-response curves of PSA-PEG 
nanoparticles against the chemo-naïve (HCC1806 PTL) and the paclitaxil-resistant (HCC1806 PAX) 
breast cancer cell lines.




























































To investigate whether PEG had an active role in the cytotoxicity of NPs, the MTT assay was also 
performed on the cells using PEG. However, it failed to produce any notable toxicity even at high 
concentrations (20 mM). Figure 4.7 shows the log(dose)-response curves of mPEG for the two cell 
lines.
Without proper visualisation methods backed by genetic manipulation and/or pharmacological 
manipulation studies (to inhibit specific uptake routes to examine others),42 it would not be 
possible to determine the pathway by which the PSA-PEG NPs are taken up by the cells. However, 
judging by the relatively large size of the vesicles and the lack of targeting ligands on the NPs, it 
can be speculated that the uptake most likely happened via macropinocytosis.1,43 This pathway 
was observed to be the main entry route for a wide array of nanoparticles, including polymeric 
ones, and of different shapes and sizes.44 However, large particles appear to only be able to enter 
157
cells either by micropinocytosis or phagocytosis.44,45 The endosomes containing the particles 
would then possibly fuse with the lysosomes where there is an abundance of hydrolytic enzymes 
(about 60 in some cells) and an acidic pH or about 4.0-5.5.46–48 It could be speculated that, after 
the degradation of the ester bonds on the PSA, some of the released SA becomes protonated at 
that pH and is able to permeate through the phospholipid membrane of the lysosome and into the 
cytoplasm of the cell.
Fig 4.7. Log(dose)-response curves of methoxy polyethylene glycol (mPEG1900) against the chemo-
naïve (HCC1806 PTL) and the paclitaxil-resistant (HCC1806 PAX) breast cancer cell lines.






























The NPs were also investigated for a potential synergetic effect with other cytotoxic drugs. 
Firstly, four drugs, bleomycin, mitomycin, and temozolomide, and zeocin were screened for their 
cytotoxic effect on both cell lines. Of the four, only bleomycin and mitomycin exhibited inhibitory 
effects. The cytotoxic effect of these agents is mainly due to their ability to bind to and damage 
cellular DNA.49,50
The IC50 values for these two drugs were then determined for the two cancer cell lines. For 
bleomycin, IC50 was 0.10 µM (95% CI: 0.07-0.14, r
2 = 0.99) and 0.14 µM (95% CI: 0.04-0.41, r2 = 
0.88) for HCC1806 PTL and HCC1806 PAX, respectively. For mitomycin, the values were 0.04 µM 
(95% CI: 0.03-0.05, r2 = 0.99) and 0.12 µM (95% CI: 0.09-0.16, r2 = 0.99) for HCC1806 PTL and 
HCC1806 PAX, respectively. These results are comparable to the values provided by The Genomics 
of Drug Sensitivity in Cancer Project for the HCC1806 cell line where the IC50 values are 0.23 µM 
for bleomycin and 0.14 µM for mitomycin.51,52 Figure 4.8 shows the normalised log(dose)response 
curves of bleomycin and mitomycin for the two cell lines. 
158
Fig 4.8. Normalised log(dose)-response curves of bleomycin and mitomycin against the chemo-naïve 
(HCC1806 PTL) and the paclitaxil-resistant (HCC1806 PAX) breast cancer cell lines.
































The individual drugs (ASA, SA, bleomycin and mitomycin), PSA-PEG NPs, and different 
combinations were tested against the cell lines using their respective IC50s under the same 
experimental conditions.
Figure 4.9 shows a comparison of the effect of different treatments, either individually or in 
combinations, on the two cancer cell lines. Generally, the parental cell line was more sensitive to 
almost all treatments than the paclitaxel-resistant cell line. Aspirin showed efficacy comparable to 
that of bleomycin and mitomycin by suppressing cell growth by 80% for the parental cell line and 
70% for the paclitaxel-resistant one. Salicylic acid exhibited almost half of the efficacy of aspirin. 
PSA-PEG vesicles showed minimal inhibition of both cell lines with inhibition of only about 22% 
for HCC1806 PTL and about 15% for HCC1806 PAX. 
Combining aspirin with the cytotoxic drugs bleomycin and mitomycin increased their efficacy 
by about 10%, while the increase was marginal or non-existent in the case of combining salicylic 
acid or the PSA-PEG nanoparticles with either drug. The increase of cytotoxicity might be due 
to the different mechanisms by which bleomycin and mitomycin, on one hand, and ASA (and 
possibly SA and its NP formulation at higher doses), on the other, exert their effects on cancer 
cells. While the cytotoxic drugs used affect cancer cells by damaging their DNA, aspirin might 
induce cell apoptosis by increasing the expression of pro-apoptotic proteins (such as Bcl2) and 
reduce the expression of anti-apoptotic proteins (such as Bax), possibly through COX-independent 
pathways.53
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Fig 4.9. A comparison of cytotoxicity of different treatments, individually and in combinations, against 
the two breast cancer cell lines. Data is represented by mean ± SD from a representative experiment 




















































If this is the case, then it would be advantageous to combine both classes, firstly to minimise the 
gruesome side effects of the cytotoxic drugs, and secondly to have a better therapeutic response with 
drug-resistant cancers. Resistance to chemotherapy has been attributed to the to the upregulation 
of anti-apoptotic proteins and the downregulation of the pro-apoptotic ones.54 It has also been 
linked to mutations in the p53 gene, impairing the connection between DNA damage (caused by 
the cytotoxic drugs) and the activation of apoptosis.55 Combining NSAIDs with chemotherapy 
could enhance the therapeutic outcome.
It should be noted, nonetheless, that this was a preliminary experiment that was performed towards 
the end of the project to form a basic idea about how the PSA-PEG NPs compare to their small-
molecule counterparts and in combination with other cytotoxic drugs. The experiment should 
be repeated at least in triplicate before any significance could be drawn from it through analysis 
of variance (ANOVA), for instance. Perhaps the biggest drawback of this experiment was the 
limit on the concentration of the NPs that could be used, but the inhibitory response that the NP 
suspensions exhibited either alone or in combination with other established cytotoxic drug, albeit 
modest, shows that the polysalicylate nanoparticles might have a potentially useful application in 
targeted therapy even when used at low concentrations.
160
Towards the end of the project, more in vitro studies were initiated for another cancer cell line, that 
being the neuroblastoma cell line; UKF-NB-3. Neuroblastoma is the most common and deadly 
solid tumour of childhood with cases ranging from spontaneous regression in some patients to 
very bad prognosis and metastasis, even with aggressive treatment, in others.56 This heterogeneity 
in prognosis and the general trend towards minimising therapy57 make a targeted approach to 
therapy a favourable option. Moreover, aspirin and its derivatives are contraindicated in children 
due to the high risk of developing Reye’s syndrome. Although not fully understood yet, the disease 
that causes deadly injuries to the brain and liver is believed to develop in children under 16 years 
of age when they are treated with salicylates during or around an incidence of viral infection.58 
If aspirin was proved to be effective in the management of neuroblastoma in children, a targeted 
approach in therapy that concentrates the drug in the solid tumour would help  mitigate, or even 
eliminate, the risk of developing Reye’s syndrome.
MTT assay showed a similar trend in response to treatments to those observed in the HCC1806 
cell lines, although the neuroblastoma cell line appeared to be slightly more sensitive that the 
breast cancer cell line. IC50 values were 0.31 mM (95% CI: 0.18-0.52, r
2 = 0.97) for ASA and 0.48 
mM (95% CI: 0.35-0.66, r2 = 0.99) for SA (Figure 4.10).
Fig 4.10. Normalised log(dose)-response curves of aspirin (ASA) and salicylic acid (SA) against the 
UKF-NB-3 neuroblastoma cell line.
















Sensitivity to PSA (Figure 4.11) also showed a similar trend with the exception that the highest 
concentration of the PSA suspension (1.25 mM, equivalent to 7.5 mM SA) killed 96% of the cell 
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culture. However, given the fact that the experiment was only carried out once and that PSA 
was used as a suspension rather than a solution, this result should be interpreted cautiously and 
requires further investigation.
Fig 4.11. Log(dose)-response curve of PSA against the UKF-NB-3 neuroblastoma cell line.














The UKF-NB-3 cell line also showed a response to PSA-PEG NPs similar to that of the other 
cell lines. IC50 was found to be 0.05 mg/mL (95% CI: 0.03-0.08, r
2 = 0.94). Figure 4.12 shows 
the normalised and non-normalised log(dose)-response curves for the PSA-PEG NPs against the 
neuroblastoma cell line.
Although this value might not be representative of a true IC50 due to the lack of a good distribution 
of points between 0% and 100% in the original (non-normalised) data, it still can be noted that the 
NPs induced an inhibitory response that is comparable across all three cell lines.
Fig 4.12. The normalised (left) and non-normalised (right) log(dose)-response curves of PSA-PEG 
NPs against the UKF-NB-3 cell line.































In anticipation of the successful synthesis of the ibuprofen-loaded polyphosphoesters, the three 
cell lines were inspected for sensitivity against ibuprofen. The drug induced a cytotoxic response 
in all three cell lines similar to that observed with ASA and SA.
IC50 values were 0.30 mM (95% CI: 0.18-0.49, r
2 = 0.97), 0.22 mM (95% CI: 0.14-0.34, r2 = 0.98), 
and 0.13 mM (95% CI: 0.09-0.18, r2 = 0.98) for HCC1806 PTL, HCC1806 PAX, and UKF-NB-3, 
respectively. Figure 4.13 illustrates the normalised log(dose)-response curve of ibuprofen against 
the three cell lines.
Like the case of ASA and SA, These values fall within the range of plasma concentrations of 
ibuprofen after a normal therapeutic dose.59 This might be another indication of the potential 
value of NSAIDs in the fight against cancer.
Fig 4.13. Normalised log(dose)-response curve of ibuprofen against HCC1806 PTL, HCC1806 PAX, 
and UKF-NB-3.



















The first in vitro study of the developed PSA-PEG NPs showed that they are able to induce 
cytotoxicity, albeit modest at low concentrations, in at least three cell lines; two breast cancer cell 
lines, one of which is chemo-resistant, and one neuroblastoma cell line. The study also confirmed 
that aspirin and its anti-inflammatory hydrolysis product, salicylic acid, do induce cytotoxicity in 
the same cell lines at clinically relevant concentrations. This proves that designing nano-vehicles 
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that can effectively deliver the anti-inflammatory salicylic acid to solid tumours might indeed 
prove to be useful in maximising the potential chemotherapeutic value of this drug. 
However, biological systems are much more complicated than a small cell culture and the MTT 
assay, despite being a good basis to evaluate the biological response, has many shortcomings 
when it comes to testing NPs. For example, not only does not account for the immunological 
response of the RES system towards NPs and other barriers that particles have to overcome before 
reaching cancer cells (e.g. the interstitial fluid pressure), but it can also be affected by other factors 
not encountered with conventional drugs, such as the fact that the adsorption of the medium’s 
proteins on the tested nanoparticles might possibly change the composition of the medium and 
deprive the cell culture of vital nutrients, complicating the results of the test.60 Moreover, one of 
the proposed mechanisms by which the NSAID-mediated suppression of PGE2 leads to curbing 
tumour growth is via the suppression of angiogenesis, cell adhesion and metastasis,61 all of which 
cannot be observed in simple cell cultures.
Nonetheless, this assay still serves as a good starting point for more sophisticated testing such as 
those carried out in vitro in 3D cell culture models or in vivo.62
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The race against cancer calls for innovative treatments that are not only efficacious against the 
vicious disease, but that also mitigate its devastating effects on all levels. Treatments that could 
enhance the patient’s quality of life effectively and safely or be used as prevention, all while reducing 
costs both during development and hospitalisation are the holy grail of cancer therapy.
This project stemmed from the concept that aspirin and other NSAIDs have shown promise in 
reducing cancer risk in susceptible patients. Being a class of drugs that is cheap, widely available, 
and with a wide therapeutic window that makes them safer to use and handle than conventional 
cytotoxic drugs, NSAIDs provided good candidates to be employed in a nanodelivery systems. 
These systems can be loaded with drugs and exclusively deliver them to tumour foci in 
concentrations much higher than conventional therapy and with much reduced adverse effects 
thanks to their unique physicochemical characteristics that help them exploit the uniqueness of 
the tumour microenvironment (TME).
The first part of Chapter 1 of this thesis explored the evidence of the efficacy of various NSAIDs 
in reducing the risk, recurrence, and metastases of different types of cancer. The strength of this 
evidence was investigated based on the types of trials and their results. Unsurprisingly, aspirin was 
the most studied NSAID since it has been the most popular of its class for decades. The strongest 
evidence came from trials that investigated the effects of aspirin on the incidence and mortality of 
colorectal cancer since those trials included a very large number of patients and for long periods 
of time. Nonetheless, aspirin and other NSAIDs have shown a positive role in different types of 
cancer as well, such as prostate, breast and kidney malignancies.
The possible mechanisms by which NSAIDs exert their anti-tumour effects were examined in the 
second part of Chapter 1. The most prominent hypothesis argues that NSAIDs suppress tumour 
growth through their inhibition of cyclooxygenases 1 and 2 (COX-1,-2) and the subsequent 
interruption in the production of prostaglandin E2 (PGE2), an eicosanoid responsible for inducing 
inflammation and the proliferation and growth of cancer cells. COX-independent mechanisms 
that lead to the induction of apoptosis have also been suggested.
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The third part of the chapter looked into the main concepts behind nanotherapy via examining the 
pathophysiological characteristics that distinguish the tumour microenvironment from healthy 
tissues and how they can be exploited. The main pathophysiological feature of TME was the leaky 
vasculature and the poor lymphatic drainage that lead to the enhanced permeability and retention 
(EPR) effect which allows nanoparticles of a certain size (ideally 100-200 nm) to penetrate the 
TME and accumulate in it. The text examined other features as well, such as the overexpression 
of certain receptors that can be used for a more targeted approach in nanomedicine. Barriers to 
nanotherapy were also discussed; phagocytosis by the reticuloendothelial system (RES), and the 
elevated interstitial fluid pressure (IFP) were among the primary concerns.
A summary followed of the relationship between the nanoparticles’ physicochemical characteristics 
like shape, size and surface charge with the biological response. The chapter concluded with 
an overview of the mainstream types of nanoparticles that are either in clinical use or under 
development and some of the examples of how different nano-systems has been developed for the 
delivery of NSAIDs, some of which were intended for cancer targeting. 
Chapter 2 presented the work done to develop NSAID-based polymeric NPs. Since the anti-
inflammatory effect of aspirin is mainly attributed to its hydrolysis product, salicylic acid, the latter 
was the main building block of the polymer. Because the molecule possesses one hydroxyl and one 
carboxyl groups, linear polymers (polysalicylate, or PSA) were achievable by the polycondensation 
of the monomer at high temperatures. This method yielded polymeric chains comprising solely of 
repeating units (between 5-30) of salicylate linked by ester bonds with an acetyl group on one end 
and a carboxyl group on the other. Factors affecting the degree of polymerisation were discussed 
as well as the possibility of the formation of unwanted products that would limit the ability to 
modify further the polymer, such as cyclic and capped polymers.
An amphiphilic block copolymer (BCP) was then created by the conjugation of polysalicylate with 
polyethylene glycol, a biocompatible polymer that would not only form the hydrophilic part of 
the BCP but that would also create a stealthing shell upon self-assembly that would prolong the 
circulation half-life of the nanoparticles by rendering them invisible to macrophages. The BCP 
had a loading capacity of around 40% of the active moiety.
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Self-assembly was then carried out using the co-solvent method and yielded interesting 
morphologies depending on the organic solvent used. While an acetone/water system produced 
spherical micelles with an average hydrodynamic diameter of 25 nm, a THF/water system yielded 
vesicles with an average hydrodynamic diameter of about ten times the size of the previous ones, 
making the latter more suitable for targeted therapy purposes. Factors controlling the self-assembly 
of the BCP, such as the solvent-polymer interactions and the length of the polymer chains, were 
discussed in detail.
Degradation studies on the PSA were also conducted in biological and nonbiological media with 
varying hydrolytic potencies to estimate the amount of the drug that could be under different 
condition. At a temperature close to that of the human body, release of the active drug was observed 
only in the basic medium while the polymer showed good stability in the presence of some blood 
components and some esterases. Accelerated conditions, on the other hand, induced drug release 
in biological media. PSA-mPEG NPs exhibited similar release trends.
These studies indicate that the synthesised NPs could be stable during circulation until they 
accumulate in solid tumours and are taken up by cancer cells where they could be broken down by 
a multitude of hydrolytic enzymes.
Several steps towards the making of another NSAID-based polymer were also accomplished. The 
intention was to create a polyphosphoester with ibuprofen linked as the pendant via ester groups. 
This polymer would then self-assemble into NPs with high biocompatibility. This biocompatibility 
stems from the fact that phosphate and its polymers are abundant in nature and make up the key 
components in the human biology from DNA to buffers and enzymes. Upon delivery to the TME, 
the polymer would supposedly break down to its basic components; phosphate, glycerol (another 
molecule that is natural to the body), and ibuprofen.
The monomer necessary for making the polymer was synthesised successfully with high purity, 
but time did not allow for the optimisation of the ring-opening polymerisation reaction, which is 
known for its sensitivity.
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3In Chapter 3, another type of SA-loaded nanocarriers were prepared. Liposomes are considered among the safest nanodelivery systems and almost all of nano-systems approved for clinical use are liposomal formulations. Their phospholipid shell resembles biological membranes they induce little to no immunological response. For this reason, they were explored as potential carriers for 
SA. 
The egg phosphatidylcholine that was fist used to make the liposomes yielded good encapsulation 
efficacy (EE) with a desirable size range but resulted in bad retention of the drug due to its low 
transition temperature. DPPC was believed to be a better alternative since it had a transition 
temperature just a few degrees above average normal body temperature. The use of DPPC yielded 
liposomes with even a higher EE that reached about 71%. However, the poor retention issue 
persisted even with the incorporation of cholesterol with the lipid to increase the rigidity of the 
phospholipid bilayer.
It was then concluded that the poor retention was due to the amphiphilic nature of SA based on 
its protonation state. Being a weak acid, it is believed that the protonated form of the acid is able 
to permeate through the membrane while the ionised version is trapped in the aqueous phase. For 
this reason, another method of loading the liposomes with SA was tested. 
In contrast to the direct (passive) loading method used earlier, the remote (active) loading method 
depended on creating a difference in pH between the inner and the outer phases of the lipid 
bilayer in order to drive the protonated form of salicylic acid through the membrane of pre-made 
empty liposomes. However, the EE of liposomes using this method was poor, with and without the 
incorporation of cholesterol. It was speculated that the presence of lysophospholipid, either due 
to the sonication method used for homogenisation or from the outdate patch of the lipid used, 
compromised the integrity of the lipid membrane and lead to leakage and poor retention.
Nonetheless, the results of these experiments raised questions about some liposomal preparations 
of SA that exist in the literature, warranting some scrutiny.
173
4The final chapter investigated the basic biological effects of the prepared PSA-PEG NPs against a triple-negative breast cancer cell line and its paclitaxel-resistant subline. MTT assay was the method of choice for the determination cell viability.The half-maximal inhibitory concentrations (IC50s) for SA and ASA were first established as a 
point of reference and were found to be in agreement with literature in regards to cancer cell line 
testing. These values were also within the range of plasma concentration after therapeutic doses 
of these drugs which emphasises the potential anti-tumour role of NSAIDs derived from clinical 
data.
The IC50 values for PSA and the PSA-PEG NPs could not be accurately determined due solubility 
issues with the former and the inability to use high concentrations of the latter. Nonetheless, they 
both exhibited a consistent cytotoxic effect on both cell lines.
A comparison of the cytotoxicity of the monomers and the NPs was carried out using their 
respective IC50s. The comparison also included conventional cytotoxic drugs as well as different 
combinations of the above. The response from the NPs was modest compared to the other drugs, 
but that was expected due to the low concentration of the NPs that could be used. Nonetheless, 
it can be speculated from the observed response and the cytotoxicity of the monomer that is 
comparable to that of conventional chemotherapeutics that SA-loaded NPs might indeed have a 
positive role in limiting the growth and metastasis of cancer upon accumulating in cancer tissue.
Future outlook
The degradability and cytotoxicity of the SA-based polymer and polymeric nanoparticles suggest 
that such nanocarriers might be of use in the fight against cancer and in boosting the patients’ 
quality of life. This calls for fine-tuning the nanocarriers to maximise their benefits.
One suggestion would be to separate the polymeric chains based on molecular weight which not 
only would be necessary to improve the dispersity profile of the polymer and consequently have 
more control over dosage, but that would also remove cyclic and capped polymers that hinder the 
synthesis of pure block co-polymers.
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As was shown in the work, different solvent systems produced different morphologies. These 
morphologies might be re-purposed in a variety of ways. For instance, even though spherical 
micelles produced from the acetone/water system might not be very effective in targeting cancer 
since they would be rapidly cleared by the kidneys, they might be useful in an intra-articular 
formulation, for example, where they would produce a sustained release of the NSAID. The inner 
phase of the vesicles produced by the THF/water system, on the other hand, could be exploited 
to load other molecules. For example, they could be loaded with either the monomer, another 
therapeutic molecule, a diagnostic agent, or a combination of all the above. 
The initial biological studies showed that the synthesised particles exhibit a cytotoxic activity 
but further in-depth studies are required. The mechanism by which particles are taken up by the 
cells ought to be established in order to understand how particles are inducing their cytotoxicity. 
This would also help in determining the cellular components that the particles encounter which 
would be useful in adjusting their drug release profile. The use of systems more sophisticated 
that conventional cell cultures, such as 3D cell cultures and animal models, would give a better 
understanding about how these nanoparticles interact with the tumour as a whole and how they 
affect components other than the cells, which are just as important for the growth and survival of 
tumours.
